pkasjqamjkwqtepshsnmpqtoeijcaotmgsyossyi length 6 318119 page 318119 

<!DOCTYPE html>

<html id="doc" lang="en" class="page-article">
<head id="Head1">
    <!-- charset must appear in the first 1024 bytes of the document -->
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />

<script>
      var SCM = SCM || {};
      if (SCM.AMA && SCM.AMA.DataLayerAsync) {
        SCM.AMA.DataLayerAsync.push("arrSisAffinity", "", "array");
        SCM.AMA.DataLayerAsync.push("SubStatus", "no", "string");
      }

      var googletag = window.googletag || {};
      googletag.cmd = googletag.cmd || [];

          
          if (typeof Storage !== "undefined")
          {
              var targetingParamStr = localStorage.getItem("bcDFPTargetingParams");
              if (targetingParamStr)
              {
                  var targetingParameters = JSON.parse(targetingParamStr);     // set page-level targeting parameters
                  jQuery.each(targetingParameters, function (index, param) {
                      googletag.cmd.push(function () {
                          window.googletag.pubads().setTargeting(param.key, param.value);
                      });
                  });
              }
          }
          
      if (!googletag.pubads) {
        (function () {
          var gads = document.createElement('script');
          var useSSL = 'https:' == document.location.protocol;
          gads.src = (useSSL ? 'https:' : 'http:') +
            '//securepubads.g.doubleclick.net/tag/js/gpt.js';
              gads.setAttribute("async", "");
              gads.setAttribute("defer", "");
          var node = document.getElementsByTagName('script')[0];
          node.parentNode.insertBefore(gads, node);
          })();

        var App = App || {};
        App.Ads = App.Ads || {};
        App.Ads.adPath = App.Ads.adPath || '/6479/' + 'ama.jama';
        App.Ads.Mappings = App.Ads.Mappings || {};
        App.Ads.slots = App.Ads.slots || [];
        App.Ads.fromGoogle = !('yes' === 'yes');

        App.isCollection = App.isCollection || !!document.getElementsByClassName('pg_collection').length;

        
        googletag.cmd.push(function () {

          googletag.pubads()
            .setTargeting('environment', ['newjama'])
            .setTargeting('site', ['ama.jama'])
            .setTargeting('sect', ['scholarly'])
            .setTargeting('sub', ['no'])
            .setTargeting('device', ['cis5550-crawler'])
            .setTargeting('usaphys', ['no'])
            .setTargeting('memberstat', ['no'])
            .setTargeting('pracset', [''])
            .setTargeting('specialty', ['other'])
            .setTargeting('occupation', [''])
            .setTargeting('useraffinity', [''])
            .setTargeting('direct', ['yes'])
            .setTargeting('bot', ['yes'])
            .setTargeting('datacenter', ['no'])
            .setTargeting('selfMPA', [''])
            .setTargeting('selfSpecialty', ['']);

          if (App.isCollection) {
            googletag.pubads().setTargeting('collection', ['']);
          }

          var testParam = getQueryVariable('test');

          if (testParam) {
            googletag.pubads().setTargeting('test', [testParam]);
          }

          function getQueryVariable(variable) {
            var query = window.location.search.substring(1);
            var vars = query.split('&');
            for (var i = 0; i < vars.length; i++) {
              var pair = vars[i].split('=');
              if (decodeURIComponent(pair[0]) == variable) {
                return decodeURIComponent(pair[1]);
              }
            }
          }

          googletag.pubads().disableInitialLoad();
          googletag.enableServices();
        });
      }
</script>


<meta name="viewport" content="width=device-width, initial-scale=1" /><meta name="format-detection" content="telephone=no" /><link rel="shortcut icon" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon.ico">
<link rel="icon" type="image/png" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon-192x192.png" sizes="192x192">
<link rel="apple-touch-icon" sizes="180x180" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/apple-touch-icon-180x180.png">
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    
    <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/dist/app.min.css?v=638488852237037766">
    
    
    
    
    <link href="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.css" type="text/css" rel="stylesheet" />
    

    <meta property="og:title" content="Adverse Reactions and Antibody Responses to an Inactivated SARS-CoV-2 Vaccineâ€”Interim Trial Analyses" />
    <meta property="og:type" content="Article" />
    <meta property="og:url" content="https://jamanetwork.com/journals/jama/fullarticle/2769612" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005_featured_1599242849.36015.png?Expires=2147483647&amp;Signature=T4oedeL18DIN1klInAiL2lXiHygeZSSHjZGVQsFOVnJI0czQsY3D2nGY~mFqGwa8GqoPBo7BEnmyvHm4HoGyWSXHAACjLuy1tTu~I9SSSI5RIpASBV6w-DhTZatRyMOzfXhaoijUcfddBkLJQrysHTV3nzbbHC2V4uyCq7ZB-oFZsDh00ozKuU~SGOyr~khz2FNBlbOWM~chwEWmfnyts48Oe6xoZH6SkjvLyEii7HIQgWgLo54UmQHnrEWHYbePVtfHymD06AHs8cM8B-jcdAZllQqmF6xONSXnhTM23nQVO1YSFCt~KwwO3h-sNybnzQduGb-5vkJGLYc~mbQYoA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f1_1599242849.65703.png?Expires=2147483647&amp;Signature=ABitLLFwpJv16Eg1h7HrVcDwuR8GhST9zpwU9cHbCH3xiPl6WJUBoyzsM3fZuyixpDmG0eLDx2~YOqy4n6BHT~BcJ7lCK4PzF3T5a7K5BHcNWnWdV0i3ArbFJfEKo2KW0xK~Zg8R-4NBZlNucnmCX3X3rH1tbI9J8RHPWEbYc84avwY8bR1gdAoKxOLt7XkK5m3OWCU6WPm7SpfL972RZMPC3iW0nrvBcz6UJKYa~QCK7kSHN3fiO7NGWCfeXc8~neEgBW93pAdMgjSkwsj9KNDQ9LS0osPAGCcWnwV4pFBTbHCwa-hrc0vFnIbxyC8hQMz5PAVCnhZdAjXNC77QCg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t1_1599242849.68828.png?Expires=2147483647&amp;Signature=UXpJflxL8e3CGnSPHBiJLSzSuXDGaGmWbM2Qa6soyTAn-ujh4~SMwqKbpHrH46Jn-ApK7Bn662eFyFN3nHb7dkMPkHYECtpFez1VZ1hCcP1SpyrM4nEgsPeONntFJPyoylmtucH7qUfXfQXwcot~LYOVQVpavHTeSi0WHMatAAr1pbSIokFDcRmNPodjxz1C3KVJFA1Smny1dIgd-wn6C~6DCQ4bU39cH6Js5AnPKvk8qdBc7N-lR-2q0icd7GZFimhvHGHa1ozYZiedeydfbW78FPYfe-CHqv4HcfKxjj18Hn3UiRHv28QS3PkLlf9JP-Na~h0KwkgNTNkU5SsEQg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t2_1599242849.7039.png?Expires=2147483647&amp;Signature=1et0kuuN2tCXILJYl3T5bSsSwt32Sl3ncR0lZgTFl4JcTEJRq6P3DTAevyWHmV82tdGpEjskd3IQviZ3KHLy9VcjiDDBV0omsyhCioU1CJtSQJ~leJ77aPo0DuQzgVU99pGMo9UbxivkCM~mDfCo6wyAlGKwWiyxfps1h9v6LN5KHWPdGt63sTzPYMg14GqncooAWgATG5N3wbJSAHo2nkCZ2udoyQp9OsgrFiU~lTJCkmTPwE2Emi1GrxyvjgwjJiEwA6tMmHxOJMTMCNLeJ7sTf231Vk~Q7O2FBsmVClzYi84bQ14bWIYApZUQT9M37haAbZnrKdHnmnk1G-FzTw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t3_1599242849.73515.png?Expires=2147483647&amp;Signature=zaAhNe33qOrc0Q1h5Tno8Koqw3Nn1KuM4Jm0rFrlIFgGF7b0fhNk6igDNeEn9D7AMXJvw8khDBHaJvK6NW9kQkdPJrQnRCZhSOLiH7TmOkBQO72sE7zTARkDc-qi-Ck3iTaR8jpeOwVxLc4royhBH8HV3-II6x-Gl~zfR9lqwbZUV79rT~bNVgK4zbQMpkCLWDeP2zND~6D8DCEDuqMmEFjx8FA5qA51c9XQoBu8opQiqk2eX1Yi6XTWLbt6uhZwsUqPn9jsTTwpRxQvYWQWRbgakd6Ei-NmMr0APOzNLahyBjf7OcUnPBelWWpxBGNtKXRUJWJmZVy0XbMthQTPzA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f2_1599242849.75078.png?Expires=2147483647&amp;Signature=Yw~FfmOcH-OCEx-tgnNe783Y-qci~tU0wbmT2llCspK0v1IE56JSNbxZFIdZQpAgm4ED~w812afqGpZ2-TjU65NZihvrZRNjatQN8~kPMAuU0M6l7rmbFxz-vZSK0OuZxYkDnVxVbKsklnq5Va1qmTDALdKA9BLbFTrbW0TVouoPsPLY~5O6yMEZmqxweWYfslUI2KVNneJ2oUkfAkfulhGkQzxMSnTmf4psEZUMggdRTwzCKYmc~jFAPyrF-6Eie0w4UcaCIh1TQl7IQVCxPPm6cpyLEjeZScTtOTP1i-r9eeAexi82u5YhpvujwiwqBp7-1fAxZnlLWykbpNDgMA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f3_1599242849.75078.png?Expires=2147483647&amp;Signature=vC7REVKVrVewZ4iwYV8PMOE7H6HIfVPfS-G9E7rhETAEFSFJUngO0gkFcoIQLbSYfS0gUGNEQW66G8F43sSyukMLxZfdY~9wqWXCgVBdxrygMEEIslUjf9pMiRssQcBLyfyDAu6JcIbMu9a~WJTfL44Q8hM-tsuIp0Ji0XceBPrRmnelFbf--V~uGjGQ4TJ4c3oR3mgKWkpGA8uvz9gq2~yYyEaq9bf~mEQ~t6tb6eqsDdniG7JtGkuS3rsQIDagaiZAIk6~jbeps-NNHQsWMDwmqdcbuvrBOvTAxkmUPYXIWUpF~JWLLt8-5MVXU89yHsWYCToR8~AhGRW6oaIIbw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:description" content="This interim analysis of 2 randomized trials compares adverse reactions and neutralizing antibody responses to inactivated coronavirus disease 2019 (COVID-19) vs adjuvant-only control vaccination, and compares the outcomes at varying vaccine doses among healthy adults in China." />
        <meta property="fb:pages" content="87087958340" />
        <meta property="fb:pages" content="122228711814384" />
        <meta property="fb:pages" content="1648414928738217" />
        <meta property="fb:pages" content="117506346528" />
        <meta property="fb:pages" content="97538728726" />
        <meta property="fb:pages" content="114116793520" />
        <meta property="fb:pages" content="100679858757" />
        <meta property="fb:pages" content="759822190741773" />
        <meta property="fb:pages" content="100265333750" />
        <meta property="fb:pages" content="234770525256" />
        <meta property="fb:pages" content="98784919862" />
        <meta property="fb:pages" content="120829458202" />
        <meta property="fb:pages" content="124842870398" />
        <meta property="fb:pages" content="110245330325636" />
        <meta name="twitter:card" content="summary_large_image" />
        <meta name="twitter:site" content="@JAMA_current" />
        <meta name="twitter:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005_featured_1599242849.36015.png?Expires=2147483647&amp;Signature=T4oedeL18DIN1klInAiL2lXiHygeZSSHjZGVQsFOVnJI0czQsY3D2nGY~mFqGwa8GqoPBo7BEnmyvHm4HoGyWSXHAACjLuy1tTu~I9SSSI5RIpASBV6w-DhTZatRyMOzfXhaoijUcfddBkLJQrysHTV3nzbbHC2V4uyCq7ZB-oFZsDh00ozKuU~SGOyr~khz2FNBlbOWM~chwEWmfnyts48Oe6xoZH6SkjvLyEii7HIQgWgLo54UmQHnrEWHYbePVtfHymD06AHs8cM8B-jcdAZllQqmF6xONSXnhTM23nQVO1YSFCt~KwwO3h-sNybnzQduGb-5vkJGLYc~mbQYoA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />




<script type="application/ld+json">
    {
  "@context": "https://schema.org/",
  "@type": "Article",
  "headline": "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of",
  "author": "Shengli Xia, BS",
  "url": "https://jamanetwork.com/journals/jama/fullarticle/2769612",
  "datePublished": "2020-09-08",
  "description": "This interim analysis of 2 randomized trials compares adverse reactions and neutralizing antibody responses to inactivated coronavirus disease 2019 (COVID-19) vs adjuvant-only control vaccination, and compares the outcomes at varying vaccine doses among healthy adults in China.",
  "publisher": {
    "@type": "Organization",
    "name": "JAMA Network",
    "logo": {
      "@type": "ImageObject",
      "url": "//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon.ico"
    }
  },
  "image": [
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f1_1599242849.65703.png?Expires=2147483647&Signature=ABitLLFwpJv16Eg1h7HrVcDwuR8GhST9zpwU9cHbCH3xiPl6WJUBoyzsM3fZuyixpDmG0eLDx2~YOqy4n6BHT~BcJ7lCK4PzF3T5a7K5BHcNWnWdV0i3ArbFJfEKo2KW0xK~Zg8R-4NBZlNucnmCX3X3rH1tbI9J8RHPWEbYc84avwY8bR1gdAoKxOLt7XkK5m3OWCU6WPm7SpfL972RZMPC3iW0nrvBcz6UJKYa~QCK7kSHN3fiO7NGWCfeXc8~neEgBW93pAdMgjSkwsj9KNDQ9LS0osPAGCcWnwV4pFBTbHCwa-hrc0vFnIbxyC8hQMz5PAVCnhZdAjXNC77QCg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t1_1599242849.68828.png?Expires=2147483647&Signature=UXpJflxL8e3CGnSPHBiJLSzSuXDGaGmWbM2Qa6soyTAn-ujh4~SMwqKbpHrH46Jn-ApK7Bn662eFyFN3nHb7dkMPkHYECtpFez1VZ1hCcP1SpyrM4nEgsPeONntFJPyoylmtucH7qUfXfQXwcot~LYOVQVpavHTeSi0WHMatAAr1pbSIokFDcRmNPodjxz1C3KVJFA1Smny1dIgd-wn6C~6DCQ4bU39cH6Js5AnPKvk8qdBc7N-lR-2q0icd7GZFimhvHGHa1ozYZiedeydfbW78FPYfe-CHqv4HcfKxjj18Hn3UiRHv28QS3PkLlf9JP-Na~h0KwkgNTNkU5SsEQg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t2_1599242849.7039.png?Expires=2147483647&Signature=1et0kuuN2tCXILJYl3T5bSsSwt32Sl3ncR0lZgTFl4JcTEJRq6P3DTAevyWHmV82tdGpEjskd3IQviZ3KHLy9VcjiDDBV0omsyhCioU1CJtSQJ~leJ77aPo0DuQzgVU99pGMo9UbxivkCM~mDfCo6wyAlGKwWiyxfps1h9v6LN5KHWPdGt63sTzPYMg14GqncooAWgATG5N3wbJSAHo2nkCZ2udoyQp9OsgrFiU~lTJCkmTPwE2Emi1GrxyvjgwjJiEwA6tMmHxOJMTMCNLeJ7sTf231Vk~Q7O2FBsmVClzYi84bQ14bWIYApZUQT9M37haAbZnrKdHnmnk1G-FzTw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t3_1599242849.73515.png?Expires=2147483647&Signature=zaAhNe33qOrc0Q1h5Tno8Koqw3Nn1KuM4Jm0rFrlIFgGF7b0fhNk6igDNeEn9D7AMXJvw8khDBHaJvK6NW9kQkdPJrQnRCZhSOLiH7TmOkBQO72sE7zTARkDc-qi-Ck3iTaR8jpeOwVxLc4royhBH8HV3-II6x-Gl~zfR9lqwbZUV79rT~bNVgK4zbQMpkCLWDeP2zND~6D8DCEDuqMmEFjx8FA5qA51c9XQoBu8opQiqk2eX1Yi6XTWLbt6uhZwsUqPn9jsTTwpRxQvYWQWRbgakd6Ei-NmMr0APOzNLahyBjf7OcUnPBelWWpxBGNtKXRUJWJmZVy0XbMthQTPzA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f2_1599242849.75078.png?Expires=2147483647&Signature=Yw~FfmOcH-OCEx-tgnNe783Y-qci~tU0wbmT2llCspK0v1IE56JSNbxZFIdZQpAgm4ED~w812afqGpZ2-TjU65NZihvrZRNjatQN8~kPMAuU0M6l7rmbFxz-vZSK0OuZxYkDnVxVbKsklnq5Va1qmTDALdKA9BLbFTrbW0TVouoPsPLY~5O6yMEZmqxweWYfslUI2KVNneJ2oUkfAkfulhGkQzxMSnTmf4psEZUMggdRTwzCKYmc~jFAPyrF-6Eie0w4UcaCIh1TQl7IQVCxPPm6cpyLEjeZScTtOTP1i-r9eeAexi82u5YhpvujwiwqBp7-1fAxZnlLWykbpNDgMA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f3_1599242849.75078.png?Expires=2147483647&Signature=vC7REVKVrVewZ4iwYV8PMOE7H6HIfVPfS-G9E7rhETAEFSFJUngO0gkFcoIQLbSYfS0gUGNEQW66G8F43sSyukMLxZfdY~9wqWXCgVBdxrygMEEIslUjf9pMiRssQcBLyfyDAu6JcIbMu9a~WJTfL44Q8hM-tsuIp0Ji0XceBPrRmnelFbf--V~uGjGQ4TJ4c3oR3mgKWkpGA8uvz9gq2~yYyEaq9bf~mEQ~t6tb6eqsDdniG7JtGkuS3rsQIDagaiZAIk6~jbeps-NNHQsWMDwmqdcbuvrBOvTAxkmUPYXIWUpF~JWLLt8-5MVXU89yHsWYCToR8~AhGRW6oaIIbw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
  ],
  "articleSection": [
    "Introduction",
    "Methods",
    "Study Design and Participants",
    "Vaccine",
    "Outcomes",
    "Statistical Analysis",
    "Results",
    "Study Participants",
    "Safety Outcomes",
    "Immunogenicity Outcomes",
    "Discussion",
    "Limitations",
    "Conclusions",
    "Article Information"
  ],
  "keyWords": "vaccines, vaccines, inactivated, aluminum hydroxide, adverse effects, neutralising antibodies, interim analysis, immunogenicity, sars-cov-2, covid19 (disease), covid-19 vaccines, antibody formation, immunologic adjuvants, pharmaceutical adjuvants, china, vaccination"
}
</script>
<meta name="citation_author" content="Shengli Xia" /><meta name="citation_author_institution" content="Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China" /><meta name="citation_author" content="Kai Duan" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Yuntao Zhang" /><meta name="citation_author_institution" content="China National Biotec Group Company Limited, Beijing, China" /><meta name="citation_author" content="Dongyang Zhao" /><meta name="citation_author_institution" content="Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China" /><meta name="citation_author" content="Huajun Zhang" /><meta name="citation_author_institution" content="Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China" /><meta name="citation_author" content="Zhiqiang Xie" /><meta name="citation_author_institution" content="Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China" /><meta name="citation_author" content="Xinguo Li" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Cheng Peng" /><meta name="citation_author_institution" content="Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China" /><meta name="citation_author" content="Yanbo Zhang" /><meta name="citation_author_institution" content="Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (Incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China" /><meta name="citation_author" content="Wei Zhang" /><meta name="citation_author_institution" content="Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China" /><meta name="citation_author" content="Yunkai Yang" /><meta name="citation_author_institution" content="China National Biotec Group Company Limited, Beijing, China" /><meta name="citation_author" content="Wei Chen" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Xiaoxiao Gao" /><meta name="citation_author_institution" content="Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China" /><meta name="citation_author" content="Wangyang You" /><meta name="citation_author_institution" content="Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China" /><meta name="citation_author" content="Xuewei Wang" /><meta name="citation_author_institution" content="China National Biotec Group Company Limited, Beijing, China" /><meta name="citation_author" content="Zejun Wang" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Zhengli Shi" /><meta name="citation_author_institution" content="Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China" /><meta name="citation_author" content="Yanxia Wang" /><meta name="citation_author_institution" content="Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China" /><meta name="citation_author" content="Xuqin Yang" /><meta name="citation_author_institution" content="China National Biotec Group Company Limited, Beijing, China" /><meta name="citation_author" content="Lianghao Zhang" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Lili Huang" /><meta name="citation_author_institution" content="Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China" /><meta name="citation_author" content="Qian Wang" /><meta name="citation_author_institution" content="China National Biotec Group Company Limited, Beijing, China" /><meta name="citation_author" content="Jia Lu" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Yongli Yang" /><meta name="citation_author_institution" content="Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China" /><meta name="citation_author" content="Jing Guo" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Wei Zhou" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Xin Wan" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Cong Wu" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Wenhui Wang" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Shihe Huang" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Jianhui Du" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Ziyan Meng" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="An Pan" /><meta name="citation_author_institution" content="Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (Incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China" /><meta name="citation_author_institution" content="National Medical Center for Major Public Health Events, Huazhong University of Science and Technology, Wuhan, Hubei, China" /><meta name="citation_author" content="Zhiming Yuan" /><meta name="citation_author_institution" content="Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China" /><meta name="citation_author" content="Shuo Shen" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author" content="Wanshen Guo" /><meta name="citation_author_institution" content="Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China" /><meta name="citation_author" content="Xiaoming Yang" /><meta name="citation_author_institution" content="National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China" /><meta name="citation_author_institution" content="China National Biotec Group Company Limited, Beijing, China" /><meta name="citation_title" content="Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials" /><meta name="citation_firstpage" content="951" /><meta name="citation_lastpage" content="960" /><meta name="citation_doi" content="10.1001/jama.2020.15543" /><meta name="citation_keyword" content="vaccines" /><meta name="citation_keyword" content="vaccines, inactivated" /><meta name="citation_keyword" content="aluminum hydroxide" /><meta name="citation_keyword" content="adverse effects" /><meta name="citation_keyword" content="neutralizing antibodies" /><meta name="citation_keyword" content="interim analysis" /><meta name="citation_keyword" content="immunogenicity" /><meta name="citation_keyword" content="sars-cov-2" /><meta name="citation_keyword" content="covid-19" /><meta name="citation_keyword" content="covid-19 vaccines" /><meta name="citation_keyword" content="antibody formation" /><meta name="citation_keyword" content="immunologic adjuvants" /><meta name="citation_keyword" content="pharmaceutical adjuvants" /><meta name="citation_keyword" content="china" /><meta name="citation_keyword" content="vaccination" /><meta name="citation_abstract" content="&lt;h3&gt;Importance&lt;/h3&gt;&lt;p&gt;A vaccine against coronavirus disease 2019 (COVID-19) is urgently needed.&lt;/p&gt;&lt;h3&gt;Objective&lt;/h3&gt;&lt;p&gt;To evaluate the safety and immunogenicity of an investigational inactivated whole-virus COVID-19 vaccine in China.&lt;/p&gt;&lt;h3&gt;Interventions&lt;/h3&gt;&lt;p&gt;In the phase 1 trial, 96 participants were assigned to 1 of the 3 dose groups (2.5, 5, and 10 Î¼g/dose) and an aluminum hydroxide (alum) adjuvantâ€“only group (nâ€‰=â€‰24 in each group), and received 3 intramuscular injections at days 0, 28, and 56. In the phase 2 trial, 224 adults were randomized to 5 Î¼g/dose in 2 schedule groups (injections on days 0 and 14 [nâ€‰=â€‰84] vs alum only [nâ€‰=â€‰28], and days 0 and 21 [nâ€‰=â€‰84] vs alum only [nâ€‰=â€‰28]).&lt;/p&gt;&lt;h3&gt;Design, Setting, and Participants&lt;/h3&gt;&lt;p&gt;Interim analysis of ongoing randomized, double-blind, placebo-controlled, phase 1 and 2 clinical trials to assess an inactivated COVID-19 vaccine. The trials were conducted in Henan Province, China, among 96 (phase 1) and 224 (phase 2) healthy adults aged between 18 and 59 years. Study enrollment began on April 12, 2020. The interim analysis was conducted on June 16, 2020, and updated on July 27, 2020.&lt;/p&gt;&lt;h3&gt;Main Outcomes and Measures&lt;/h3&gt;&lt;p&gt;The primary safety outcome was the combined adverse reactions 7 days after each injection, and the primary immunogenicity outcome was neutralizing antibody response 14 days after the whole-course vaccination, which was measured by a 50% plaque reduction neutralization test against live severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).&lt;/p&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;p&gt;Among 320 patients who were randomized (mean age, 42.8 years; 200 women [62.5%]), all completed the trial up to 28 days after the whole-course vaccination. The 7-day adverse reactions occurred in 3 (12.5%), 5 (20.8%), 4 (16.7%), and 6 (25.0%) patients in the alum only, low-dose, medium-dose, and high-dose groups, respectively, in the phase 1 trial; and in 5 (6.0%) and 4 (14.3%) patients who received injections on days 0 and 14 for vaccine and alum only, and 16 (19.0%) and 5 (17.9%) patients who received injections on days 0 and 21 for vaccine and alum only, respectively, in the phase 2 trial. The most common adverse reaction was injection site pain, followed by fever, which were mild and self-limiting; no serious adverse reactions were noted. The geometric mean titers of neutralizing antibodies in the low-, medium-, and high-dose groups at day 14 after 3 injections were 316 (95% CI, 218-457), 206 (95% CI, 123-343), and 297 (95% CI, 208-424), respectively, in the phase 1 trial, and were 121 (95% CI, 95-154) and 247 (95% CI, 176-345) at day 14 after 2 injections in participants receiving vaccine on days 0 and 14 and on days 0 and 21, respectively, in the phase 2 trial. There were no detectable antibody responses in all alum-only groups.&lt;/p&gt;&lt;h3&gt;Conclusions and Relevance&lt;/h3&gt;&lt;p&gt;In this interim report of the phase 1 and phase 2 trials of an inactivated COVID-19 vaccine, patients had a low rate of adverse reactions and demonstrated immunogenicity; the study is ongoing. Efficacy and longer-term adverse event assessment will require phase 3 trials.&lt;/p&gt;&lt;h3&gt;Trial Registration&lt;/h3&gt;&lt;p&gt;Chinese Clinical Trial Registry Identifier:ChiCTR2000031809&lt;/p&gt;" /><meta name="citation_journal_title" content="JAMA" /><meta name="citation_journal_abbrev" content="JAMA" /><meta name="citation_volume" content="324" /><meta name="citation_issue" content="10" /><meta name="citation_publication_date" content="2020/09/08" /><meta name="citation_issn" content="0098-7484" /><meta name="citation_publisher" content="American Medical Association" /><meta name="citation_reference" content="World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Accessed July 30, 2020. https://covid19.who.int/ " /><meta name="citation_reference" content="World Health Organization. Draft landscape of COVID-19 candidate vaccines. Accessed July 30, 2020. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines " /><meta name="citation_reference" content="citation_title=Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.; citation_author=Zhu  FC; citation_author=Li  YH; citation_author=Guan  XH;  citation_journal_title=Lancet;  citation_year=2020;  citation_volume=395;  citation_issue=10240;  citation_pages=1845-1854; " /><meta name="citation_reference" content="citation_title=Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.; citation_author=Zhu  FC; citation_author=Guan  XH; citation_author=Li  YH;  citation_journal_title=Lancet; " /><meta name="citation_reference" content="Sahin U,Muik A,Derhovanessian E,. Concurrent human antibody and T H 1 type T-cell responses elicited by a COVID-19 RNA vaccine. medRxiv. Preprint posted July 20, 2020. doi: 10.1101/2020.07.17.20140533 " /><meta name="citation_reference" content="Mulligan MJ,Lyke KE,Kitchin N,. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. medRxiv. Preprint posted July 1, 2020. doi: 10.1101/2020.06.30.20142570 " /><meta name="citation_reference" content="citation_title=An mRNA vaccine against SARS-CoV-2 - preliminary report.; citation_author=mRNA-1273 Study Group; citation_author=Jackson  LA; citation_author=Anderson  EJ; citation_author=Rouphael  NG;  citation_journal_title=N Engl J Med; " /><meta name="citation_reference" content="citation_title=Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.; citation_author=Oxford COVID Vaccine Trial Group; citation_author=Folegatti  PM; citation_author=Ewer  KJ; citation_author=Aley  PK;  citation_journal_title=Lancet; " /><meta name="citation_reference" content="citation_title=Key steps in vaccine development.; citation_author=Stern  PL;  citation_journal_title=Ann Allergy Asthma Immunol;  citation_year=2020;  citation_volume=125;  citation_issue=1;  citation_pages=17-27; " /><meta name="citation_reference" content="citation_title=Development of an inactivated vaccine candidate for SARS-CoV-2.; citation_author=Gao  Q; citation_author=Bao  L; citation_author=Mao  H;  citation_journal_title=Science;  citation_year=2020;  citation_volume=369;  citation_issue=6499;  citation_pages=77-81; " /><meta name="citation_reference" content="citation_title=Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2.; citation_author=Wang  H; citation_author=Zhang  Y; citation_author=Huang  B;  citation_journal_title=Cell; " /><meta name="citation_reference" content="citation_title=Effectiveness of convalescent plasma therapy in severe COVID-19 patients.; citation_author=Duan  K; citation_author=Liu  B; citation_author=Li  C;  citation_journal_title=Proc Natl Acad Sci U S A;  citation_year=2020;  citation_volume=117;  citation_issue=17;  citation_pages=9490-9496; " /><meta name="citation_reference" content="citation_title=Antibody responses to SARS-CoV-2 in patients with COVID-19.; citation_author=Long  QX; citation_author=Liu  BZ; citation_author=Deng  HJ;  citation_journal_title=Nat Med;  citation_year=2020;  citation_volume=26;  citation_issue=6;  citation_pages=845-848; " /><meta name="citation_reference" content="Luchsinger LL,Ransegnola B,Jin D,. Serological analysis of New York City COVID19 convalescent plasma donors. medRxiv. Preprint posted June 9, 2020. doi: 10.1101/2020.06.08.20124792 " /><meta name="citation_reference" content="citation_title=Convergent antibody responses to SARS-CoV-2 in convalescent individuals.; citation_author=Robbiani  DF; citation_author=Gaebler  C; citation_author=Muecksch  F;  citation_journal_title=Nature; " /><meta name="citation_reference" content="citation_title=Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients.; citation_author=Wang  X; citation_author=Guo  X; citation_author=Xin  Q;  citation_journal_title=Clin Infect Dis; " /><meta name="citation_reference" content="Wu F,Wang A,Liu M,. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv. Preprint posted April 20, 2020. doi: 10.1101/2020.03.30.20047365 " /><meta name="citation_reference" content="citation_title=Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.; citation_author=Zhao  J; citation_author=Yuan  Q; citation_author=Wang  H;  citation_journal_title=Clin Infect Dis; " /><meta name="citation_reference" content="Liu T,Wu S,Tao H,. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan: implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2. medRxiv. Preprint posted June 16, 2020. doi: 10.1101/2020.06.13.20130252 " /><meta name="citation_reference" content="citation_title=Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.; citation_author=Long  QX; citation_author=Tang  XJ; citation_author=Shi  QL;  citation_journal_title=Nat Med; " /><meta name="citation_reference" content="citation_title=Rapid decay of antiâ€“SARS-CoV-2 antibodies in persons with mild Covid-19.; citation_author=Ibarrondo  FJ; citation_author=Fulcher  JA; citation_author=Goodman-Meza  D;  citation_journal_title=N Engl J Med; " /><meta name="citation_reference" content="citation_title=Disappearance of antibodies to SARS-associated coronavirus after recovery.; citation_author=Cao  WC; citation_author=Liu  W; citation_author=Zhang  PH; citation_author=Zhang  F; citation_author=Richardus  JH;  citation_journal_title=N Engl J Med;  citation_year=2007;  citation_volume=357;  citation_issue=11;  citation_pages=1162-1163; " /><meta name="citation_reference" content="citation_title=Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.; citation_author=Lin  JT; citation_author=Zhang  JS; citation_author=Su  N;  citation_journal_title=Antivir Ther;  citation_year=2007;  citation_volume=12;  citation_issue=7;  citation_pages=1107-1113; " /><meta name="citation_reference" content="citation_title=A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial.; citation_author=VRC 301 Study Team; citation_author=Martin  JE; citation_author=Louder  MK; citation_author=Holman  LA;  citation_journal_title=Vaccine;  citation_year=2008;  citation_volume=26;  citation_issue=50;  citation_pages=6338-6343; " /><meta name="citation_reference" content="citation_title=SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.; citation_author=Le Bert  N; citation_author=Tan  AT; citation_author=Kunasegaran  K;  citation_journal_title=Nature; " /><meta name="citation_reference" content="citation_title=Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.; citation_author=Eroshenko  N; citation_author=Gill  T; citation_author=Keaveney  MK; citation_author=Church  GM; citation_author=Trevejo  JM; citation_author=Rajaniemi  H;  citation_journal_title=Nat Biotechnol;  citation_year=2020;  citation_volume=38;  citation_issue=7;  citation_pages=789-791; " /><meta name="citation_reference" content="citation_title=Rapid COVID-19 vaccine development.; citation_author=Graham  BS;  citation_journal_title=Science;  citation_year=2020;  citation_volume=368;  citation_issue=6494;  citation_pages=945-946; " /><meta name="citation_reference" content="citation_title=Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.; citation_author=Corbett  KS; citation_author=Flynn  B; citation_author=Foulds  KE;  citation_journal_title=N Engl J Med; " /><meta name="citation_reference" content="citation_title=SARS-CoV-2 infection protects against rechallenge in rhesus macaques.; citation_author=Chandrashekar  A; citation_author=Liu  J; citation_author=Martinot  AJ;  citation_journal_title=Science; " /><meta name="citation_reference" content="citation_title=Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.; citation_author=Deng  W; citation_author=Bao  L; citation_author=Liu  J;  citation_journal_title=Science; " /><meta name="citation_reference" content="citation_title=Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated measles virus vaccines.; citation_author=Fulginiti  VA; citation_author=Eller  JJ; citation_author=Downie  AW; citation_author=Kempe  CH;  citation_journal_title=JAMA;  citation_year=1967;  citation_volume=202;  citation_issue=12;  citation_pages=1075-1080; " /><meta name="citation_reference" content="citation_title=Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.; citation_author=Kim  HW; citation_author=Canchola  JG; citation_author=Brandt  CD;  citation_journal_title=Am J Epidemiol;  citation_year=1969;  citation_volume=89;  citation_issue=4;  citation_pages=422-434; " /><meta name="citation_reference" content="citation_title=COVID-19 vaccine design: the Janus face of immune enhancement.; citation_author=Hotez  PJ; citation_author=Corry  DB; citation_author=Bottazzi  ME;  citation_journal_title=Nat Rev Immunol;  citation_year=2020;  citation_volume=20;  citation_issue=6;  citation_pages=347-348; " /><meta name="citation_reference" content="citation_title=COVID-19 vaccines: neutralizing antibodies and the alum advantage.; citation_author=Hotez  PJ; citation_author=Corry  DB; citation_author=Strych  U; citation_author=Bottazzi  ME;  citation_journal_title=Nat Rev Immunol;  citation_year=2020;  citation_volume=20;  citation_issue=7;  citation_pages=399-400; " /><meta name="citation_fulltext_world_readable" content="" /><meta name="citation_pdf_url" content="https://jamanetwork.com/journals/jama/articlepdf/2769612/jama_xia_2020_pc_200005_1599242849.34452.pdf" />

    
        <title>Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials | Global Health | JAMA | JAMA Network</title>

    <meta name="description" content="This interim analysis of 2 randomized trials compares adverse reactions and neutralizing antibody responses to inactivated coronavirus disease 2019">


    <link rel="canonical" href="https://jamanetwork.com/journals/jama/fullarticle/2769612" />









    
    <script src="//cdn.jamanetwork.com/UI/app/dist/head.min.js?v=638488852268208351"></script>
     
     <script src="https://r451.jamanetwork.com/script.js"></script>
        <div class="widget-WidgetLoader widget-instance-AMA_AdTag_HeaderScript">
        
    <meta class="SCM-SharedWidgets-AsyncHeaderAdLoader" data-url="/AMA/AdTag/AMA_AdTag_HeaderScript" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:0,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}">
 
    </div>
</head>

<body data-sitename="jama" class="pg_article " data-thm="jama">
    
    <script>
        
        var App = App || {};
        App.suppressAds = App.suppressAds || !!document.getElementsByClassName('suppress-ads').length;
        App.suppressGtm = App.suppressGtm || !!document.getElementsByClassName('suppress-gtm').length;
    </script>

    

        <div id="ad-interstitial" class="ad-interstitial">
            <script>
      googletag.cmd.push(function() {
        if (App.suppressAds) { return; }
        App.Ads.slots[13] = googletag.defineOutOfPageSlot(App.Ads.adPath + '/scholarly', 'ad-interstitial')
          .setTargeting('pos', ['interstitial'])
          .addService(googletag.pubads());
        googletag.display('ad-interstitial');
        googletag.pubads().refresh([App.Ads.slots[13]], {changeCorrelator: false});
      });
            </script>
        </div>




    
    <a class="accessible js-skip-to-navigation" href="#skip-to-navigation">[Skip to Navigation]</a>

    <!-- Google Tag Manager --><noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-WNKSNP" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-WNKSNP');</script><!-- End Google Tag Manager -->

    
    
    <span class="hide tagmanagervalue" data-attribute="productName" data-value="JAMA" data-type="string"></span>
    <form method="post" action="./2769612" id="webform" class="m0">
<input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="LzVeKZ85NMd/6BQ4RXHOmpYQuM3xKgtuJiIAeqmFPPHrPN66vhObhZk/Q1AVlWsJrYxTrWiQWn9aqulRIaiM2nMLK4U=" />

<input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="2173C2F0" />
<input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="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" />
        
        <input id="hdnSiteID" type="hidden" value="3" />
        <input id="hdnDomain" type="hidden" value=".jamanetwork.com" />

        
        

        
        

    <section class="master-header">
        


<script type='text/javascript'>
    var App = App || {};
    App.LoginUserInfo = {
        isInstLoggedIn: [0],
        currentSessionId: 'jvjlj2etm55fmm2olk1jer35'
    };
</script>



<input name="ctl00$ctl00$BodyContent$Header$hfGlobalSearchSiteURL" type="hidden" id="hfGlobalSearchSiteURL" value="https://jamanetwork.com/" />

<input name="ctl00$ctl00$BodyContent$Header$hfAppIsPaidUser" type="hidden" id="hfAppIsPaidUser" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsMember" type="hidden" id="hfAppIsMember" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppSubscribedTo" type="hidden" id="hfAppSubscribedTo" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsIndividual" type="hidden" id="hfAppIsIndividual" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppHasAccess" type="hidden" id="hfAppHasAccess" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsReferredFromGoogle" type="hidden" id="hfAppIsReferredFromGoogle" value="False" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrAutoSuggestMinimumCharactersLength" type="hidden" id="hfSolrAutoSuggestMinimumCharactersLength" value="2" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalName" type="hidden" id="hfSolrJournalName" value="JAMA" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalID" type="hidden" id="hfSolrJournalID" value="J67" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsLucy" type="hidden" id="hfAppIsLucy" value="false" />


<div class="header-wrap">
    <header class="header">
            <div class="widget-GdprCookieBanner widget-instance-GdprCookieBanner">
        <div class="gdpr-cookie-wrapper js-gdpr-banner">
	<div class="gdpr-cookie-body">
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our <a href="https://jamanetwork.com/pages/privacy-policy#cookies">Cookie Policy</a>&nbsp;<span class="pipe">|</span>&nbsp;<a href="javascript:;" class="js-gdpr-cookie-acceptLink at-acceptgdpr">Continue</a>	</div>
            <input id="hdnDomain" type="hidden" value=".jamanetwork.com" />

    <input id="hdnDomainGdpr" type="hidden" value=".jamanetwork.com" />
    <input id="hdnClientIdGdpr" type="hidden" value="3" />

</div> 
    </div>

        <div class="network-bar">
            <a class="jama-network" href="/" title="JAMA Network Home">
                <img alt="JAMA Network Home" class="title-image" width="443" height="52" src="//cdn.jamanetwork.com/UI/app/svg/Jama_Network_Logo.svg">
            </a>
            
        </div>

        <a class="nav-toggler" href="#nav">
            <div class="nav-toggler-indicator">
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
            </div>
            <div class="nav-toggler-site">
                <span id="BodyContent_Header_siteFullNamenav" class="nav-toggler-microsite"><span class='network'>JAMA</span></span>
            </div>
        </a>
        <nav id="nav" class="nav hide" >
            <div class="nav-journal-level sb-nav-journal-level">
                <a href="https://jamanetwork.com/journals/jama" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_0" class="home">Home</a><a href="https://jamanetwork.com/journals/jama/newonline" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_1" class="new-online">New Online</a><a href="https://jamanetwork.com/journals/jama/currentissue" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_2" class="current-issue">Current Issue</a><a href="https://jamanetwork.com/journals/jama/pages/for-authors" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_3" class="for-authors">For Authors</a>
            </div>
            <div class="nav-journals">
                    <div class="widget-SelfServeContent widget-instance-HamburgerPublicationMenu">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="HamburgerPublicationMenu" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .nav-journals {margin-bottom: 1em;}
    .nav-heading {color: #B9B9B9;border-bottom: 1px solid #242424;border-top: 1px solid #242424;font-size: 1.15em;font-weight: 400;margin: 0;padding: .7em .75em;text-transform: uppercase;}
    a.no-bullet:before {content:none !important;}
    .nav-heading {font-size: 1.15em;margin-bottom:0;padding-left: 38px;}
    .nav-journals a.theme-jama {background-color: #242424;border-bottom: 1px solid #fff;border-top: 1px solid #fff;color: #fff;font-size: 1.15em;margin-bottom: 8px;padding: 11px 0 9px 37px;}
    .nav-journals a.theme-jama::before {background: unset;content: "\e91b";display: none;font-family: ama_icons !important;font-size: 1.25em;line-height: 1;}
    .nav-journals a.theme-jama-network-open {border-bottom:0;}
    .nav .widget-instance-HamburgerPublicationMenu a {padding-left: 36px;}
    .fake-ribbon {border-left: 8px solid #BE1E32;}
    .fake-ribbon a:before {content:none;}
    .nav .widget-instance-HamburgerPublicationMenu .fake-ribbon a {padding-left:30px;}
</style>
<h2 class="nav-heading">Journals</h2>
<a href="/journals/jama" class="theme-jama">JAMA</a>
<a href="/journals/jamanetworkopen" class="theme-jama-network-open">JAMA Network Open</a>
<a href="/journals/jamacardiology" class="theme-jama-cardiology">JAMA Cardiology</a>
<a href="/journals/jamadermatology" class="theme-jama-dermatology">JAMA Dermatology</a>
<a href="/journals/jama-health-forum" class="theme-jama-health-forum">JAMA Health Forum</a>
<a href="/journals/jamainternalmedicine" class="theme-jama-internal-medicine">JAMA Internal Medicine</a>
<a href="/journals/jamaneurology" class="theme-jama-neurology">JAMA Neurology</a>
<a href="/journals/jamaoncology" class="theme-jama-oncology">JAMA Oncology</a>
<a href="/journals/jamaophthalmology" class="theme-jama-ophthalmology">JAMA Ophthalmology </a>
<a href="/journals/jamaotolaryngology" class="theme-jama-otolaryngology-head-neck-surgery">JAMA Otolaryngologyâ€“Head &amp; Neck Surgery</a>
<a href="/journals/jamapediatrics" class="theme-jama-pediatrics">JAMA Pediatrics</a>
<a href="/journals/jamapsychiatry" class="theme-jama-psychiatry">JAMA Psychiatry</a>
<a href="/journals/jamasurgery" class="theme-jama-surgery">JAMA Surgery</a>
<a href="/journals/archneurpsyc" class="theme-archives-of-neurology-psychiatry-1919-1959-">Archives of Neurology &amp; Psychiatry (1919-1959)</a>
<h2 class="nav-heading">Podcasts</h2>
<a href="/journals/jama/pages/jama-clinical-reviews">Clinical Reviews</a>
<a href="/journals/jama/pages/jama-editors-summary">Editors' Summary</a>
<a href="/journals/jama/pages/jama-medical-news">Medical News</a>
<a href="/journals/jama/pages/jama-author-interviews">Author Interviews</a>
<a href="/pages/audio" class="no-bullet">More</a>


</div>

 
    </div>
    
            </div>
            <div class="nav-network-other">
                <a href="https://edhub.ama-assn.org/jn-learning" id="BodyContent_Header_rptOtherResources_aItemResourceList_0" class="is-b link-jn-learning-cme" target="_blank">JN Learning / CME</a><a href="https://store.jamanetwork.com/index.aspx?productcode=64" id="BodyContent_Header_rptOtherResources_aItemResourceList_1" class="is-b link-subscribe" target="_blank">Subscribe</a><a href="https://careers.jamanetwork.com/" id="BodyContent_Header_rptOtherResources_aItemResourceList_2" class="is-b link-jobs" target="_blank">Jobs</a><a href="https://jamanetwork.com/pages/resources-for-librarians" id="BodyContent_Header_rptOtherResources_aItemResourceList_3" class="is-b link-institutions-librarians">Institutions / Librarians</a><a href="https://jamanetwork.com/pages/reprints-and-permissions" id="BodyContent_Header_rptOtherResources_aItemResourceList_4" class="is-b link-reprints-permissions" rel="nofollow">Reprints &amp; Permissions</a>
            </div>
            <div class="white text-xxs">
                <div class="p05 ml4 mr3 mb1 mt10 flex hamburger-menu-legal">
                    <a href="/pages/conditions-of-use" class="p0" rel="nofollow">Terms of Use</a>
                    <span class="pl1 pr1">| </span>
                    <a href="/pages/privacy-policy" class="p0" rel="nofollow">Privacy Policy</a>
                    <span class="pl1 pr1">| </span>
                    <a href="/pages/accessibility-statement" class="p0" rel="nofollow">Accessibility Statement</a>
                </div>
                <div class="ta-c">
                    <span class="pb1">2024 American Medical Association. All Rights Reserved</span>
                </div>
            </div>
        </nav>

        

        
        <a class="toolbar-search-trigger is-b" data-mobile-tog-target=".site-search"></a>

        
        <div id="site-search" role="search" class="site-search">
            <div class="site-search-bar">
                
                <div role="search">
                    <select name="ctl00$ctl00$BodyContent$Header$ddlForSearch" id="BodyContent_Header_ddlForSearch" Name="dropDownList" class="cs-select cs-skin-border" title="Search Site Selector" role="options" aria-labelledby="searchLabel">
	<option value="J*">Search All</option>
	<option value="3">JAMA</option>
	<option value="214">JAMA Network Open</option>
	<option value="192">JAMA Cardiology</option>
	<option value="12">JAMA Dermatology</option>
	<option value="261">JAMA Forum Archive</option>
	<option value="193">JAMA Health Forum</option>
	<option value="15">JAMA Internal Medicine</option>
	<option value="16">JAMA Neurology</option>
	<option value="159">JAMA Oncology</option>
	<option value="17">JAMA Ophthalmology</option>
	<option value="18">JAMA Otolaryngologyâ€“Head &amp; Neck Surgery</option>
	<option value="19">JAMA Pediatrics</option>
	<option value="14">JAMA Psychiatry</option>
	<option value="20">JAMA Surgery</option>
	<option value="23">Archives of Neurology &amp; Psychiatry</option>

</select>
                </div>
                
                <div class="search-input-container">
                    <input type="search" name="textbox" autocomplete="off" role="textbox" id="search-term" aria-labelledby="searchLabel" class="search-term at-microsite-search-term" placeholder="Enter Search Term" maxlength="255" title="Enter Search Term">
                  
                    <ul id="umbrellaSiteAutoCompleteResults" class="term-list hidden"></ul>
                    
                    <label style="display:none" for="umbrellaSiteSearchInputHint" id="searchLabel">Input Search Term</label>
                      <input class="searchTerm search-input" name="textbox" role="textbox" type="text" id="umbrellaSiteSearchInputHint" aria-labelledby="searchLabel" title="Input Search Term" autocomplete="off">
                </div>
                <!-- /.search-input-container -->
                
                <a name="button" role="button" class="search-button is-b" alt="search button" href="javascript:;"></a>
            </div>
        </div>
        
        <div id="BodyContent_Header_GlobalSignIn_auth" class="auth">
            <a class="auth--trigger is-b is-a" href="javascript:;">
                <span id="BodyContent_Header_GlobalSignIn_spnUserFullName" class="user-full-name">Sign In</span>
            </a>

            <div class="auth--dropdown js-signIn-dropdown">
                
                <div class="auth--option auth--ind">
                    
                    <div id="BodyContent_Header_GlobalSignIn_divUserFullName" class="auth--ind-user"></div>                    
                    
                    <div id="BodyContent_Header_GlobalSignIn_divIndSignIn" class="auth--ind-auth">
                        <div class="auth--title">Individual Sign In</div>
                        <a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2769612" id="BodyContent_Header_GlobalSignIn_oauthSignInLink" rel="nofollow" class="auth--ind-sign-in">Sign in</a><a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2769612" id="BodyContent_Header_GlobalSignIn_oauthSignUpLink" rel="nofollow" class="auth--ind-create">Create an Account</a>
                    </div>
                </div>

                
                <div id="BodyContent_Header_GlobalSignIn_divInstSignIn" class="auth--option auth--inst">

                    
                    
                    <div class="auth--inst-auth">
                        <div class="auth--title">Access through your institution</div>
                        <a href="/signinshibboleth?returnUrl=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2769612" id="BodyContent_Header_GlobalSignIn_institutionSignIn" rel="nofollow" class="auth--shib">Sign In</a>
                    </div>
                    </div>
 
                                               
                <div id="BodyContent_Header_GlobalSignIn_divPurchaseOptions" class="auth--option auth--purchase">
                    <div class="auth--title">Purchase Options:</div>
                    
                    <a id="BodyContent_Header_GlobalSignIn_lnkSubscribeJournal" class="auth--subscribe" rel="nofollow" href="https://store.jamanetwork.com/index.aspx?productcode=64">Subscribe to the JAMA journal</a>
                </div>

                
                

                
            </div>
        </div>




    </header>
</div>


<div class="editors-choice-header">
</div>

<div id="BodyContent_Header_divAds" class="header-ad-wrap sb-background-primary-dark">
        <div class="leader-ad desktop-only">
            
                <div class="widget-WidgetLoader widget-instance-AMA_AdTag_LeaderboardAd">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_LeaderboardAd" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:1,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;atf&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

        </div>
    </div>

<!-- /.header-ad-wrap -->


    </section>


    <section class="master-main">
        
    <div class="social-share hide" data-share-journal="JAMA_current" data-share-title="Adverse Reactions and Antibody Responses to an Inactivated SARS-CoV-2 Vaccineâ€”Interim Trial Analyses"></div>

        <div class="widget-UserContentAccessWrite widget-instance-AMA_LocalStorage_Article">
        <div class="SCM-SharedWidgets-LocalStorage-UserContentAccessWrite" data-values='{"id":"2769612","type":"Article","date":"5/5/2024 5:42:30 AM"}'></div>
 
    </div>
    <div class="widget-ArticleToggleView widget-instance-AMA_ArticleToggleView">
        
    <div class="widget-ArticleFullView widget-instance-AMA_ArticleFullView">
        
<script>
    (function () {
        var bodyElem = document.querySelector('body');
        var className = 'split-screen';

        if (bodyElem.classList) {
            bodyElem.classList.add(className);
        } else {
            el.className += ' ' + className;
        }
    })();
</script>


<div id="resources-panel" class="resources-panel">
                <span class="hide tagmanagervalue" data-attribute="template" data-value="splitscreen" data-type="string"></span>


    <div class="tab-nav">
        <a class="tab-nav-trigger tab-nav-full-text tablet-down" href="#full-text-tab">
            <i class="icon-full_text"><span class="sr-t">full text icon</span></i>
            <div class="tab-nav-tab-name">Full Text</div>
        </a>
        <a class="tab-nav-trigger tab-nav-contents target-tab-active" href="#contents-tab">
            <i class="icon-contents"><span class="sr-t">contents icon</span></i>
            <div class="tab-nav-tab-name">Contents</div>
        </a>
        <a class="tab-nav-trigger tab-nav-figure-table" href="#figure-table-tab">
            <i class="icon-figures"><span class="sr-t">figure icon</span></i>
            <div class="tab-nav-tab-name">Figures / <br> Tables</div>
        </a>
        <a class="tab-nav-trigger tab-nav-multimedia" href="#multimedia-tab">
            <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i>
            <div class="tab-nav-tab-name">Multimedia</div>
        </a>
        <a class="tab-nav-trigger tab-nav-supplemental" href="#supplemental-tab">
            <i class="icon-attach"><span class="sr-t">attach icon</span></i>
            <div class="tab-nav-tab-name">Supplemental <br> Content</div>
        </a>
        <a class="tab-nav-trigger tab-nav-references" href="#references-tab">
            <i class="icon-references"><span class="sr-t">references icon</span></i>
            <div class="tab-nav-tab-name">References</div>
        </a>
        <a class="tab-nav-trigger tab-nav-related" href="#related-tab">
            <i class="icon-related"><span class="sr-t">related icon</span></i>
            <div class="tab-nav-tab-name">Related</div>
        </a>
        <a class="tab-nav-trigger tab-nav-comments" href="#comments-tab">
            <i class="icon-user-comments"><span class="sr-t">comments icon</span></i>
            <div class="tab-nav-tab-name">Comments</div>
        </a>
    </div>



    <div class="resource-tabs">
        <div id="contents-tab" class="resource-tab js-resource-tab contents-tab tab-active">
            <div class="contents-tab-contents">
            <a id="pdf-link" class="toolbar-tool toolbar-pdf al-link pdfaccess" data-article-id="2769612" data-article-url="/journals/jama/articlepdf/2769612/jama_xia_2020_pc_200005_1599242849.34452.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span>
            </a>
    <div class="widget-ArticleJumpLinks widget-instance-AMA_ArticleJumpLinks_Widget">
            <a href="#top" class="section-jump-link contents-tab-jump-link top-of-article" data-tab-toggle=".tab-nav-full-text">Top of Article</a>
    <ul class="section-jump-links bullet ml2 pl1">
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#247319348" data-tab-toggle=".tab-nav-full-text">Key Points</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#247319349" data-tab-toggle=".tab-nav-full-text">Abstract</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#247319354" data-tab-toggle=".tab-nav-full-text">Introduction</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#247319358" data-tab-toggle=".tab-nav-full-text">Methods</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#247319374" data-tab-toggle=".tab-nav-full-text">Results</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#247319389" data-tab-toggle=".tab-nav-full-text">Discussion</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#247319401" data-tab-toggle=".tab-nav-full-text">Conclusions</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#247319403" data-tab-toggle=".tab-nav-full-text">Article Information</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#247319404" data-tab-toggle=".tab-nav-full-text">References</a></li>
    </ul>
 
    </div>
    <div class="widget-SelfServeContent widget-instance-AMA_Contents_Tab_SelfServe">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="v2_article_content_tab" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="bc_right_rail_article_promo"><!-- Content Goes Here --></div>


</div>

 
    </div>

            </div>
            <div class="contents-tab-ad">
                <div id="split-screen-contab"></div>
            </div>
        </div>

        
        <div id="figure-table-tab" class="resource-tab js-resource-tab figure-table-tab need-jobs-ad">
    <div class="widget-ArticleFiguresAndTables widget-instance-AMA_Article_Figures_Tab">
        <div class="figure-table-wrapper thm-bd-top"><div class="figure-label">Figure 1. Â Screening, Randomization, and Inclusion in Safety and Immunogenicity Analyses of Inactivated Vaccine for SARS-CoV-2</div><a id="jpc200005f1" class="figure-table-anchor"></a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="jpc200005f1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f1_1599242849.65703.png?Expires=1717543792&amp;Signature=1CjaP4DDzT0bsrw-JLA6KqymSrNHFtHSFkWscN0nZigfkJgyRbGD5TxT7oKthCpIw96slzcRZ-Z5E3NltGg2tYfUftcqTx0rBrcN0XNU4SKmmjanptqWedR18hHp49IpomJu1V1pJCapOUl3a1MhHdpOn8bSDn0rVeyLnCn3e0hZLuaFwGrPeIjvG4j~1E7-lMYz2A25DmdTp~DcOJXaYI4gxomQUSid7M8L7KaItmVW5F8n2W4fABA2IRY2zU9JCzGxR3oeKDoBANUMd-z087O67R6-WDW6wD5O0QYCJfewyJQDFO7~MxKvSAj4jeX4-Aw4imSfUlhnHjAlCfEE3w__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="jpc200005f1" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f1_1599242849.65703.png?Expires=1717543792&Signature=1CjaP4DDzT0bsrw-JLA6KqymSrNHFtHSFkWscN0nZigfkJgyRbGD5TxT7oKthCpIw96slzcRZ-Z5E3NltGg2tYfUftcqTx0rBrcN0XNU4SKmmjanptqWedR18hHp49IpomJu1V1pJCapOUl3a1MhHdpOn8bSDn0rVeyLnCn3e0hZLuaFwGrPeIjvG4j~1E7-lMYz2A25DmdTp~DcOJXaYI4gxomQUSid7M8L7KaItmVW5F8n2W4fABA2IRY2zU9JCzGxR3oeKDoBANUMd-z087O67R6-WDW6wD5O0QYCJfewyJQDFO7~MxKvSAj4jeX4-Aw4imSfUlhnHjAlCfEE3w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=247319363&ar=2769612&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"></span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"></span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f1_1599242849.65703.png?Expires=1717543792&amp;Signature=1CjaP4DDzT0bsrw-JLA6KqymSrNHFtHSFkWscN0nZigfkJgyRbGD5TxT7oKthCpIw96slzcRZ-Z5E3NltGg2tYfUftcqTx0rBrcN0XNU4SKmmjanptqWedR18hHp49IpomJu1V1pJCapOUl3a1MhHdpOn8bSDn0rVeyLnCn3e0hZLuaFwGrPeIjvG4j~1E7-lMYz2A25DmdTp~DcOJXaYI4gxomQUSid7M8L7KaItmVW5F8n2W4fABA2IRY2zU9JCzGxR3oeKDoBANUMd-z087O67R6-WDW6wD5O0QYCJfewyJQDFO7~MxKvSAj4jeX4-Aw4imSfUlhnHjAlCfEE3w__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="jpc200005f1" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/m_jpc200005f1_1599242849.65703.png?Expires=1717543792&amp;Signature=45Nv4UT2jEoVezZOEzI5n0U6yFWsubhUZCAhIrC2lCFZuBsehtlMPDxicxJZGXyQduZbOPjYRlJfQ7ava6I1P-hdIQRm2o3~T~UJUe~n1tMAclQvPoTUzAMCyuNUXW0wMDlwLmH6GCbjdUph2nLl2uAGzIXL-wtZ4l6ZKL8FfzbFVEUsD676m~9oF931MbP6c8VWIvxHFQfzXpsKSaOq0HS8Gw9jzarcLs5gkdCDWEQ2yIEM5yD1p07Xpl1GZxHqshKTkWMn0FL3A69edAS436AVGhY2YuR0MD39v2CpXcj15Rk-r6fvQwkNsFCRX3rRCTGkIyQucxTHZg6y8FeZ5Q__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Screening, Randomization, and Inclusion in Safety and Immunogenicity Analyses of Inactivated Vaccine for SARS-CoV-2" class="content-img lazy" path-from-xml="jpc200005f1" /></a></div></div><div class="figure-caption clip-last-child"><p class="para"><sup>a</sup>Laboratory tests included routine blood tests, liver enzymes, total bilirubin, creatinine, urea nitrogen, urine protein, urine sugar, and urinary occult blood. Details of the list and definition of abnormal values are provided in the protocol in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 1</a>.</p><p class="para"><sup>b</sup>The comorbidities in the exclusion criteria included cardiovascular disease, cancer, respiratory disease, autoimmune disease, tuberculosis, severe liver disease, congenital malformation, mental illness, nervous system diseases, uncontrolled hypertension and diabetes, severe malnutrition, fever within 14 days, and other diseases that could affect participation and compliance in the trial as judged by the investigators.</p><p class="para"><sup>c</sup>The low, medium, and high doses represent 2.5, 5, and 10 Î¼g/dose, respectively.</p></div></div><div class="figure-table-wrapper thm-bd-top"><div class="figure-label">Figure 2. Â Antibody Responses at Different Time Points in the Phase 1 Trial</div><a id="jpc200005f2" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="jpc200005f2" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f2_1599242849.75078.png?Expires=1717543792&amp;Signature=Y6LJAvZ5A32qTFVQe01xGvoJBlf7LyPzQdIq1GBryvLTKUTw5dzTlz~L-0NjjqhAlmxFLvmCvNWLIGpC0o5znmZbdZknMznnpVYgzV0xaCzBTsj0--imNwv4-c8J1TwB5vsVaVLRy96ypvaDbf4xpvhR6obxYBFwIhP7ZEKkGCFvvaSIMebkKKjVaZMVRiapFNqF2qUOYNh2jg7nFVKau9g~70-98StJZ-bI88t2~Ej6T312OszQfn8TAO2wd5K~dW2hW7hxeFM2HRqjcYohTQiPa8lv6nybWZwhzCdpAF9lQySkhY36eBNes4P2vXmuzZREgd64-RsONFRWB~A~iQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="jpc200005f2" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f2_1599242849.75078.png?Expires=1717543792&Signature=Y6LJAvZ5A32qTFVQe01xGvoJBlf7LyPzQdIq1GBryvLTKUTw5dzTlz~L-0NjjqhAlmxFLvmCvNWLIGpC0o5znmZbdZknMznnpVYgzV0xaCzBTsj0--imNwv4-c8J1TwB5vsVaVLRy96ypvaDbf4xpvhR6obxYBFwIhP7ZEKkGCFvvaSIMebkKKjVaZMVRiapFNqF2qUOYNh2jg7nFVKau9g~70-98StJZ-bI88t2~Ej6T312OszQfn8TAO2wd5K~dW2hW7hxeFM2HRqjcYohTQiPa8lv6nybWZwhzCdpAF9lQySkhY36eBNes4P2vXmuzZREgd64-RsONFRWB~A~iQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=247319387&ar=2769612&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f2_1599242849.75078.png?Expires=1717543792&amp;Signature=Y6LJAvZ5A32qTFVQe01xGvoJBlf7LyPzQdIq1GBryvLTKUTw5dzTlz~L-0NjjqhAlmxFLvmCvNWLIGpC0o5znmZbdZknMznnpVYgzV0xaCzBTsj0--imNwv4-c8J1TwB5vsVaVLRy96ypvaDbf4xpvhR6obxYBFwIhP7ZEKkGCFvvaSIMebkKKjVaZMVRiapFNqF2qUOYNh2jg7nFVKau9g~70-98StJZ-bI88t2~Ej6T312OszQfn8TAO2wd5K~dW2hW7hxeFM2HRqjcYohTQiPa8lv6nybWZwhzCdpAF9lQySkhY36eBNes4P2vXmuzZREgd64-RsONFRWB~A~iQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="jpc200005f2" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/m_jpc200005f2_1599242849.75078.png?Expires=1717543792&amp;Signature=jbYYp0jnwELdH9D4G6xQJNIUHs2HuoR0vCi-Wi5E0T8FdgIFyxmJ3~Z5EgmF~KFiOUlDrO5mByGSJ1Rzor~v6tgIlAXgYwsYIPUZZevUiuzE12ObJP1H1mBOlHkcmDnXXm71MWotvd-N2tBojVa66XPAUW6fEgTlU-Er5prlOvertmTC0sOzuC9MB7hR9oq0PvMmJdFG32Z7qlQc6JW2Ad9dAzWQwze6BKOTMuKhBs4p2w3Y7HcO8KQY9mMXnfDKtGEyns6v3jd4QxNq3oXIWFayvv3xUNqoTNijx8ng-FE6PXNwRqGAlU6QPQXbn-BmffeRgyH9boeYOZ~xk2mf3Q__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Antibody Responses at Different Time Points in the Phase 1 Trial" class="content-img lazy" path-from-xml="jpc200005f2" /></a></div></div><div class="figure-caption clip-last-child"><p class="para">The dots represent individual participant values. Boxplots show the 25th, 50th (median), and 75th percentiles. Whiskers extend to the upper and lower adjacent values, the farthest values within 1.5â€‰Ã—â€‰the interquartile range beyond the 25th and 75th percentiles. The numbers below the boxes indicate the number of participants at the lowest measurable value. Alum indicates aluminum hydroxide; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.</p></div></div><div class="figure-table-wrapper thm-bd-top"><div class="figure-label">Figure 3. Â Antibody Responses 14 Days After the Second Dose in the Phase 2 Trial</div><a id="jpc200005f3" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="jpc200005f3" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f3_1599242849.75078.png?Expires=1717543792&amp;Signature=sVL1~oACPDCvws01TD3G6oL0fMGU74XcUdPPz~pyHrc7hH0XJGCQ63ju86eP14z6ZrSggxKmpGdLkl8wPC3ONLbSUqOwF7B-M7bR24LQyJH31Zg76ZF-8h4WbpCae3nLQrvQWP3tAtu82kh0LjR~oFAIjFYJxH~A~Lnuz1U3G2uVes~oy4c6FgRoUrGr4Lr1vM9gcBveLibiWlammBH9yMZ4e0N0F4ZxBKBqwLWSfxulJ0nfB0dlFigsGV1Pq-lTR71UB~pSIKEqnH1t0-ROslsVdnuJHsgkmMmnVgEb6beN~e1RIIosKDahx-qOeQ3BZOMDQqsBlSWqf5QNZEHjLA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="jpc200005f3" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f3_1599242849.75078.png?Expires=1717543792&Signature=sVL1~oACPDCvws01TD3G6oL0fMGU74XcUdPPz~pyHrc7hH0XJGCQ63ju86eP14z6ZrSggxKmpGdLkl8wPC3ONLbSUqOwF7B-M7bR24LQyJH31Zg76ZF-8h4WbpCae3nLQrvQWP3tAtu82kh0LjR~oFAIjFYJxH~A~Lnuz1U3G2uVes~oy4c6FgRoUrGr4Lr1vM9gcBveLibiWlammBH9yMZ4e0N0F4ZxBKBqwLWSfxulJ0nfB0dlFigsGV1Pq-lTR71UB~pSIKEqnH1t0-ROslsVdnuJHsgkmMmnVgEb6beN~e1RIIosKDahx-qOeQ3BZOMDQqsBlSWqf5QNZEHjLA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=247319388&ar=2769612&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005f3_1599242849.75078.png?Expires=1717543792&amp;Signature=sVL1~oACPDCvws01TD3G6oL0fMGU74XcUdPPz~pyHrc7hH0XJGCQ63ju86eP14z6ZrSggxKmpGdLkl8wPC3ONLbSUqOwF7B-M7bR24LQyJH31Zg76ZF-8h4WbpCae3nLQrvQWP3tAtu82kh0LjR~oFAIjFYJxH~A~Lnuz1U3G2uVes~oy4c6FgRoUrGr4Lr1vM9gcBveLibiWlammBH9yMZ4e0N0F4ZxBKBqwLWSfxulJ0nfB0dlFigsGV1Pq-lTR71UB~pSIKEqnH1t0-ROslsVdnuJHsgkmMmnVgEb6beN~e1RIIosKDahx-qOeQ3BZOMDQqsBlSWqf5QNZEHjLA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="jpc200005f3" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/m_jpc200005f3_1599242849.75078.png?Expires=1717543792&amp;Signature=AULbW6qIrXt19eeVdFQv~Co~a9BaPi94F8TKUKgse3xQo~4xpEJ9X4E6ByVWGWMRHTagPG0zlfkzKq7pcjHZhicAfJzX2UIRN0jPhNXk6m-MMJkhTFyEHrV~4~WmsHMYqxnWBvDZFGWGDmvIG60w2INxm1qpw91U~qfnKk9aqQSZskKdIt7IsYq3ekVoy6nxfhv3jYE~SFTf9Fyh6u6fkEJ4TMTBnaGslJiOIG2WIC3YbGr4~C9AJHbEyAAyAzMbayz4~4FneKnR1ftgNBmKBHHUHArP-ivFiSh7HkNFPfLVc7FtnTlofel6EFnXs8B4XwuvIrstfrciH2joUy~n-w__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Antibody Responses 14 Days After the Second Dose in the Phase 2 Trial" class="content-img lazy" path-from-xml="jpc200005f3" /></a></div></div><div class="figure-caption clip-last-child"><p class="para">Prevaccination is not shown; there were 14 participants in both aluminum hydroxide (alum)â€“only groups and 42 in both of the medium-dose vaccine groups. No measurable antibody responses could be detected at baseline, and thus, the baseline values were all imputed by the lower limit of detection of the assays, which was 5 for the neutralizing antibody measurement and 10 for the specific IgG-binding antibody measurement. The dots represent individual participant values. Boxplots show the 25th, 50th (median), and 75th percentiles. Whiskers extend to the upper and lower adjacent values, the farthest values within 1.5â€‰Ã—â€‰the interquartile range beyond the 25th and 75th percentiles. The numbers below the boxes indicate the number of participants at the lowest measurable value. Only half of the participants in the phase 2 trial were scheduled for the hormoral immunogenicity measurement at day 14 after the second injection. SARS-CoV-2 indicates severe acute respiratory syndrome coronavirus 2.</p></div></div> 
    </div>
    <div class="widget-ArticleFiguresAndTables widget-instance-AMA_Article_Tables_Tab">
        <div class="figure-table-wrapper thm-bd-top"><div class="table-label">Table 1. Â Baseline Characteristics of the Study Participants<sup>a</sup></div><a class="figure-table-anchor" id="jpc200005t1"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="jpc200005t1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t1_1599242849.68828.png?Expires=1717543792&amp;Signature=pK1xck68PgJPgSaBVd6BQiOQY2bbdmzNj0uF~gnOZ-TnbS56RbCnK0DcsxLPpAZbzzIi2IS~x5H3fX9VV9s1-NFihSxiJl4PicZP7dJqTtJ3DAjK-HeFIoHl9G4mAUHha3LeQJtV77K9ZqJpTlucL3VMpEda1h7j6lOwyyT6Z6l9gUS~ZhJmiXFP2k7x09MXYDvpL946AT~Qk44BDYqIaK7CaVHYBTHq7LpBE6YX1SvFa4wmY9WdEn6Nvb5cPtY~eBwRahwC-KwMCCKxEUmYE79fjETVT7gGzu51yaCOvyHuh3rwPWAT4NUAia9YPXH5yEHyKB50TSCxAwNKyOlitA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="jpc200005t1" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t1_1599242849.68828.png?Expires=1717543792&Signature=pK1xck68PgJPgSaBVd6BQiOQY2bbdmzNj0uF~gnOZ-TnbS56RbCnK0DcsxLPpAZbzzIi2IS~x5H3fX9VV9s1-NFihSxiJl4PicZP7dJqTtJ3DAjK-HeFIoHl9G4mAUHha3LeQJtV77K9ZqJpTlucL3VMpEda1h7j6lOwyyT6Z6l9gUS~ZhJmiXFP2k7x09MXYDvpL946AT~Qk44BDYqIaK7CaVHYBTHq7LpBE6YX1SvFa4wmY9WdEn6Nvb5cPtY~eBwRahwC-KwMCCKxEUmYE79fjETVT7gGzu51yaCOvyHuh3rwPWAT4NUAia9YPXH5yEHyKB50TSCxAwNKyOlitA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=247319377&ar=2769612&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t1_1599242849.68828.png?Expires=1717543792&amp;Signature=pK1xck68PgJPgSaBVd6BQiOQY2bbdmzNj0uF~gnOZ-TnbS56RbCnK0DcsxLPpAZbzzIi2IS~x5H3fX9VV9s1-NFihSxiJl4PicZP7dJqTtJ3DAjK-HeFIoHl9G4mAUHha3LeQJtV77K9ZqJpTlucL3VMpEda1h7j6lOwyyT6Z6l9gUS~ZhJmiXFP2k7x09MXYDvpL946AT~Qk44BDYqIaK7CaVHYBTHq7LpBE6YX1SvFa4wmY9WdEn6Nvb5cPtY~eBwRahwC-KwMCCKxEUmYE79fjETVT7gGzu51yaCOvyHuh3rwPWAT4NUAia9YPXH5yEHyKB50TSCxAwNKyOlitA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="jpc200005t1" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/m_jpc200005t1_1599242849.68828.png?Expires=1717543792&amp;Signature=2TquzJz0pCwdhM2yVIs7oSyfvAdOrXx7KHrWQOjZsuuOVafkTXKpwL1MWAY8cGiWpp8D1COO6~2X6~EVwIJaTxzbtjObDEMsp6eN0Rk~PJBh~WFW27Qx-T7ChZQA85sB3nkuGh5Fe0cA-hlofsesvcRjN03uxZxjVUgUtOuNw46I1XpNux3Ksm0Jy-tQA8k6mltVY1jG56FmZVpcEp8i0zdGvHtUBnHvdQJOzCPEgLAQxBjCWOMCwomDQlAPl-qObHWfack4DwA9iSdP20vsJEbZgDMOXgzsdiO35PVZx9gEb5SLIRPIOEvUBv0cZ3Fxbfh5IIf8sZyoleyDrarXtg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Baseline Characteristics of the Study Participantsa" class="content-img lazy" path-from-xml="jpc200005t1" /></a></div></div><div class="table-caption"></div></div><div class="figure-table-wrapper thm-bd-top"><div class="table-label">Table 2. Â Adverse Reactions After 3 Doses in the Phase 1 Trial and 2 Doses in the Phase 2 Trial in the Safety Set<sup>a</sup></div><a class="figure-table-anchor" id="jpc200005t2"></a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="jpc200005t2" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t2_1599242849.7039.png?Expires=1717543792&amp;Signature=LxqBf5kJ2iUeECr7SSxLTVNfTaARk5gboSTzpDjajxmBhNrZVuCo9FTy3RDNt9Euw35P~E50NTRmQ94~sF-lJH1lFjteValU4OhyhpJGFWsWbzkd0YWKF0Tke0OZGNJ4i5XUfWuLtBbIARCXkyLnpetdEobJtGsqSf9UzRnJqCw~9UyCRy-5eT5-69zyvmdOFMVUmVlzVAPLdEq4haeQ5-mMh~SpRH8FBwh57t1zdf-Z7ByLv-~bPPKLUZMRfVva9kM2tNXqquN6pF7X3ClT~pmuNj2wgS7sjRTLE23Uncl9VOvKrjIrvZJgac3qJdTW2zQAlXpIoF3UEpdEMwqzHA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="jpc200005t2" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t2_1599242849.7039.png?Expires=1717543792&Signature=LxqBf5kJ2iUeECr7SSxLTVNfTaARk5gboSTzpDjajxmBhNrZVuCo9FTy3RDNt9Euw35P~E50NTRmQ94~sF-lJH1lFjteValU4OhyhpJGFWsWbzkd0YWKF0Tke0OZGNJ4i5XUfWuLtBbIARCXkyLnpetdEobJtGsqSf9UzRnJqCw~9UyCRy-5eT5-69zyvmdOFMVUmVlzVAPLdEq4haeQ5-mMh~SpRH8FBwh57t1zdf-Z7ByLv-~bPPKLUZMRfVva9kM2tNXqquN6pF7X3ClT~pmuNj2wgS7sjRTLE23Uncl9VOvKrjIrvZJgac3qJdTW2zQAlXpIoF3UEpdEMwqzHA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=247319380&ar=2769612&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"></span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"></span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t2_1599242849.7039.png?Expires=1717543792&amp;Signature=LxqBf5kJ2iUeECr7SSxLTVNfTaARk5gboSTzpDjajxmBhNrZVuCo9FTy3RDNt9Euw35P~E50NTRmQ94~sF-lJH1lFjteValU4OhyhpJGFWsWbzkd0YWKF0Tke0OZGNJ4i5XUfWuLtBbIARCXkyLnpetdEobJtGsqSf9UzRnJqCw~9UyCRy-5eT5-69zyvmdOFMVUmVlzVAPLdEq4haeQ5-mMh~SpRH8FBwh57t1zdf-Z7ByLv-~bPPKLUZMRfVva9kM2tNXqquN6pF7X3ClT~pmuNj2wgS7sjRTLE23Uncl9VOvKrjIrvZJgac3qJdTW2zQAlXpIoF3UEpdEMwqzHA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="jpc200005t2" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/m_jpc200005t2_1599242849.7039.png?Expires=1717543792&amp;Signature=mfeiN6bubJxUsPnJkkTpTKWjbOsGDnIqOL~X4ax1HYELI6QHW7FqZDvCDm3cBPA1-QEuz3MucSgcj1eq-tOYBeLk6iuHFtDOxuj00RAiEWIEFwE7jJK6QlBj2QUUTpPGC~t4jbGK70PnCauP5~lMJe6xUQ-Rz31waUsgojf5B2dcI-4T1CwXzKe~kp8iz1V5iYXGwPFT2~eN~MWLI6biDR7LrXi-EvGO3DJcj2NSdvhCnpNQlggZ4Fzz9-dWwk4iudoDNljSI~W3JutF3Own2fSiUv3GRqAfy0JzQmAZIzndqEmPZM2Fe7YBnnXg1BLkowN3XTlkrSauo~iQ33DboA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Adverse Reactions After 3 Doses in the Phase 1 Trial and 2 Doses in the Phase 2 Trial in the Safety Seta" class="content-img lazy" path-from-xml="jpc200005t2" /></a></div></div><div class="table-caption"></div></div><div class="figure-table-wrapper thm-bd-top"><div class="table-label">Table 3. Â Antibody Responses 14 Days After 3 Doses in the Phase 1 Trial and 2 Doses in the Phase 2 Trial<sup>a</sup></div><a class="figure-table-anchor" id="jpc200005t3"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="jpc200005t3" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t3_1599242849.73515.png?Expires=1717543792&amp;Signature=3SucfsnR7Nnwdrl-ygZD2nMaUtLCr54dXyRJvQK1UKcXcg~tp~JWAnSsPO7J5wL1GXvcZ4vcjQg9vkmQxrFEfSFkNlZpqx9-mIz3HoTMxd243j~9J-pgUnHv84OPFaYROgnLe1RhvXumDThcU3szueWoTwxwHfU3nDDXWjOnEWNY8KibxhTAhzJfF7lPOWu9-emupmO6ZIlOZSnzq23hb2v7tauu6qsnI9-CGrXQJKt9aUFst7mjQfFrkEzZdJd54n62UKS2yjubCMM7r56qUvLPxd5ck3LpmQhh9IIT0NfmzefsoEhB4weFUDAXtA16FlODRR2voMd-9Ky1R1bLXg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="jpc200005t3" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t3_1599242849.73515.png?Expires=1717543792&Signature=3SucfsnR7Nnwdrl-ygZD2nMaUtLCr54dXyRJvQK1UKcXcg~tp~JWAnSsPO7J5wL1GXvcZ4vcjQg9vkmQxrFEfSFkNlZpqx9-mIz3HoTMxd243j~9J-pgUnHv84OPFaYROgnLe1RhvXumDThcU3szueWoTwxwHfU3nDDXWjOnEWNY8KibxhTAhzJfF7lPOWu9-emupmO6ZIlOZSnzq23hb2v7tauu6qsnI9-CGrXQJKt9aUFst7mjQfFrkEzZdJd54n62UKS2yjubCMM7r56qUvLPxd5ck3LpmQhh9IIT0NfmzefsoEhB4weFUDAXtA16FlODRR2voMd-9Ky1R1bLXg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=247319384&ar=2769612&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005t3_1599242849.73515.png?Expires=1717543792&amp;Signature=3SucfsnR7Nnwdrl-ygZD2nMaUtLCr54dXyRJvQK1UKcXcg~tp~JWAnSsPO7J5wL1GXvcZ4vcjQg9vkmQxrFEfSFkNlZpqx9-mIz3HoTMxd243j~9J-pgUnHv84OPFaYROgnLe1RhvXumDThcU3szueWoTwxwHfU3nDDXWjOnEWNY8KibxhTAhzJfF7lPOWu9-emupmO6ZIlOZSnzq23hb2v7tauu6qsnI9-CGrXQJKt9aUFst7mjQfFrkEzZdJd54n62UKS2yjubCMM7r56qUvLPxd5ck3LpmQhh9IIT0NfmzefsoEhB4weFUDAXtA16FlODRR2voMd-9Ky1R1bLXg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="jpc200005t3" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/m_jpc200005t3_1599242849.73515.png?Expires=1717543792&amp;Signature=K~AKys8bbAj5ysKlJfmulM5j5k2ev7vYxLf9M5vJYOtE3UBcowdU0DMZP0oGN8TxxRfuLI5Yi7xSWyqRpu9KLPJcnfnQERBhU~nR9wPPnyYPLey2GghX3~WhqeIKlA3oH2zNoPkG4BwDi6Rymp9E5KKSfDzrl1odkPNGk~ujiaVnPNmqAE1SbqtcpKsJ6j8keO8qTsM2GvWwr-wtSLEESKNQDxADSuhjdbEFaGlI1x4hFIHFf61Pas4TxfOxyjcpYT0g6nMxsPuaCcJaYhxVgsL5HUM~Ps7ZDH7bAThp3SXH24uCbz9sd0-WdgXKSccO0137j1yTPQcvwHcTMWC5Ow__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Antibody Responses 14 Days After 3 Doses in the Phase 1 Trial and 2 Doses in the Phase 2 Triala" class="content-img lazy" path-from-xml="jpc200005t3" /></a></div></div><div class="table-caption"></div></div> 
    </div>

        </div>

        
        <div id="multimedia-tab" class="resource-tab js-resource-tab multimedia-tab need-jobs-ad">

        </div>

        
        <div id="supplemental-tab" class="resource-tab js-resource-tab supplemental-tab need-jobs-ad">
    <div class="widget-ArticleDataSupplements widget-instance-AMA_Data_Supplements_Tab">
            <div class="supplement">
        <a id="note-JPC200005-1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005supp1_prod_1599242849.34452.pdf?Expires=1717906475&amp;Signature=XapPkl4J~1l7RNOMDzyotxw8aB-vA-tyh9ys~YvOWG8UJD5NiBYP4KOsl5JlqNDGzIWw3545sPfVDziEF0LVw2lCYJ0SdW75dWnDG17ivNJEA9ZKR7HWuz~HiE9yk12oo0yduU9gwSvSoNws6xWWB4Scj3-T-ZcQgLae2M6oz3WMyL8N891Rl-SgWZQFdOgptmXzkKF4Ht0aopS6geXoOFPq~TonH6pnDjpkUrtkkWfvI9OLsO5ffCtJmJXn6lmcAWJblet-Qe8~4plNYI4Xw0XVBFjS7so1wuwxTuUGwNZOytJluE4Se5mn6he8bYpVk~Lqw1E1H4Cpb2L1egQLQg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" class="supplement-link supplement-download stats-supplement-download" rel=&quot;nofollow&quot;>
            <div class="pdf supplement-type"></div>
                <div class="supplement-title"><span class="title-label">Supplement 1.</span><p class="para">Trial Protocol</p></div>
        </a>        
    </div>
    <div class="supplement">
        <a id="note-JPC200005-1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005supp2_prod_1599242849.36015.pdf?Expires=1717906475&amp;Signature=QludCU-~ZScBbjcjlgQvRnqFyQ1aX97IRbdhAkLEvx7MekM~KlFGTDhPjtPAHcr32hUl7SGo5CARv2dKDzEIvGO-Qv-IUVJ7s1ipogl4GChpzoY0CV~-9KRaNDBX7jZnJz7VjVXkenfdxJ-t02FFFhiz7jygLt3rfmZoO3w2Ls9I0oy8Zi8xAgwgNRvOd2DDkKAXTGNY49YuDdJJumDv0a6YnExKCtSzN~kHrHSDZjnVq81jvABo4wyPTV582idq-GNhoWwcHLfMq-8vjdr90pbrGuGgYOzx9FaXQIc9iCVoe-T-bL2zCYPG4sAzuSomQsGuAH89XiCewAcFvht9EQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" class="supplement-link supplement-download stats-supplement-download" rel=&quot;nofollow&quot;>
            <div class="pdf supplement-type"></div>
                <div class="supplement-title"><span class="title-label">Supplement 2.</span><p class="para">Statistical Analysis Plan</p></div>
        </a>        
    </div>
    <div class="supplement">
        <a id="note-JPC200005-1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005supp3_prod_1599242849.36015.pdf?Expires=1717906475&amp;Signature=DvVpSEggL1JzYASB2b8yaBDRiISMfetFWwEaukniajofXQMyHD5XCtkwgmfxdnyhBUZbboAJ12~9xdrqgnUaELB1YG2wd0cXJXX9a2Iz32kCebFmKXdDl-h~pmu8-Z6OdmZglFtZ~EPJ1vf0mp03zpHLKR5wcU6UpZLVpuK9sowD3JKoq5WdbP0dkSpSHWUmw5OySZLfA81d0VIwA7kMEd-EcdkxcdtKSMkaBax8mBnlZxHL7HT4uZ92PUUJMiR8xdUTBSrUlkhAihjGQNN83jt31dfLTJdU8cRk83zL-YmuP-UxIlkUSONtgzacoB0Thshc4O121AJL1leJOP4~gA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" class="supplement-link supplement-download stats-supplement-download" rel=&quot;nofollow&quot;>
            <div class="pdf supplement-type"></div>
                <div class="supplement-title"><span class="title-label">Supplement 3.</span><p class="para">eMethods</p><p class="para">eTable 1. Grading Scales for Systemic and Local Adverse Events</p><p class="para">eTable 2. Total Adverse Reactions After Each Dose in the Phase 1 and 2 Trials</p><p class="para">eTable 3. Total Adverse Events 28 Days after Three Doses in the Phase 1 Trial and Two Doses in the Phase 2 Trial</p><p class="para">eTable 4. Abnormal Laboratory Parameters after three Vaccinations in the Phase 1 Clinical Trial</p><p class="para">eTable 5. Geometric Mean Titer (95% Confidence Interval) of Antibodies in Different Time Points in the Two Trials</p><p class="para">eFigure 1. Schedule of Biospecimen Collection and Related Tests</p><p class="para">eFigure 2. Lymphocyte Subset Distribution Analysis in the Phase 1 Trial</p><p class="para">eFigure 3. Changes in T Helper 1 Cell Related Cytokines in the Phase 1 Trial</p><p class="para">eFigure 4. Changes in T Helper 2 Cell Related Cytokines in the Phase 1 Trial</p><p class="para">eFigure 5. Changes in T Helper 17 Cell Related Cytokines in the Phase 1 Trial</p><p class="para">eFigure 6. Changes in Other Cytokines in the Phase 1 Trial</p></div>
        </a>        
    </div>
    <div class="supplement">
        <a id="note-JPC200005-1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005supp4_prod_1599242849.36015.pdf?Expires=1717906475&amp;Signature=zBY6PuAe7r9s5aBO~RjEfDytsk9MzN~lWAS3slpuhRulFxi6XvYLQ-UYGDwKKXaj0M8BANp5XmoCeU2TWurcpAk5QaojMytACpx1fndKUOXuh1~NW0qc4cQydx8o1LTIHFKyQu0de6PDnWkfF3qCuTmb4ZPdXKEjwObRx~4Lv2LcPmzX1jygZAJKrkJ-6k22DcT~7MKb0Me~2Fp4qbwzPh4d8zCVNjM4gQ-vV1x0wx4oPoKWIeXhYjaVr7k0I5DXfKNtG1wwtaXeQPkiUbsCT9R~1~ZeooCef95i22jifWyGNOTPpHpEOCziloWvNg5bC25PcA8bQRlh1RcIp4mIOw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" class="supplement-link supplement-download stats-supplement-download" rel=&quot;nofollow&quot;>
            <div class="pdf supplement-type"></div>
                <div class="supplement-title"><span class="title-label">Supplement 4.</span><p class="para">Data Sharing Statement</p></div>
        </a>        
    </div>
    <div class="supplement">
        <a id="note-jpc200005-og" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/938551/jpc200005_featured_1599242849.36015.png?Expires=1717906475&amp;Signature=dgTP1Ea-2ulJHm7CL2SIpO1-Smjld2LYlpcoMEI4vN1HPU2-Udg8ZLCBCmEiTZuBaCBlqXzf6qOO4WJl5xCtz0wRp9Id7Bds031O0whmTM5JEYMgq9~2pBR5jIZHBEqGhGDfHUnkYwiJjdsk1bfl7qdTI1D9N4v4WrIndFKJdlC5GxcJn5riB~vOKrKcORDudVoTLlD-MiyB06boTBQCFkQVfrlmmzUnV8vmoLy77P0K5XlERw1pHJmwlqEGR~0hXXtMDM~ZILWHjVJ726QOQ54rqrhCKtBLSZauJdohNr7BnsYA4g9j~8Kg~3KnyDGTVMHV8S2gi3U8R3xAmyrIXQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" class="supplement-link supplement-download stats-supplement-download" >
            <div class="image supplement-type"></div>
        </a>        
    </div>

 
    </div>

        </div>

        
        <div id="references-tab" class="resource-tab js-resource-tab references-tab need-jobs-ad">
            <div class="references-wrap">
    <div class="widget-SectionDisplay widget-instance-AMA_References_Tab">
        
<div class="references"><div class="reference"><a class="reference-number" id="jpc200005r1">1.</a><div class="reference-content">World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Accessed July 30, 2020. <a href="https://covid19.who.int/">https://covid19.who.int/</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r2">2.</a><div class="reference-content">World Health Organization. Draft landscape of COVID-19 candidate vaccines. Accessed July 30, 2020. <a href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r3">3.</a><div class="reference-content">Zhu
        Â FCï»¿, Li
        Â YHï»¿, Guan
        Â XHï»¿, 
    Â et al. Â Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Lancet</i>. 2020;395(10240):1845-1854. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(20)31208-3">10.1016/S0140-6736(20)31208-3</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32450106" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safety%2C%20tolerability%2C%20and%20immunogenicity%20of%20a%20recombinant%20adenovirus%20type-5%20vectored%20COVID-19%20vaccine%3A%20a%20dose-escalation%2C%20open-label%2C%20non-randomised%2C%20first-in-human%20trial.&amp;author=FC%20Zhu&amp;author=YH%20Li&amp;author=XH%20Guan&amp;publication_year=2020&amp;journal=Lancet&amp;volume=395&amp;pages=1845-1854" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0140-6736(20)31208-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0140-6736(20)31208-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r4">4.</a><div class="reference-content">Zhu
        Â FCï»¿, Guan
        Â XHï»¿, Li
        Â YHï»¿, 
    Â et al. Â Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Lancet</i>. Published online July 20, 2020. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(20)31605-6">10.1016/S0140-6736(20)31605-6</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32702299" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Immunogenicity%20and%20safety%20of%20a%20recombinant%20adenovirus%20type-5-vectored%20COVID-19%20vaccine%20in%20healthy%20adults%20aged%2018%20years%20or%20older%3A%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20phase%202%20trial.&amp;author=FC%20Zhu&amp;author=XH%20Guan&amp;author=YH%20Li&amp;publication_year=&amp;journal=Lancet&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r5">5.</a><div class="reference-content">Sahin
        Â Uï»¿, Muik
        Â Aï»¿, Derhovanessian
        Â Eï»¿, 
    Â et al. Concurrent human antibody and T<sub>H</sub>1 type T-cell responses elicited by a COVID-19 RNA vaccine. <i>medRxiv</i>. Preprint posted July 20, 2020. doi:<a href="http://dx.doi.org/10.1101/2020.07.17.20140533">10.1101/2020.07.17.20140533</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r6">6.</a><div class="reference-content">Mulligan
        Â MJï»¿, Lyke
        Â KEï»¿, Kitchin
        Â Nï»¿, 
    Â et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. <i>medRxiv</i>. Preprint posted July 1, 2020. doi:<a href="http://dx.doi.org/10.1101/2020.06.30.20142570">10.1101/2020.06.30.20142570</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r7">7.</a><div class="reference-content">Jackson
        Â LAï»¿, Anderson
        Â EJï»¿, Rouphael
        Â NGï»¿, 
    Â et al; mRNA-1273 Study Group. Â An mRNA vaccine against SARS-CoV-2 - preliminary report.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â N Engl J Med</i>. Published online July 14, 2020. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2022483">10.1056/NEJMoa2022483</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32663912" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=An%20mRNA%20vaccine%20against%20SARS-CoV-2%20-%20preliminary%20report.&amp;author=LA%20Jackson&amp;author=EJ%20Anderson&amp;author=NG%20Rouphael&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r8">8.</a><div class="reference-content">Folegatti
        Â PMï»¿, Ewer
        Â KJï»¿, Aley
        Â PKï»¿, 
    Â et al; Oxford COVID Vaccine Trial Group. Â Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.Â <i xmlns:helper="urn:XsltStringHelper">Â  Lancet</i>. Published online July 20, 2020. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(20)31604-4">10.1016/S0140-6736(20)31604-4</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32702298" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safety%20and%20immunogenicity%20of%20the%20ChAdOx1%20nCoV-19%20vaccine%20against%20SARS-CoV-2%3A%20a%20preliminary%20report%20of%20a%20phase%201%2F2%2C%20single-blind%2C%20randomised%20controlled%20trial.&amp;author=PM%20Folegatti&amp;author=KJ%20Ewer&amp;author=PK%20Aley&amp;publication_year=&amp;journal=Lancet&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r9">9.</a><div class="reference-content">Stern
        Â PLï»¿. Â Key steps in vaccine development.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Ann Allergy Asthma Immunol</i>. 2020;125(1):17-27. doi:<a href="http://dx.doi.org/10.1016/j.anai.2020.01.025">10.1016/j.anai.2020.01.025</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32044451" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Key%20steps%20in%20vaccine%20development.&amp;author=PL%20Stern&amp;publication_year=2020&amp;journal=Ann%20Allergy%20Asthma%20Immunol&amp;volume=125&amp;pages=17-27" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.anai.2020.01.025" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.anai.2020.01.025" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r10">10.</a><div class="reference-content">Gao
        Â Qï»¿, Bao
        Â Lï»¿, Mao
        Â Hï»¿, 
    Â et al. Â Development of an inactivated vaccine candidate for SARS-CoV-2.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Science</i>. 2020;369(6499):77-81. doi:<a href="http://dx.doi.org/10.1126/science.abc1932">10.1126/science.abc1932</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32376603" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Development%20of%20an%20inactivated%20vaccine%20candidate%20for%20SARS-CoV-2.&amp;author=Q%20Gao&amp;author=L%20Bao&amp;author=H%20Mao&amp;publication_year=2020&amp;journal=Science&amp;volume=369&amp;pages=77-81" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1126/science.abc1932" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1126/science.abc1932" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r11">11.</a><div class="reference-content">Wang
        Â Hï»¿, Zhang
        Â Yï»¿, Huang
        Â Bï»¿, 
    Â et alï»¿ Â Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Cell</i>. Published online June 6, 2020. doi:<a href="http://dx.doi.org/10.1016/j.cell.2020.06.008">10.1016/j.cell.2020.06.008</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Development%20of%20an%20inactivated%20vaccine%20candidate%2C%20BBIBP-CorV%2C%20with%20potent%20protection%20against%20SARS-CoV-2.&amp;author=H%20Wang&amp;author=Y%20Zhang&amp;author=B%20Huang&amp;publication_year=&amp;journal=Cell&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r12">12.</a><div class="reference-content">Duan
        Â Kï»¿, Liu
        Â Bï»¿, Li
        Â Cï»¿, 
    Â et al. Â Effectiveness of convalescent plasma therapy in severe COVID-19 patients.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Proc Natl Acad Sci U S A</i>. 2020;117(17):9490-9496. doi:<a href="http://dx.doi.org/10.1073/pnas.2004168117">10.1073/pnas.2004168117</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32253318" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effectiveness%20of%20convalescent%20plasma%20therapy%20in%20severe%20COVID-19%20patients.&amp;author=K%20Duan&amp;author=B%20Liu&amp;author=C%20Li&amp;publication_year=2020&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=117&amp;pages=9490-9496" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1073/pnas.2004168117" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1073/pnas.2004168117" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r13">13.</a><div class="reference-content">Long
        Â QXï»¿, Liu
        Â BZï»¿, Deng
        Â HJï»¿, 
    Â et al. Â Antibody responses to SARS-CoV-2 in patients with COVID-19.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nat Med</i>. 2020;26(6):845-848. doi:<a href="http://dx.doi.org/10.1038/s41591-020-0897-1">10.1038/s41591-020-0897-1</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32350462" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antibody%20responses%20to%20SARS-CoV-2%20in%20patients%20with%20COVID-19.&amp;author=QX%20Long&amp;author=BZ%20Liu&amp;author=HJ%20Deng&amp;publication_year=2020&amp;journal=Nat%20Med&amp;volume=26&amp;pages=845-848" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/s41591-020-0897-1" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/s41591-020-0897-1" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r14">14.</a><div class="reference-content">Luchsinger
        Â LLï»¿, Ransegnola
        Â Bï»¿, Jin
        Â Dï»¿, 
    Â et al. Serological analysis of New York City COVID19 convalescent plasma donors. <i>medRxiv</i>. Preprint posted June 9, 2020. doi:<a href="http://dx.doi.org/10.1101/2020.06.08.20124792">10.1101/2020.06.08.20124792</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r15">15.</a><div class="reference-content">Robbiani
        Â DFï»¿, Gaebler
        Â Cï»¿, Muecksch
        Â Fï»¿, 
    Â et al. Â Convergent antibody responses to SARS-CoV-2 in convalescent individuals.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nature</i>. Published online June 18, 2020. doi:<a href="http://dx.doi.org/10.1038/s41586-020-2456-9">10.1038/s41586-020-2456-9</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32555388" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Convergent%20antibody%20responses%20to%20SARS-CoV-2%20in%20convalescent%20individuals.&amp;author=DF%20Robbiani&amp;author=C%20Gaebler&amp;author=F%20Muecksch&amp;publication_year=&amp;journal=Nature&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r16">16.</a><div class="reference-content">Wang
        Â Xï»¿, Guo
        Â Xï»¿, Xin
        Â Qï»¿, 
    Â et al. Â Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Clin Infect Dis</i>. Published online June 4, 2020. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa721">10.1093/cid/ciaa721</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32497196" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Neutralizing%20antibodies%20responses%20to%20SARS-CoV-2%20in%20COVID-19%20inpatients%20and%20convalescent%20patients.&amp;author=X%20Wang&amp;author=X%20Guo&amp;author=Q%20Xin&amp;publication_year=&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r17">17.</a><div class="reference-content">Wu
        Â Fï»¿, Wang
        Â Aï»¿, Liu
        Â Mï»¿, 
    Â et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. <i>medRxiv</i>. Preprint posted April 20, 2020. doi:<a href="http://dx.doi.org/10.1101/2020.03.30.20047365">10.1101/2020.03.30.20047365</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r18">18.</a><div class="reference-content">Zhao
        Â Jï»¿, Yuan
        Â Qï»¿, Wang
        Â Hï»¿, 
    Â et al. Â Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Clin Infect Dis</i>. Published online March 28, 2020. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa344">10.1093/cid/ciaa344</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32221519" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antibody%20responses%20to%20SARS-CoV-2%20in%20patients%20of%20novel%20coronavirus%20disease%202019.&amp;author=J%20Zhao&amp;author=Q%20Yuan&amp;author=H%20Wang&amp;publication_year=&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r19">19.</a><div class="reference-content">Liu
        Â Tï»¿, Wu
        Â Sï»¿, Tao
        Â Hï»¿, 
    Â et al. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan: implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2. <i>medRxiv</i>. Preprint posted June 16, 2020. doi:<a href="http://dx.doi.org/10.1101/2020.06.13.20130252">10.1101/2020.06.13.20130252</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r20">20.</a><div class="reference-content">Long
        Â QXï»¿, Tang
        Â XJï»¿, Shi
        Â QLï»¿, 
    Â et al. Â Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nat Med</i>. Published online June 18, 2020. doi:<a href="http://dx.doi.org/10.1038/s41591-020-0965-6">10.1038/s41591-020-0965-6</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32555424" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Clinical%20and%20immunological%20assessment%20of%20asymptomatic%20SARS-CoV-2%20infections.&amp;author=QX%20Long&amp;author=XJ%20Tang&amp;author=QL%20Shi&amp;publication_year=&amp;journal=Nat%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r21">21.</a><div class="reference-content">Ibarrondo
        Â FJï»¿, Fulcher
        Â JAï»¿, Goodman-Meza
        Â Dï»¿, 
    Â et al. Â Rapid decay of antiâ€“SARS-CoV-2 antibodies in persons with mild Covid-19.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â N Engl J Med</i>. Published online July 21, 2020. doi:<a href="http://dx.doi.org/10.1056/NEJMc2025179">10.1056/NEJMc2025179</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32706954" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Rapid%20decay%20of%20anti%E2%80%93SARS-CoV-2%20antibodies%20in%20persons%20with%20mild%20Covid-19.&amp;author=FJ%20Ibarrondo&amp;author=JA%20Fulcher&amp;author=D%20Goodman-Meza&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r22">22.</a><div class="reference-content">Cao
        Â WCï»¿, Liu
        Â Wï»¿, Zhang
        Â PHï»¿, Zhang
        Â Fï»¿, Richardus
        Â JHï»¿. Â Disappearance of antibodies to SARS-associated coronavirus after recovery.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â N Engl J Med</i>. 2007;357(11):1162-1163. doi:<a href="http://dx.doi.org/10.1056/NEJMc070348">10.1056/NEJMc070348</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17855683" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Disappearance%20of%20antibodies%20to%20SARS-associated%20coronavirus%20after%20recovery.&amp;author=WC%20Cao&amp;author=W%20Liu&amp;author=PH%20Zhang&amp;author=F%20Zhang&amp;author=JH%20Richardus&amp;publication_year=2007&amp;journal=N%20Engl%20J%20Med&amp;volume=357&amp;pages=1162-1163" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMc070348" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMc070348" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r23">23.</a><div class="reference-content">Lin
        Â JTï»¿, Zhang
        Â JSï»¿, Su
        Â Nï»¿, 
    Â et al. Â Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Antivir Ther</i>. 2007;12(7):1107-1113.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/18018769" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safety%20and%20immunogenicity%20from%20a%20phase%20I%20trial%20of%20inactivated%20severe%20acute%20respiratory%20syndrome%20coronavirus%20vaccine.&amp;author=JT%20Lin&amp;author=JS%20Zhang&amp;author=N%20Su&amp;publication_year=2007&amp;journal=Antivir%20Ther&amp;volume=12&amp;pages=1107-1113" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r24">24.</a><div class="reference-content">Martin
        Â JEï»¿, Louder
        Â MKï»¿, Holman
        Â LAï»¿, 
    Â et al; VRC 301 Study Team. Â A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Vaccine</i>. 2008;26(50):6338-6343. doi:<a href="http://dx.doi.org/10.1016/j.vaccine.2008.09.026">10.1016/j.vaccine.2008.09.026</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/18824060" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20SARS%20DNA%20vaccine%20induces%20neutralizing%20antibody%20and%20cellular%20immune%20responses%20in%20healthy%20adults%20in%20a%20phase%20I%20clinical%20trial.&amp;author=JE%20Martin&amp;author=MK%20Louder&amp;author=LA%20Holman&amp;publication_year=2008&amp;journal=Vaccine&amp;volume=26&amp;pages=6338-6343" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.vaccine.2008.09.026" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.vaccine.2008.09.026" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r25">25.</a><div class="reference-content">Le Bert
        Â Nï»¿, Tan
        Â ATï»¿, Kunasegaran
        Â Kï»¿, 
    Â et al. Â SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nature</i>. Published online July 15, 2020. doi:<a href="http://dx.doi.org/10.1038/s41586-020-2550-z">10.1038/s41586-020-2550-z</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32668444" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2-specific%20T%20cell%20immunity%20in%20cases%20of%20COVID-19%20and%20SARS%2C%20and%20uninfected%20controls.&amp;author=N%20Le Bert&amp;author=AT%20Tan&amp;author=K%20Kunasegaran&amp;publication_year=&amp;journal=Nature&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r26">26.</a><div class="reference-content">Eroshenko
        Â Nï»¿, Gill
        Â Tï»¿, Keaveney
        Â MKï»¿, Church
        Â GMï»¿, Trevejo
        Â JMï»¿, Rajaniemi
        Â Hï»¿. Â Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nat Biotechnol</i>. 2020;38(7):789-791. doi:<a href="http://dx.doi.org/10.1038/s41587-020-0577-1">10.1038/s41587-020-0577-1</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32504046" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Implications%20of%20antibody-dependent%20enhancement%20of%20infection%20for%20SARS-CoV-2%20countermeasures.&amp;author=N%20Eroshenko&amp;author=T%20Gill&amp;author=MK%20Keaveney&amp;author=GM%20Church&amp;author=JM%20Trevejo&amp;author=H%20Rajaniemi&amp;publication_year=2020&amp;journal=Nat%20Biotechnol&amp;volume=38&amp;pages=789-791" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/s41587-020-0577-1" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/s41587-020-0577-1" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r27">27.</a><div class="reference-content">Graham
        Â BSï»¿. Â Rapid COVID-19 vaccine development.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Science</i>. 2020;368(6494):945-946. doi:<a href="http://dx.doi.org/10.1126/science.abb8923">10.1126/science.abb8923</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32385100" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Rapid%20COVID-19%20vaccine%20development.&amp;author=BS%20Graham&amp;publication_year=2020&amp;journal=Science&amp;volume=368&amp;pages=945-946" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1126/science.abb8923" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1126/science.abb8923" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r28">28.</a><div class="reference-content">Corbett
        Â KSï»¿, Flynn
        Â Bï»¿, Foulds
        Â KEï»¿, 
    Â et al. Â Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â N Engl J Med</i>. Published online July 28, 2020. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2024671">10.1056/NEJMoa2024671</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32722908" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Evaluation%20of%20the%20mRNA-1273%20vaccine%20against%20SARS-CoV-2%20in%20nonhuman%20primates.&amp;author=KS%20Corbett&amp;author=B%20Flynn&amp;author=KE%20Foulds&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r29">29.</a><div class="reference-content">Chandrashekar
        Â Aï»¿, Liu
        Â Jï»¿, Martinot
        Â AJï»¿, 
    Â et al. Â SARS-CoV-2 infection protects against rechallenge in rhesus macaques.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Science</i>. Published online May 20, 2020. doi:<a href="http://dx.doi.org/10.1126/science.abc4776">10.1126/science.abc4776</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32434946" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2%20infection%20protects%20against%20rechallenge%20in%20rhesus%20macaques.&amp;author=A%20Chandrashekar&amp;author=J%20Liu&amp;author=AJ%20Martinot&amp;publication_year=&amp;journal=Science&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r30">30.</a><div class="reference-content">Deng
        Â Wï»¿, Bao
        Â Lï»¿, Liu
        Â Jï»¿, 
    Â et al. Â Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Science</i>. Published online July 2, 2020. doi:<a href="http://dx.doi.org/10.1126/science.abc5343">10.1126/science.abc5343</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32616673" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Primary%20exposure%20to%20SARS-CoV-2%20protects%20against%20reinfection%20in%20rhesus%20macaques.&amp;author=W%20Deng&amp;author=L%20Bao&amp;author=J%20Liu&amp;publication_year=&amp;journal=Science&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r31">31.</a><div class="reference-content">Fulginiti
        Â VAï»¿, Eller
        Â JJï»¿, Downie
        Â AWï»¿, Kempe
        Â CHï»¿. Â Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated measles virus vaccines.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â JAMA</i>. 1967;202(12):1075-1080. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jama.1967.03130250057008">10.1001/jama.1967.03130250057008</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/6072745" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Altered%20reactivity%20to%20measles%20virus%3A%20atypical%20measles%20in%20children%20previously%20immunized%20with%20inactivated%20measles%20virus%20vaccines.&amp;author=VA%20Fulginiti&amp;author=JJ%20Eller&amp;author=AW%20Downie&amp;author=CH%20Kempe&amp;publication_year=1967&amp;journal=JAMA&amp;volume=202&amp;pages=1075-1080" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.1967.03130250057008" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.1967.03130250057008" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r32">32.</a><div class="reference-content">Kim
        Â HWï»¿, Canchola
        Â JGï»¿, Brandt
        Â CDï»¿, 
    Â et al. Â Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Am J Epidemiol</i>. 1969;89(4):422-434. doi:<a href="http://dx.doi.org/10.1093/oxfordjournals.aje.a120955">10.1093/oxfordjournals.aje.a120955</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/4305198" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Respiratory%20syncytial%20virus%20disease%20in%20infants%20despite%20prior%20administration%20of%20antigenic%20inactivated%20vaccine.&amp;author=HW%20Kim&amp;author=JG%20Canchola&amp;author=CD%20Brandt&amp;publication_year=1969&amp;journal=Am%20J%20Epidemiol&amp;volume=89&amp;pages=422-434" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/oxfordjournals.aje.a120955" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/oxfordjournals.aje.a120955" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r33">33.</a><div class="reference-content">Hotez
        Â PJï»¿, Corry
        Â DBï»¿, Bottazzi
        Â MEï»¿. Â COVID-19 vaccine design: the Janus face of immune enhancement.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nat Rev Immunol</i>. 2020;20(6):347-348. doi:<a href="http://dx.doi.org/10.1038/s41577-020-0323-4">10.1038/s41577-020-0323-4</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32346094" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=COVID-19%20vaccine%20design%3A%20the%20Janus%20face%20of%20immune%20enhancement.&amp;author=PJ%20Hotez&amp;author=DB%20Corry&amp;author=ME%20Bottazzi&amp;publication_year=2020&amp;journal=Nat%20Rev%20Immunol&amp;volume=20&amp;pages=347-348" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/s41577-020-0323-4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/s41577-020-0323-4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r34">34.</a><div class="reference-content">Hotez
        Â PJï»¿, Corry
        Â DBï»¿, Strych
        Â Uï»¿, Bottazzi
        Â MEï»¿. Â COVID-19 vaccines: neutralizing antibodies and the alum advantage.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nat Rev Immunol</i>. 2020;20(7):399-400. doi:<a href="http://dx.doi.org/10.1038/s41577-020-0358-6">10.1038/s41577-020-0358-6</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32499636" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=COVID-19%20vaccines%3A%20neutralizing%20antibodies%20and%20the%20alum%20advantage.&amp;author=PJ%20Hotez&amp;author=DB%20Corry&amp;author=U%20Strych&amp;author=ME%20Bottazzi&amp;publication_year=2020&amp;journal=Nat%20Rev%20Immunol&amp;volume=20&amp;pages=399-400" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/s41577-020-0358-6" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/s41577-020-0358-6" xmlns:helper="urn:XsltStringHelper"> </span></div></div></div> 
    </div>

            </div>
        </div>

        
        <div id="related-tab" class="resource-tab js-resource-tab related-tab need-jobs-ad">
    <div class="widget-ArticleLinks widget-instance-AMA_See_Also_Related_Content">
        
    <ul class="article-links related-content">

            <li class="article-link related-article odd">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2766371" class="td-n">
                        <div class="related-article-title">Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Viewpoint</div>
                    <div class="related-article-date">June 23, 2020</div>
                    <div class="related-article-excerpt">This Viewpoint describes how the National Institutes of Health is partnering with more than a dozen biopharmaceutical companies and multiple other agencies to develop an international strategy for a coordinated research response to the COVID-19 pandemic, including prioritizing vaccine and drug candidates.</div>
                    <div class="related-article-authors">Francis S.Â Collins,Â MD, PhD; PaulÂ Stoffels,Â MD</div>
                </a>
            </li>
            <li class="article-link related-article even">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2768156" class="td-n">
                        <div class="related-article-title">Safeguards Needed for Development of COVID-19 Vaccines</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Viewpoint</div>
                    <div class="related-article-date">August 4, 2020</div>
                    <div class="related-article-excerpt">This Viewpoint lists 4 safeguards policy makers should consider before release of a COVID-19 vaccine, including ensuring effectiveness through clinical trials, providing evidence of safety, requiring informed consent before vaccination, and establishing comprehensive adverse effects monitoring systems.</div>
                    <div class="related-article-authors">NicoleÂ Lurie,Â MD, MSPH; Joshua M.Â Sharfstein,Â MD; Jesse L.Â Goodman,Â MD, MPH</div>
                </a>
            </li>
            <li class="article-link related-article odd">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2769609" class="td-n">
                        <div class="related-article-title">An Inactivated Virus Candidate Vaccine to Prevent COVID-19</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Editorial</div>
                    <div class="related-article-date">September 8, 2020</div>
                    <div class="related-article-excerpt"></div>
                    <div class="related-article-authors">Mark J.Â Mulligan,Â MD</div>
                </a>
            </li>
            <li class="article-link related-article even">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2770485" class="td-n">
                        <div class="related-article-title">COVID-19 and mRNA Vaccinesâ€”First Large Test for a New Approach</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Medical News & Perspectives</div>
                    <div class="related-article-date">September 22, 2020</div>
                    <div class="related-article-excerpt">This Medical News article discusses the leading vaccine candidates against the novel coronavirus.</div>
                    <div class="related-article-authors">JenniferÂ Abbasi</div>
                </a>
            </li>
            <li class="article-link related-article odd">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/2770244" class="td-n">
                        <div class="related-article-title">Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Viewpoint</div>
                    <div class="related-article-date">October 6, 2020</div>
                    <div class="related-article-excerpt">This Viewpoint reviews the enormous political and public pressures the FDA is likely to be under in fall 2020 to provide emergency authorization or approval of candidate COVID-19 vaccines, and urges adherence to existing science-based protocols for approval to ensure vaccine safety and acceptance and thus protect the publicâ€™s health.</div>
                    <div class="related-article-authors">JerryÂ Avorn,Â MD; AaronÂ Kesselheim,Â MD, JD, MPH</div>
                </a>
            </li>
    </ul>
 
    </div>
    <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links">
        
    <div class="sm-linked-content">
                <div class="sm-linked-content--item">
                    <a href="https://jamanetwork.com/journals/jama/pages/coronavirus-alert" target="_blank" class="sm-linked-content--link fw-b sb-tc"><i class="icon-url d-ib thm-col"></i>COVID-19 Resource Center</a>
                </div>
    </div>
 
    </div>
    <div class="widget-RelatedTopics widget-instance-AMA_Related_Topics">
        
        <div class="related-topics-block">
            <h4 class="related-topics-heading topic-suggestions-heading sb-sc">
See More About            </h4>
            <div class="related-topics topic-suggestions">
    <a href="https://jamanetwork.com/collections/5670/global-health" id="item_Link" class="related-topic topic-suggestion no-wrap sb-anchor-light">Global Health</a>    <a href="https://jamanetwork.com/collections/5950/vaccination" id="item_Link_1" class="related-topic topic-suggestion no-wrap sb-anchor-light">Vaccination</a>    <a href="https://jamanetwork.com/collections/42128/public-health" id="item_Link_2" class="related-topic topic-suggestion no-wrap sb-anchor-light">Public Health</a>    <a href="https://jamanetwork.com/collections/46099/coronavirus-covid-19" id="item_Link_3" class="related-topic topic-suggestion no-wrap sb-anchor-light">Coronavirus (COVID-19)</a>            </div>
        </div>
 
    </div>
                <div class="ymal--footer">
    <div class="widget-WidgetLoader widget-instance-AMA_PersonalizedContent_SplitScreenView_Footer">
        <div class="SCM-SharedWidgets-AsyncWidgetLoader" data-url="/Personalization/PersonalizedContent/AMA_PersonalizedContent_SplitScreenView_Footer" data-params="{&quot;parameters&quot;:{&quot;resourceIdToExclude&quot;:2769612,&quot;resourceTypeToExclude&quot;:3},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

                </div>
                <hr />
                <div class="manage-interest">
                    <h4><a href="#" class="manage-interests-link-no-access thm-col-sec">Select Your Interests</a></h4>
    <div class="widget-ManageCollectionInterests widget-instance-ManageCollectionInterests_SplitScreen">
        <div class="manage-interests-modal reveal-modal small modal" data-reveal>
<div class="manage-interests--header">
    <div class="widget-SelfServeContent widget-instance-AMA_ManageInterests_Header">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="AllSitesManageInterestsHeader" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style>
    h4 {
    font-size: 20px !important;
    }
</style>
<h4>Select Your Interests</h4>
<p>Customize your JAMA Network experience by selecting one or more topics from the list below.</p>


</div>

 
    </div>

</div><div class="manage-interests--categories">
    <ul class="category-list">
            <li><span class="category-list-item " data-categoryid="46425">Academic Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5489">Acid Base, Electrolytes, Fluids</span></li>
            <li><span class="category-list-item " data-categoryid="5504">Allergy and Clinical Immunology</span></li>
            <li><span class="category-list-item " data-categoryid="46447">American Indian or Alaska Natives</span></li>
            <li><span class="category-list-item " data-categoryid="5510">Anesthesiology</span></li>
            <li><span class="category-list-item " data-categoryid="42143">Anticoagulation</span></li>
            <li><span class="category-list-item " data-categoryid="6261">Art and Images in Psychiatry</span></li>
            <li><span class="category-list-item " data-categoryid="44024">Artificial Intelligence</span></li>
            <li><span class="category-list-item " data-categoryid="42097">Assisted Reproduction</span></li>
            <li><span class="category-list-item " data-categoryid="42099">Bleeding and Transfusion</span></li>
            <li><span class="category-list-item " data-categoryid="5548">Cardiology</span></li>
            <li><span class="category-list-item " data-categoryid="44036">Caring for the Critically Ill Patient</span></li>
            <li><span class="category-list-item " data-categoryid="6255">Challenges in Clinical Electrocardiography</span></li>
            <li><span class="category-list-item " data-categoryid="46435">Climate and Health</span></li>
            <li><span class="category-list-item " data-categoryid="46448">Climate Change</span></li>
            <li><span class="category-list-item " data-categoryid="44038">Clinical Challenge</span></li>
            <li><span class="category-list-item " data-categoryid="5589">Clinical Decision Support</span></li>
            <li><span class="category-list-item " data-categoryid="44039">Clinical Implications of Basic Neuroscience</span></li>
            <li><span class="category-list-item " data-categoryid="5614">Clinical Pharmacy and Pharmacology</span></li>
            <li><span class="category-list-item " data-categoryid="5575">Complementary and Alternative Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="44040">Consensus Statements</span></li>
            <li><span class="category-list-item " data-categoryid="46099">Coronavirus (COVID-19)</span></li>
            <li><span class="category-list-item " data-categoryid="5584">Critical Care Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="46325">Cultural Competency</span></li>
            <li><span class="category-list-item " data-categoryid="44019">Dental Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5598">Dermatology</span></li>
            <li><span class="category-list-item " data-categoryid="44011">Diabetes and Endocrinology</span></li>
            <li><span class="category-list-item " data-categoryid="46320">Diagnostic Test Interpretation</span></li>
            <li><span class="category-list-item " data-categoryid="42054">Drug Development</span></li>
            <li><span class="category-list-item " data-categoryid="5620">Electronic Health Records</span></li>
            <li><span class="category-list-item " data-categoryid="5621">Emergency Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5819">End of Life, Hospice, Palliative Care</span></li>
            <li><span class="category-list-item " data-categoryid="42107">Environmental Health</span></li>
            <li><span class="category-list-item " data-categoryid="46387">Equity, Diversity, and Inclusion</span></li>
            <li><span class="category-list-item " data-categoryid="42108">Ethics</span></li>
            <li><span class="category-list-item " data-categoryid="5644">Facial Plastic Surgery</span></li>
            <li><span class="category-list-item " data-categoryid="44012">Gastroenterology and Hepatology</span></li>
            <li><span class="category-list-item " data-categoryid="5664">Genetics and Genomics</span></li>
            <li><span class="category-list-item " data-categoryid="44041">Genomics and Precision Health</span></li>
            <li><span class="category-list-item " data-categoryid="5668">Geriatrics</span></li>
            <li><span class="category-list-item " data-categoryid="5670">Global Health</span></li>
            <li><span class="category-list-item " data-categoryid="46427">Guide to Statistics and Methods</span></li>
            <li><span class="category-list-item " data-categoryid="5672">Guidelines</span></li>
            <li><span class="category-list-item " data-categoryid="5674">Hair Disorders</span></li>
            <li><span class="category-list-item " data-categoryid="42113">Health Care Delivery Models</span></li>
            <li><span class="category-list-item " data-categoryid="42114">Health Care Economics, Insurance, Payment</span></li>
            <li><span class="category-list-item " data-categoryid="42116">Health Care Quality</span></li>
            <li><span class="category-list-item " data-categoryid="5680">Health Care Reform</span></li>
            <li><span class="category-list-item " data-categoryid="5830">Health Care Safety</span></li>
            <li><span class="category-list-item " data-categoryid="5682">Health Care Workforce</span></li>
            <li><span class="category-list-item " data-categoryid="5679">Health Disparities</span></li>
            <li><span class="category-list-item " data-categoryid="46328">Health Inequities</span></li>
            <li><span class="category-list-item " data-categoryid="44020">Health Policy</span></li>
            <li><span class="category-list-item " data-categoryid="46451">Health Systems Science</span></li>
            <li><span class="category-list-item " data-categoryid="5688">Hematology</span></li>
            <li><span class="category-list-item " data-categoryid="5692">History of Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5514">Humanities</span></li>
            <li><span class="category-list-item " data-categoryid="5697">Hypertension</span></li>
            <li><span class="category-list-item " data-categoryid="44043">Images in Neurology</span></li>
            <li><span class="category-list-item " data-categoryid="45887">Implementation Science</span></li>
            <li><span class="category-list-item " data-categoryid="5702">Infectious Diseases</span></li>
            <li><span class="category-list-item " data-categoryid="44044">Innovations in Health Care Delivery</span></li>
            <li><span class="category-list-item " data-categoryid="44070">JAMA Infographic</span></li>
            <li><span class="category-list-item " data-categoryid="5716">Law and Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="45308">Leading Change</span></li>
            <li><span class="category-list-item " data-categoryid="44045">Less is More</span></li>
            <li><span class="category-list-item " data-categoryid="46327">LGBTQIA Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5720">Lifestyle Behaviors</span></li>
            <li><span class="category-list-item " data-categoryid="45311">Medical Coding</span></li>
            <li><span class="category-list-item " data-categoryid="5738">Medical Devices and Equipment</span></li>
            <li><span class="category-list-item " data-categoryid="44023">Medical Education</span></li>
            <li><span class="category-list-item " data-categoryid="5739">Medical Education and Training</span></li>
            <li><span class="category-list-item " data-categoryid="5713">Medical Journals and Publishing</span></li>
            <li><span class="category-list-item " data-categoryid="5746">Melanoma</span></li>
            <li><span class="category-list-item " data-categoryid="44025">Mobile Health and Telemedicine</span></li>
            <li><span class="category-list-item " data-categoryid="5766">Narrative Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5769">Nephrology</span></li>
            <li><span class="category-list-item " data-categoryid="5777">Neurology</span></li>
            <li><span class="category-list-item " data-categoryid="44052">Neuroscience and Psychiatry</span></li>
            <li><span class="category-list-item " data-categoryid="44053">Notable Notes</span></li>
            <li><span class="category-list-item " data-categoryid="5787">Nursing</span></li>
            <li><span class="category-list-item " data-categoryid="5788">Nutrition</span></li>
            <li><span class="category-list-item " data-categoryid="44027">Nutrition, Obesity, Exercise</span></li>
            <li><span class="category-list-item " data-categoryid="5791">Obesity</span></li>
            <li><span class="category-list-item " data-categoryid="44013">Obstetrics and Gynecology</span></li>
            <li><span class="category-list-item " data-categoryid="5796">Occupational Health</span></li>
            <li><span class="category-list-item " data-categoryid="5801">Oncology</span></li>
            <li><span class="category-list-item " data-categoryid="5804">Ophthalmology</span></li>
            <li><span class="category-list-item " data-categoryid="5808">Orthopedics</span></li>
            <li><span class="category-list-item " data-categoryid="5811">Otolaryngology</span></li>
            <li><span class="category-list-item " data-categoryid="44028">Pain Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="46446">Palliative Care</span></li>
            <li><span class="category-list-item " data-categoryid="44029">Pathology and Laboratory Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="45306">Patient Care</span></li>
            <li><span class="category-list-item " data-categoryid="6258">Patient Information</span></li>
            <li><span class="category-list-item " data-categoryid="5843">Pediatrics</span></li>
            <li><span class="category-list-item " data-categoryid="44060">Performance Improvement</span></li>
            <li><span class="category-list-item " data-categoryid="45315">Performance Measures</span></li>
            <li><span class="category-list-item " data-categoryid="42050">Perioperative Care and Consultation</span></li>
            <li><span class="category-list-item " data-categoryid="42125">Pharmacoeconomics</span></li>
            <li><span class="category-list-item " data-categoryid="42126">Pharmacoepidemiology</span></li>
            <li><span class="category-list-item " data-categoryid="5851">Pharmacogenetics</span></li>
            <li><span class="category-list-item " data-categoryid="44030">Pharmacy and Clinical Pharmacology</span></li>
            <li><span class="category-list-item " data-categoryid="5856">Physical Medicine and Rehabilitation</span></li>
            <li><span class="category-list-item " data-categoryid="42059">Physical Therapy</span></li>
            <li><span class="category-list-item " data-categoryid="45313">Physician Leadership</span></li>
            <li><span class="category-list-item " data-categoryid="44061">Poetry</span></li>
            <li><span class="category-list-item " data-categoryid="45316">Population Health</span></li>
            <li><span class="category-list-item " data-categoryid="46445">Primary Care</span></li>
            <li><span class="category-list-item " data-categoryid="45309">Professional Well-being</span></li>
            <li><span class="category-list-item " data-categoryid="44064">Professionalism</span></li>
            <li><span class="category-list-item " data-categoryid="5871">Psychiatry and Behavioral Health</span></li>
            <li><span class="category-list-item " data-categoryid="42128">Public Health</span></li>
            <li><span class="category-list-item " data-categoryid="5877">Pulmonary Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="42129">Radiology</span></li>
            <li><span class="category-list-item " data-categoryid="42058">Regulatory Agencies</span></li>
            <li><span class="category-list-item " data-categoryid="46443">Reproductive Health</span></li>
            <li><span class="category-list-item " data-categoryid="5916">Research, Methods, Statistics</span></li>
            <li><span class="category-list-item " data-categoryid="42142">Resuscitation</span></li>
            <li><span class="category-list-item " data-categoryid="5896">Rheumatology</span></li>
            <li><span class="category-list-item " data-categoryid="46326">Risk Management</span></li>
            <li><span class="category-list-item " data-categoryid="38802">Scientific Discovery and the Future of Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5833">Shared Decision Making and Communication</span></li>
            <li><span class="category-list-item " data-categoryid="5912">Sleep Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5915">Sports Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5533">Stem Cell Transplantation</span></li>
            <li><span class="category-list-item " data-categoryid="5921">Substance Use and Addiction Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5923">Surgery</span></li>
            <li><span class="category-list-item " data-categoryid="44065">Surgical Innovation</span></li>
            <li><span class="category-list-item " data-categoryid="44066">Surgical Pearls</span></li>
            <li><span class="category-list-item " data-categoryid="44067">Teachable Moment</span></li>
            <li><span class="category-list-item " data-categoryid="45310">Technology and Finance</span></li>
            <li><span class="category-list-item " data-categoryid="44034">The Art of JAMA</span></li>
            <li><span class="category-list-item " data-categoryid="44037">The Arts and Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="6257">The Rational Clinical Examination</span></li>
            <li><span class="category-list-item " data-categoryid="5936">Tobacco and e-Cigarettes</span></li>
            <li><span class="category-list-item " data-categoryid="5938">Toxicology</span></li>
            <li><span class="category-list-item " data-categoryid="46433">Translational Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="42136">Trauma and Injury</span></li>
            <li><span class="category-list-item " data-categoryid="5942">Treatment Adherence</span></li>
            <li><span class="category-list-item " data-categoryid="46323">Ultrasonography</span></li>
            <li><span class="category-list-item " data-categoryid="5947">Urology</span></li>
            <li><span class="category-list-item " data-categoryid="44069">Users&#39; Guide to the Medical Literature</span></li>
            <li><span class="category-list-item " data-categoryid="5950">Vaccination</span></li>
            <li><span class="category-list-item " data-categoryid="5955">Venous Thromboembolism</span></li>
            <li><span class="category-list-item " data-categoryid="45312">Veterans Health</span></li>
            <li><span class="category-list-item " data-categoryid="5957">Violence</span></li>
            <li><span class="category-list-item " data-categoryid="42139">Women&#39;s Health</span></li>
            <li><span class="category-list-item " data-categoryid="45307">Workflow and Process</span></li>
            <li><span class="category-list-item " data-categoryid="42140">Wound Care, Infection, Healing</span></li>
    </ul>
</div>

    
<div class="manage-interests--save-preferences">
    <div class="save-preferences-btn thm-bg ">
        <span class="save-preferences-btn-text fw-b">Save Preferences</span>
    </div>
</div>
<div class="manage-interests--privacy-terms"> <a class="manage-interests--privacy-terms-color" href="/pages/privacy-policy">Privacy Policy</a> | <a class="manage-interests--privacy-terms-color" href="/pages/terms-of-use">Terms of Use</a></div>

    
    <a class="close-reveal-modal icon-close"></a>
</div> 
    </div>

                </div>
                <h4 class="thm-col-sec" align="center">
                    Others Also Liked
                </h4>
                <div id="trendmd-suggestions"></div>

        </div>


        
        <div id="comments-tab" class="resource-tab js-resource-tab comments-tab js-comments-tab single-comment-view">



        </div>
    </div>
</div>

<a id="skip-to-navigation" href="#" tabindex="-1"></a>
<div id="content-panel" class="content-panel">
    <a id="top"></a>

    <div id="full-text-tab" class="resource-tab js-resource-tab full-text-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_ErrataArticleLinks_FullText">
         
    </div>
    <div class="widget-ArticleLinks widget-instance-AMA_ArticleLinks_ToErrata_FullText">
        
 
    </div>
    <div class="widget-ArticleNavLinks widget-instance-AMA_ArticleNavLinks">
                <a class="toc-link btn" href="https://jamanetwork.com/journals/jama/issue/324/10">This Issue</a>
 
    </div>



            <div class="article-metrics-wrapper" id="divArticleLevelMetrics">
    <div class="widget-ArticleLevelMetrics widget-instance-AMA_ArticleMetrics">
        

    <div class="artmet-condensed-wrap clearfix">
        <div class="artmet-condensed-stats clearfix">
                <div class="artmet-item artmet-views">
                    <span class="artmet-text sb-sc">Views</span>
                    <span class="artmet-number sb-sc">269,537</span>
                </div>
                                <div class="artmet-item artmet-citations">
                            <a class="artmet-citations-link" href="https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=silverchair&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000571867000018&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL" target="_blank">
                                <span class="artmet-text">Citations</span>
                                <span class="artmet-number">517</span>
                            </a>
                    </div>
                                <div class="artmet-item artmet-altmetric">
    <div class="widget-AltmetricLink widget-instance-AMAv2_ArticleLevelMetrics_AltmetricLinkSummary">
            <!-- Altmetrics -->
    <div id="altmetricEmbedId" class='altmetric-embed' data-link-target="_blank" data-badge-type="text" data-hide-no-mentions="false" data-doi="10.1001/jama.2020.15543"
     
        
        ></div>
 
    </div>

                    </div>

        </div>

        <div class="artmet-modal-trigger-wrap">
            <a rel="nofollow" class="artmet-modal-trigger" data-article-id="2769612"><i class="icon-metrics"></i><span>View Metrics</span></a>
        </div>
    </div>

 
    </div>

            </div>
        <ul class="toolbar">
            <li class="toolbar-pdf-wrap toolbar-tool-wrap">
            <a id="pdf-link" class="toolbar-tool toolbar-pdf al-link pdfaccess" data-article-id="2769612" data-article-url="/journals/jama/articlepdf/2769612/jama_xia_2020_pc_200005_1599242849.34452.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span>
            </a>

            </li>
            <li class="toolbar-share-wrap toolbar-tool-wrap">
                <div class="toolbar-tool">
                    <a class="st-custom-button addthis_button_twitter is-b toolbar-twitter toolbar-share"
                       data-network="twitter"
                       data-title=""
                       data-url=""
                       data-email-subject=""
                       rel="nofollow"
                       href="javascript:;">
                        <span class="share-text">X</span>
                    </a>
                    <a class="st-custom-button addthis_button_facebook is-b toolbar-facebook toolbar-share"
                       data-network="facebook"
                       data-title=""
                       data-url=""
                       data-email-subject=""
                       rel="nofollow"
                       href="javascript:;">
                        <span class="share-text">Facebook</span>
                    </a>
                    <a class="toolbar-share-more-link is-a" rel="nofollow"><span class="icon icon-carrot_down social-arrow"></span><span class="more-text-wrap">More</span></a>
                    <div class="toolbar-share-more">
                        <a class="st-custom-button addthis_button_linkedin is-b toolbar-linkedin toolbar-share"
                           data-network="linkedin"
                           data-title=""
                           data-url=""
                           data-email-subject=""
                           rel="nofollow"
                           href="javascript:;">
                            <span class="share-text">LinkedIn</span>
                        </a>
                    </div>
                </div>
            </li>

            <li class="toolbar-citation-wrap toolbar-tool-wrap">
    <div class="widget-ToolboxGetCitation widget-instance-AMA_Get_Citation">
        
        <a class="toolbar-tool toolbar-citation is-b stats-citation" rel="nofollow" data-reveal-id="get-citation" data-reveal>
            <span class="toolbar-link-text">Cite</span>
            <span class="toolbar-link-text-extra">This</span>
        </a>
    <div id="get-citation" class="reveal-modal get-citation" data-reveal>
        <h3 class="get-citation-title">Citation</h3>
        <p class="get-citation-citation">Xia S<span class='al-author-delim'>, </span>Duan K<span class='al-author-delim'>, </span>Zhang Y, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes<span class="subtitle"><span class="colon-for-citation-subtitle">: </span>Interim Analysis of 2 Randomized Clinical Trials</span>. <em>JAMA.</em> 2020;324(10):951â€“960. doi:10.1001/jama.2020.15543</p>
        <h4 class="get-citation-download-heading">Manage citations:</h4>
        <div class="get-citation-types">
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2769612&amp;resourceType=3&amp;citationFormat=0">Ris (Zotero)</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2769612&amp;resourceType=3&amp;citationFormat=1">EndNote</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2769612&amp;resourceType=3&amp;citationFormat=2">BibTex</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2769612&amp;resourceType=3&amp;citationFormat=3">Medlars</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2769612&amp;resourceType=3&amp;citationFormat=0">ProCite</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2769612&amp;resourceType=3&amp;citationFormat=3">RefWorks</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2769612&amp;resourceType=3&amp;citationFormat=0">Reference Manager</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=2769612&amp;resourceType=3&amp;citationFormat=0">Mendeley</a>
        </div>

        <p class="get-citation-copyright">&#169; 2024 </p>
        <a class="close-reveal-modal icon-close" rel="nofollow"></a>
    </div>


 
    </div>

            </li>
            <li class="toolbar-permissions-wrap toolbar-tool-wrap">
    <div class="widget-ToolboxPermissions widget-instance-AMA_Get_Permissions">
            <a href="http://s100.copyright.com/AppDispatchServlet?publisherName=AMA&amp;publication=0098-7484&amp;title=Effect+of+an+Inactivated+Vaccine+Against+SARS-CoV-2+on+Safety+and+Immunogenicity+Outcomes%3a+Interim+Analysis+of+2+Randomized+Clinical+Trials&amp;publicationDate=2020-09-08&amp;volumeNum=324&amp;issueNum=10&amp;author=Xia%2c+Shengli%3b+Duan%2c+Kai&amp;startPage=951&amp;endPage=960&amp;contentId=10.1001%2fjama.2020.15543&amp;oa=&amp;orderBeanReset=True" rel="nofollow" id="PermissionsLink" class="toolbar-tool toolbar-permissions is-b" target="_blank"><span class="toolbar-link-text">Permissions</span></a>
 
    </div>

            </li>
        </ul>

    <div class="widget-ArticleTopInfo widget-instance-AMA_ArticleTop_Info_Widget">
        

    <div class="meta-access-type free-access is-b"></div>


            <span class="hide tagmanagervalue" data-attribute="articleId" data-value="2769612" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="arrArticleAuthor" data-value="Shengli%C2%A0Xia%2C%C2%A0BS,Kai%C2%A0Duan%2C%C2%A0PhD,Yuntao%C2%A0Zhang%2C%C2%A0PhD,Dongyang%C2%A0Zhao%2C%C2%A0BS,Huajun%C2%A0Zhang%2C%C2%A0PhD,Zhiqiang%C2%A0Xie%2C%C2%A0MD,Xinguo%C2%A0Li%2C%C2%A0MD,Cheng%C2%A0Peng%2C%C2%A0MD,Yanbo%C2%A0Zhang%2C%C2%A0MD,Wei%C2%A0Zhang%2C%C2%A0MD,Yunkai%C2%A0Yang%2C%C2%A0MD,Wei%C2%A0Chen%2C%C2%A0MSc,Xiaoxiao%C2%A0Gao%2C%C2%A0PhD,Wangyang%C2%A0You%2C%C2%A0MD,Xuewei%C2%A0Wang%2C%C2%A0MD,Zejun%C2%A0Wang%2C%C2%A0PhD,Zhengli%C2%A0Shi%2C%C2%A0PhD,Yanxia%C2%A0Wang%2C%C2%A0BS,Xuqin%C2%A0Yang%2C%C2%A0MD,Lianghao%C2%A0Zhang%2C%C2%A0MSc,Lili%C2%A0Huang%2C%C2%A0BS,Qian%C2%A0Wang%2C%C2%A0MD,Jia%C2%A0Lu%2C%C2%A0PhD,Yongli%C2%A0Yang%2C%C2%A0PhD,Jing%C2%A0Guo%2C%C2%A0PhD,Wei%C2%A0Zhou%2C%C2%A0PhD,Xin%C2%A0Wan%2C%C2%A0MD,Cong%C2%A0Wu%2C%C2%A0MD,Wenhui%C2%A0Wang%2C%C2%A0MD,Shihe%C2%A0Huang%2C%C2%A0PhD,Jianhui%C2%A0Du%2C%C2%A0MD,Ziyan%C2%A0Meng%2C%C2%A0MD,An%C2%A0Pan%2C%C2%A0PhD,Zhiming%C2%A0Yuan%2C%C2%A0PhD,Shuo%C2%A0Shen%2C%C2%A0PhD,Wanshen%C2%A0Guo%2C%C2%A0BS,Xiaoming%C2%A0Yang%2C%C2%A0MD" data-type="array"></span>
            <span class="hide tagmanagervalue" data-attribute="articleDOI" data-value="10.1001/jama.2020.15543" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="articleTitle" data-value="Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes&lt;span class=&quot;subtitle&quot;&gt;&lt;span class=&quot;colon-for-citation-subtitle&quot;&gt;: &lt;/span&gt;Interim Analysis of 2 Randomized Clinical Trials&lt;/span&gt;" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="type" data-value="Preliminary Communication" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="issueVolume" data-value="324" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="issueNo" data-value="10" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="publishDate" data-value="September 8, 2020" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="topics" data-value="Global Health, Vaccination, Public Health, Coronavirus (COVID-19)" data-type="array"></span>
            <span class="hide tagmanagervalue" data-attribute="topicCode" data-value="5670, 5950, 42128, 46099" data-type="array"></span>
            <span class="hide tagmanagervalue" data-attribute="category" data-value="Research" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="journalClub" data-value="No" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="contentStatus" data-value="Free" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="articlePubState" data-value="Final" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="contentMedium" data-value="Article" data-type="string"></span>


        <div class="meta-article-type-wrap">
            <div class="meta-article-type thm-col">Preliminary Communication </div>
        </div>
        <div class="meta-date">August 13, 2020</div>
        <div class="meta-article-title-wrap">
            
            <h1 class="meta-article-title ">Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes<span class="subtitle"><span class="colon-for-citation-subtitle">: </span>Interim Analysis of 2 Randomized Clinical Trials</span></h1>

            
        </div>
            <div class="meta-authors">
                <span class="meta-authors--limited"><span class="wi-fullname brand-fg"><a href="/searchresults?author=Shengli+Xia&q=Shengli+Xia" rel=nofollow target="_blank">ShengliÂ Xia,Â BS<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Kai+Duan&q=Kai+Duan" rel=nofollow target="_blank">KaiÂ Duan,Â PhD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Yuntao+Zhang&q=Yuntao+Zhang" rel=nofollow target="_blank">YuntaoÂ Zhang,Â PhD<sup>3</sup></a></span>; <a class="meta-authors--etal td-u stats-meta-authors--etal">et al</a></span>
                <span class="meta-authors--remaining"><span class="wi-fullname brand-fg"><a href="/searchresults?author=Dongyang+Zhao&q=Dongyang+Zhao" rel=nofollow target="_blank">DongyangÂ Zhao,Â BS<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Huajun+Zhang&q=Huajun+Zhang" rel=nofollow target="_blank">HuajunÂ Zhang,Â PhD<sup>4</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Zhiqiang+Xie&q=Zhiqiang+Xie" rel=nofollow target="_blank">ZhiqiangÂ Xie,Â MD<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Xinguo+Li&q=Xinguo+Li" rel=nofollow target="_blank">XinguoÂ Li,Â MD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Cheng+Peng&q=Cheng+Peng" rel=nofollow target="_blank">ChengÂ Peng,Â MD<sup>4</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Yanbo+Zhang&q=Yanbo+Zhang" rel=nofollow target="_blank">YanboÂ Zhang,Â MD<sup>5</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Wei+Zhang&q=Wei+Zhang" rel=nofollow target="_blank">WeiÂ Zhang,Â MD<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Yunkai+Yang&q=Yunkai+Yang" rel=nofollow target="_blank">YunkaiÂ Yang,Â MD<sup>3</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Wei+Chen&q=Wei+Chen" rel=nofollow target="_blank">WeiÂ Chen,Â MSc<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Xiaoxiao+Gao&q=Xiaoxiao+Gao" rel=nofollow target="_blank">XiaoxiaoÂ Gao,Â PhD<sup>4</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Wangyang+You&q=Wangyang+You" rel=nofollow target="_blank">WangyangÂ You,Â MD<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Xuewei+Wang&q=Xuewei+Wang" rel=nofollow target="_blank">XueweiÂ Wang,Â MD<sup>3</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Zejun+Wang&q=Zejun+Wang" rel=nofollow target="_blank">ZejunÂ Wang,Â PhD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Zhengli+Shi&q=Zhengli+Shi" rel=nofollow target="_blank">ZhengliÂ Shi,Â PhD<sup>4</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Yanxia+Wang&q=Yanxia+Wang" rel=nofollow target="_blank">YanxiaÂ Wang,Â BS<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Xuqin+Yang&q=Xuqin+Yang" rel=nofollow target="_blank">XuqinÂ Yang,Â MD<sup>3</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Lianghao+Zhang&q=Lianghao+Zhang" rel=nofollow target="_blank">LianghaoÂ Zhang,Â MSc<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Lili+Huang&q=Lili+Huang" rel=nofollow target="_blank">LiliÂ Huang,Â BS<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Qian+Wang&q=Qian+Wang" rel=nofollow target="_blank">QianÂ Wang,Â MD<sup>3</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Jia+Lu&q=Jia+Lu" rel=nofollow target="_blank">JiaÂ Lu,Â PhD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Yongli+Yang&q=Yongli+Yang" rel=nofollow target="_blank">YongliÂ Yang,Â PhD<sup>6</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Jing+Guo&q=Jing+Guo" rel=nofollow target="_blank">JingÂ Guo,Â PhD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Wei+Zhou&q=Wei+Zhou" rel=nofollow target="_blank">WeiÂ Zhou,Â PhD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Xin+Wan&q=Xin+Wan" rel=nofollow target="_blank">XinÂ Wan,Â MD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Cong+Wu&q=Cong+Wu" rel=nofollow target="_blank">CongÂ Wu,Â MD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Wenhui+Wang&q=Wenhui+Wang" rel=nofollow target="_blank">WenhuiÂ Wang,Â MD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Shihe+Huang&q=Shihe+Huang" rel=nofollow target="_blank">ShiheÂ Huang,Â PhD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Jianhui+Du&q=Jianhui+Du" rel=nofollow target="_blank">JianhuiÂ Du,Â MD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Ziyan+Meng&q=Ziyan+Meng" rel=nofollow target="_blank">ZiyanÂ Meng,Â MD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=An+Pan&q=An+Pan" rel=nofollow target="_blank">AnÂ Pan,Â PhD<sup>5,7</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Zhiming+Yuan&q=Zhiming+Yuan" rel=nofollow target="_blank">ZhimingÂ Yuan,Â PhD<sup>4</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Shuo+Shen&q=Shuo+Shen" rel=nofollow target="_blank">ShuoÂ Shen,Â PhD<sup>2</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Wanshen+Guo&q=Wanshen+Guo" rel=nofollow target="_blank">WanshenÂ Guo,Â BS<sup>1</sup></a></span><span class='al-author-delim'>; </span><span class="wi-fullname brand-fg"><a href="/searchresults?author=Xiaoming+Yang&q=Xiaoming+Yang" rel=nofollow target="_blank">XiaomingÂ Yang,Â MD<sup>2,3</sup></a></span></span>
            </div>
            <div class="meta-author">
                <a class="meta-author-title is-b stats-meta-author-toggle" data-tog-target=".meta-author-content">Author Affiliations</a>
                    <a class="meta-articleinfo-jumplink section-jump-link scroll-to stats-scroll-to-articleinfo" data-tab-toggle=".tab-nav-full-text" href="#247319403">Article Information</a>


                <div class="meta-author-content">
                        <ul class="meta-author-affiliations">
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>1</sup>Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>2</sup>National Engineering Technology Research Center for Combined Vaccines, Wuhan Institute of Biological Products Co Ltd, Wuhan, Hubei, China</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>3</sup>China National Biotec Group Company Limited, Beijing, China</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>4</sup>Chinese Academy of Sciences Key Laboratory of Special Pathogens, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei, China</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>5</sup>Department of Epidemiology and Biostatistics, Ministry of Education Key Laboratory of Environment and Health and State Key Laboratory of Environmental Health (Incubation), School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>6</sup>Department of Epidemiology and Biostatistics, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China</div>
                                </li>
                                <li class="meta-author-affiliation">
                                        <div class="meta-author-name"><sup>7</sup>National Medical Center for Major Public Health Events, Huazhong University of Science and Technology, Wuhan, Hubei, China</div>
                                </li>
                        </ul>



                </div>
            </div>
        <div class="meta-citation-wrap">
            <span class="meta-citation-journal-name">JAMA. </span><span class="meta-citation"> 2020;324(10):951-960. doi:10.1001/jama.2020.15543</span>
        </div>

 
    </div>
    <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links">
        
    <div class="sm-linked-content">
                <div class="sm-linked-content--item">
                    <a href="https://jamanetwork.com/journals/jama/pages/coronavirus-alert" target="_blank" class="sm-linked-content--link fw-b sb-tc"><i class="icon-url d-ib thm-col"></i>COVID-19 Resource Center</a>
                </div>
    </div>
 
    </div>
    <div class="widget-LinkedContentToolbar widget-instance-AMA_LinkedContentToolbar">
        
<div class="linked-content-toolbar">
    
    <div class="hidden js-search-open-multimedia-by-default" showContentByDefault="False"></div>
    <div class="linked-content-controls">
        <a class="linked-content-trigger td-n stats-graphical-abstract" href="#graphical-abstract-tab">
            <i class="icon-visual-abstract"><span class="sr-t">visual abstract icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Visual <div>Abstract</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-editorial-comment" href="#editorial-comment-tab">
            <i class="icon-document"><span class="sr-t">editorial comment icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Editorial <div>Comment</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-related-articles" href="#related-articles-tab">
            <i class="icon-related"><span class="sr-t">related articles icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Related <div>Articles</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-author-interviews" href="#author-interviews-tab">
            <i class="icon-author_interview"><span class="sr-t">author interview icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Interviews</div>
        </a>
        <a class="linked-content-trigger td-n stats-more-multimedia" href="#more-multimedia-tab">
            <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Multimedia</div>
        </a>
        <a class="linked-content-trigger td-n stats-listen-to-this-article" href="#listen-to-this-article-tab">
            <i class="icon-audio"><span class="sr-t">audio icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Listen to <div>this article</div></div>
        </a>
    </div>

    
<div class="linked-content-tabs">
    <div id="graphical-abstract-tab" class="linked-content-tab graphical-abstract-tab">
    <div class="widget-SectionDisplay widget-instance-AMA_GraphicalAbstract_Tab">
        
 
    </div>

    </div>

    
    <div id="editorial-comment-tab" class="linked-content-tab editorial-comment-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_EditorialComments">
        
    <ul class="article-abstract-links related-abstract-content">
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2769609">
                            <div class="related-article-type">Editorial</div>
                        <div class="related-article-title sb-tc">An Inactivated Virus Candidate Vaccine to Prevent COVID-19</div>
                    </a>
                    <div class="related-article-authors">Mark J.Â Mulligan,Â MD</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
    </ul>
 
    </div>

    </div>

    
    <div id="related-articles-tab" class="linked-content-tab related-article-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedArticle">
        
    <ul class="article-abstract-links related-abstract-content">
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2766371">
                            <div class="related-article-type">Viewpoint</div>
                        <div class="related-article-title sb-tc">Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)</div>
                    </a>
                    <div class="related-article-authors">Francis S.Â Collins,Â MD, PhD; PaulÂ Stoffels,Â MD</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2768156">
                            <div class="related-article-type">Viewpoint</div>
                        <div class="related-article-title sb-tc">Safeguards Needed for Development of COVID-19 Vaccines</div>
                    </a>
                    <div class="related-article-authors">NicoleÂ Lurie,Â MD, MSPH; Joshua M.Â Sharfstein,Â MD; Jesse L.Â Goodman,Â MD, MPH</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2770485">
                            <div class="related-article-type">Medical News & Perspectives</div>
                        <div class="related-article-title sb-tc">COVID-19 and mRNA Vaccinesâ€”First Large Test for a New Approach</div>
                    </a>
                    <div class="related-article-authors">JenniferÂ Abbasi</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/2770244">
                            <div class="related-article-type">Viewpoint</div>
                        <div class="related-article-title sb-tc">Regulatory Decision-making on COVID-19 Vaccines During a Public Health Emergency</div>
                    </a>
                    <div class="related-article-authors">JerryÂ Avorn,Â MD; AaronÂ Kesselheim,Â MD, JD, MPH</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
    </ul>
 
    </div>
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedEditorsChoices">
        
 
    </div>

    </div>

    
    <div id="author-interviews-tab" class="linked-content-tab linked-author-interviews-tab">
    <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_AuthorInterviews">
         
    </div>

    </div>

    
    <div id="listen-to-this-article-tab" class="linked-content-tab linked-listen-to-this-article-tab">
    <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_ListenToThisArticle">
         
    </div>

    </div>

    
    <div id="more-multimedia-tab" class="linked-content-tab more-multimedia-tab">

    </div>
</div>
</div> 
    </div>

            <div class="widget-ArticleFulltext widget-instance-AMA_Article_FullText_Widget">
        <div class="article-full-text" data-userHasAccess="True">
    

            <a class="article-section-id-anchor" id="247319348"></a>
<span class="heading-text thm-col h3 cb section-type-keyPoints decorated-hed sb-sc ">Key Points</span><p><strong>Question</strong>Â 
    <span>What are the safety and immunogenicity of an inactivated vaccine against coronavirus disease 2019 (COVID-19)?</span></p><p><strong>Findings</strong>Â 
    <span>This was an interim analysis of 2 randomized placebo-controlled trials. In 96 healthy adults in a phase 1 trial of patients randomized to aluminum hydroxide (alum) only and low, medium, and high vaccine doses on days 0, 28, and 56, 7-day adverse reactions occurred in 12.5%, 20.8%, 16.7%, and 25.0%, respectively; geometric mean titers of neutralizing antibodies at day 14 after the third injection were 316, 206 and 297 in the low-, medium-, and high-dose groups, respectively. In 224 healthy adults randomized to the medium dose, 7-day adverse reactions occurred in 6.0% and 14.3% of the participants who received injections on days 0 and 14 vs alum only, and 19.0% and 17.9% who received injections on days 0 and 21 vs alum only, respectively; geometric mean titers of neutralizing antibodies in the vaccine groups at day 14 after the second injection were 121 vs 247, respectively.</span></p><p><strong>Meaning</strong>Â 
    <span>This inactivated COVID-19 vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy will require phase 3 trials.</span></p>            <a class="article-section-id-anchor" id="247319349"></a>
                        <div class="h3 cb section-type-abstract decorated-hed ">

                            <div class="heading-text thm-col sb-sc">
                                Abstract
                            </div>
                        </div>
<p><strong>Importance</strong>Â 
    <span>A vaccine against coronavirus disease 2019 (COVID-19) is urgently needed.</span></p><p><strong>Objective</strong>Â 
    <span>To evaluate the safety and immunogenicity of an investigational inactivated whole-virus COVID-19 vaccine in China.</span></p><p><strong>Interventions</strong>Â 
    <span>In the phase 1 trial, 96 participants were assigned to 1 of the 3 dose groups (2.5, 5, and 10 Î¼g/dose) and an aluminum hydroxide (alum) adjuvantâ€“only group (nâ€‰=â€‰24 in each group), and received 3 intramuscular injections at days 0, 28, and 56. In the phase 2 trial, 224 adults were randomized to 5 Î¼g/dose in 2 schedule groups (injections on days 0 and 14 [nâ€‰=â€‰84] vs alum only [nâ€‰=â€‰28], and days 0 and 21 [nâ€‰=â€‰84] vs alum only [nâ€‰=â€‰28]).</span></p><p><strong>Design, Setting, and Participants</strong>Â 
    <span>Interim analysis of ongoing randomized, double-blind, placebo-controlled, phase 1 and 2 clinical trials to assess an inactivated COVID-19 vaccine. The trials were conducted in Henan Province, China, among 96 (phase 1) and 224 (phase 2) healthy adults aged between 18 and 59 years. Study enrollment began on April 12, 2020. The interim analysis was conducted on June 16, 2020, and updated on July 27, 2020.</span></p><p><strong>Main Outcomes and Measures</strong>Â 
    <span>The primary safety outcome was the combined adverse reactions 7 days after each injection, and the primary immunogenicity outcome was neutralizing antibody response 14 days after the whole-course vaccination, which was measured by a 50% plaque reduction neutralization test against live severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).</span></p><p><strong>Results</strong>Â 
    <span>Among 320 patients who were randomized (mean age, 42.8 years; 200 women [62.5%]), all completed the trial up to 28 days after the whole-course vaccination. The 7-day adverse reactions occurred in 3 (12.5%), 5 (20.8%), 4 (16.7%), and 6 (25.0%) patients in the alum only, low-dose, medium-dose, and high-dose groups, respectively, in the phase 1 trial; and in 5 (6.0%) and 4 (14.3%) patients who received injections on days 0 and 14 for vaccine and alum only, and 16 (19.0%) and 5 (17.9%) patients who received injections on days 0 and 21 for vaccine and alum only, respectively, in the phase 2 trial. The most common adverse reaction was injection site pain, followed by fever, which were mild and self-limiting; no serious adverse reactions were noted. The geometric mean titers of neutralizing antibodies in the low-, medium-, and high-dose groups at day 14 after 3 injections were 316 (95% CI, 218-457), 206 (95% CI, 123-343), and 297 (95% CI, 208-424), respectively, in the phase 1 trial, and were 121 (95% CI, 95-154) and 247 (95% CI, 176-345) at day 14 after 2 injections in participants receiving vaccine on days 0 and 14 and on days 0 and 21, respectively, in the phase 2 trial. There were no detectable antibody responses in all alum-only groups.</span></p><p><strong>Conclusions and Relevance</strong>Â 
    <span>In this interim report of the phase 1 and phase 2 trials of an inactivated COVID-19 vaccine, patients had a low rate of adverse reactions and demonstrated immunogenicity; the study is ongoing. Efficacy and longer-term adverse event assessment will require phase 3 trials.</span></p><p><strong>Trial Registration</strong>Â 
    <span>Chinese Clinical Trial Registry Identifier: <a href="http://www.chictr.org.cn/hvshowproject.aspx?id=27698">ChiCTR2000031809</a></span></p>            <div class="movable-ad-target bta"> </div>
            <a class="article-section-id-anchor" id="247319354"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Introduction
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319355"></a>
<p class="para">Coronavirus disease 2019 (COVID-19) is an emerging respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that had infected more than 16 million individuals and caused more than 656â€¯000 deaths worldwide by July 29, 2020.<sup><a href="#jpc200005r1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> A safe and effective vaccine against COVID-19 is urgently needed.</p>            <a class="article-section-id-anchor" id="247319356"></a>
<p class="para">There are currently more than 160 COVID-19 candidate vaccines in development worldwide, and 25 are in different phases of clinical trials using different platforms.<sup><a href="#jpc200005r2" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">2</a></sup> The results of the phase 1 and 2 trials of several vaccines, such as a recombinant adenovirus type-5 (Ad5)â€“vectored vaccine, a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19), and 2 mRNA vaccines, have been published or made available on preprint servers.<sup><a href="#jpc200005r3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a></sup><sup>-<a href="#jpc200005r3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup> Inactivated vaccines have been widely used for the prevention of emerging respiratory diseases for decades,<sup><a href="#jpc200005r9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup> and results from preclinical studies of 2 inactivated COVID-19 vaccines have shown that the vaccines could protect rhesus macaques against SARS-CoV-2 with varying efficacy.<sup><a href="#jpc200005r10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup><sup>,<a href="#jpc200005r11" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">11</a></sup> However, results from clinical trials in humans have not been reported for the inactivated vaccines.</p>            <a class="article-section-id-anchor" id="247319357"></a>
<p class="para">This report is the preliminary assessment of the safety outcomes 28 days and immunogenicity outcomes 14 days after 3 doses in a phase 1 trial and 2 doses in a phase 2 trial of an inactivated COVID-19 vaccine candidate in healthy adults in China.</p>            <a class="article-section-id-anchor" id="247319358"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Methods
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319359"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Study Design and Participants
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319360"></a>
<p class="para">These double-blind, randomized, placebo-controlled phase 1 and 2 trials were designed by the Wuhan Institute of Biological Products Co Ltd and Henan Provincial Center for Disease Control and Prevention (CDC). The study protocol, available in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 1</a>, was approved by the institutional review board of Henan Provincial CDC. The statistical analysis plan is available in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 2</a>. Written informed consents were obtained from all participants before enrollment. The ongoing trials are being performed and data collected by the investigators at the CDC of Wuzhi Country, Henan Province, beginning on April 12, 2020. An independent data and safety monitoring board is monitoring the safety data and evaluating the risks among the participants during the trial. An interim analysis was conducted on June 16, 2020, and updated on July 27, 2020.</p>            <a class="article-section-id-anchor" id="247319361"></a>
<p class="para">Healthy adults, aged 18 to 59 years, without history of SARS-CoV (via on-site inquiry) or SARS-CoV-2 infection (via serological and nucleic acid test) were eligible for enrollment in the study, and details of the inclusion and exclusion criteria are provided in the eMethods in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 3</a>. The participants were sequentially assigned a computer-generated randomization number, and stratified block randomization (block size, 8) by subgroups was adopted. Within each randomization block, the ratio of vaccine vs placebo was 3:1. All the vaccines and placebos were supplied in coded, identical-appearing, single-dose vials. Participants received 200 renminbi (US $29) for each blood sample donation.</p>            <a class="article-section-id-anchor" id="247319362"></a>
<p class="para">In the phase 1 trial, participants were randomly and equally assigned to 3 vaccine dose groups (low, medium, and high doses with 2.5-, 5-, and 10-Î¼g antigen protein content per dose, respectively, corresponding to 100, 200, and 400 Wuhan units/dose in the protocol) and a control group of aluminum hydroxide (alum) adjuvant only, and received intramuscular injections on days 0, 28, and 56 (<a href="#jpc200005f1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 1</a>). In the phase 2 trial, participants were randomly divided into 2 schedule groups (days 0 and 14, and days 0 and 21) using the medium (5-Î¼g) dose. Within each schedule group, the ratio of receiving vaccine and alum only was 3:1 (<a href="#jpc200005f1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 1</a>).</p>            <a class="article-section-id-anchor" id="247319364"></a>
<p class="para">Participants were sequentially enrolled and received injections based on sentinel data. Participants in the low-dose group in the phase 1 trial received injections first, and adverse events were monitored for 7 days. If no vaccine-related severe adverse events were observed, participants in the medium-dose group in phase 1 received injections on day 8. Subsequently, participants in the high-dose group in phase 1 and participants in the medium-dose group in phase 2 received injections 8 days later if no vaccine-related severe adverse events were observed in the medium-dose group in phase 1.</p>            <a class="article-section-id-anchor" id="247319365"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Vaccine
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319366"></a>
<p class="para">A SARS-CoV-2 strain (WIV04 strain, National Genomic Data Center of the Chinese Academy of Science accession No. SAMC133237, and GenBank accession number MN996528) was isolated from a patient in the Jinyintan Hospital, Wuhan. The virus was cultivated in a qualified Vero cell line for propagation, and the supernatant of the infected cells was inactivated with Î²-propiolactone (1:4000 vol/vol at 2 to 8 Â°C for 48 hours. Following clarification of cell debris and ultrafiltration, the second Î²-propiolactone inactivation was performed in the same conditions as the first inactivation. The vaccine was adsorbed to 0.5-mg alum and packed into prefilled syringes in 0.5-mL sterile phosphate-buffered saline without preservative. The placebo group contained only sterile phosphate-buffered saline and alum adjuvant. All the vaccines and placebos were approved by the National Institutes for Food and Drug Control of China.</p>            <a class="article-section-id-anchor" id="247319367"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Outcomes
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319368"></a>
<p class="para">The participants were asked to record any injection siteâ€“specific adverse reactions (eg, pain, redness, and swelling) and systemic adverse reactions (eg, fever, headache, and fatigue) on diary cards within 7 days of each injection, which were summed and considered as the primary safety outcome in both phases. Any other unsolicited symptoms were also recorded during a 28-day follow-up period after each injection, and were considered as the secondary safety outcome. In the phase 1 trial, laboratory safety tests (including routine blood tests, liver enzymes, total bilirubin, creatinine, urea nitrogen, urine protein, urine sugar, and urinary occult blood) were performed before and 4 days after each injection to assess any toxic effects after vaccination. Blood lymphocyte subset distribution (eg, CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> T cells; natural killer cells; and B cells) and key cytokines (eg, tumor necrosis factor, IFN-Î³, IL-2, IL-4, IL-5, and IL-6) were measured via flow cytometry before and 14 days after each injection. The schedule of biospecimen sample collections and related tests are shown in eFigure 1 in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 3</a>. The hematologic and biochemical markers were considered secondary safety measures in the phase 1 trial, and detailed methods for the laboratory measures are described in the eMethods in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 3</a>. The grading criteria of adverse reactions or events and the relationship with receiving injections were decided by the investigators before unblinding according to the standard guidelines issued by the National Medical Products Administration of China, and details are shown in eTable 1 in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 3</a>.</p>            <a class="article-section-id-anchor" id="247319369"></a>
<p class="para">The primary humoral immunogenicity outcomes included the neutralizing antibody titers and the specific IgG-binding antibody titers. In the phase 1 trial, blood samples were collected before and at days 4 and 14 after each injection, as well as day 21 after the first dose. In the phase 2 trial, blood samples were collected before the first dose among all participants and at day 14 after the second dose among half of the participants whose randomization numbers were in the first half of the group list, which was considered as the immunogenicity subset in the analysis. The neutralization capacity induced by vaccine against live SARS-CoV-2 (BetaCoV/Wuhan/AMMS01/2020 activated) was analyzed in triplicate by plaque reduction neutralization test (PRNT), and the PRNT<sub>50</sub> values were reported as a measure to determine the extent to which serum can be diluted and still reduce SARS-CoV-2 plaque formation by 50%. The total specific IgG antibody responses were measured with an in-houseâ€“developed enzyme-linked immunosorbent assay kit, which used the inactivated whole SARS-CoV-2 as coating antigen. Details of the immunogenicity assays have been previously reported<sup><a href="#jpc200005r12" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">12</a></sup> and are provided in the eMethods in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 3</a>. The lower limit of detection was 5 for the neutralizing antibody test and 10 for the specific IgG antibody test, and those below the detection limit (eg, all baseline values) were assigned to 5 or 10, respectively, for further analysis. Seroconversion rate, as a secondary immunogenicity outcome, was defined as at least a 4-fold increase of antibody titers over baseline, thus the threshold was 20 for the neutralizing antibody titers and 40 for the specific IgG antibody titers.</p>            <a class="article-section-id-anchor" id="247319370"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Statistical Analysis
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319371"></a>
<p class="para">The statistical analysis plan is included in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 2</a>. The sample size was not determined based on the statistical power calculation; however, a minimum sample size of 20 to 30 participants was recommended for the phase 1 vaccine trial by the National Medical Products Administration of China. Both phases were designed at the same time, thus the sample size in the phase 2 trial was not calculated based on results from the phase 1 trial, but determined based on expert opinion of previous research experiences to be at least 3-fold that of the phase 1 trial.</p>            <a class="article-section-id-anchor" id="247319372"></a>
<p class="para">The safety analysis was performed on data from all participants who received at least 1 dose. The number and proportion of participants with adverse reactions or events and the detailed safety profiles were compared across groups. The immunogenicity analysis was performed on data from the full analysis set of participants who received at least 1 dose and had results of any blood biomarker measurements before or after injections, and missing values were planned to be imputed by the last observation carried forward method; however, there were no missing data. The Ï‡<sup>2</sup> test or Fisher exact test (when data were sparse) was used to analyze categorical data, and the <i>t</i> test or the Mann-Whitney U test (for nonnormally distributed data) was used to analyze log-transformed antibody titers between vaccine and alum-only groups. Differences across groups at different time points were analyzed by analysis of variance. Analyses were conducted using SPSS software, version 25.0 (IBM SPSS Inc). Hypothesis testing was 2-sided with an Î± value of .05. Because of the potential type I error due to multiple comparisons, findings for analyses of secondary end points should be interpreted as exploratory.</p>            <a class="article-section-id-anchor" id="247319373"></a>
<p class="para">To accelerate the vaccine development procedure and provide evidence for the phase 3 trial, an interim analysis was added to the protocol on June 14, 2020, to partially unblind some groups while the trial was ongoing. The groups that were unblinded in the current analysis were chosen for 2 major reasons. First, data were available for up to 14 days after 2 injections in those groups in both phases. Second, those groups had results for 3 different doses (low, medium, and high doses) and 3 injection procedures (2 injections on days 0 and 14, on days 0 and 21, or on days 0 and 28), which provided evidence for the design of the next phase. The data and safety monitoring board reviewed the data and results on June 16, 2020, and recommended that the preliminary analysis report be provided to the principal investigator and sponsor. The summary-level results of safety and humoral immunogenicity for these groups were released to the public; however, the individual data were not made public. The field investigators and participants remained blinded and the planned assessments were continued as specified in the protocol. On July 27, 2020, the results were further updated for the phase 1 trial with data available up to 28 days for safety assessment and 14 days for humoral immunogenicity assessment after the third injection. Data of extended follow-up visits (days 28, 90, 180, and 360 after the whole-course vaccination in both phases) were not yet available and are not reported in the current analysis. The other groups in the phase 2 trial (low-, medium-, and high-dose groups with 3 injections [days 0, 28, and 56; nâ€‰=â€‰80 in each group], a medium-dose group with 2 injections [days 0 and 28; nâ€‰=â€‰112], and a 1-injection group with the high dose [nâ€‰=â€‰112]) remain blinded as specified in the protocol, and results from those groups are not yet available.</p>            <a class="article-section-id-anchor" id="247319374"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Results
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319375"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Study Participants
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319376"></a>
<p class="para">Between April 12 and May 2, 2020, a total of 481 volunteers were screened, and 96 were included in the phase 1 trial and 224 in the phase 2 trial (<a href="#jpc200005f1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 1</a>). All participants completed immunizations and scheduled visits within the prescribed time. The baseline characteristics of the participants are shown in <a href="#jpc200005t1" class="table-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 1</a>. The mean (SD) age was 41.2 (9.6) years and 43.5 (9.1) years in the phase 1 and 2 trials, respectively; there were 58 women (60.4%) in phase 1 and 142 women (63.4%) in phase 2.</p>            <a class="article-section-id-anchor" id="247319378"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Safety Outcomes
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319379"></a>
<p class="para">The combined injection site and systemic reaction symptoms (according to solicited reports) are shown in <a href="#jpc200005t2" class="table-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 2</a>. Within 7 days after injection, adverse reactions were reported by 48 (15.0%) of 320 participants in the trials. Specifically, the number of participants reporting adverse reactions was 5 (20.8%), 4 (16.7%), 6 (25.0%), and 3 (12.5%) in the low-dose, medium-dose, high-dose, and alum-only groups, respectively, in the phase 1 trial; and 5 (6.0%), 4 (14.3%), 16 (19.0%) and 5 (17.9%) in the groups who received the medium dose at days 0 and 14, alum only at days 0 and 14, the medium dose at days 0 and 21, and alum only at days 0 and 21, respectively, in the phase 2 trial. The most common adverse reaction was injection site pain (14 in phase 1 and 21 in phase 2), followed by fever (2 in phase 1 and 8 in phase 2). All adverse reactions were mild (grade 1 or 2), transient, and self-limiting, and did not require any treatment. No other adverse reactions were reported between days 8 and 28 after injection. There were no major differences across 3 injections in phase 1 or 2 injections in phase 2 (eTable 2 in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 3</a>). Unsolicited adverse events (regardless of relations with the immunization) are shown in eTable 3 in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 3</a>. Four severe adverse events (grade 3) occurred during the follow-up but all were unrelated to the immunization.</p>            <a class="article-section-id-anchor" id="247319381"></a>
<p class="para">In the phase 1 trial, the laboratory safety tests before and on day 4 after each injection revealed very few transient abnormalities in blood biochemical tests or urinalysis tests without special treatment (eTable 4 in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 3</a>). The blood lymphocyte subset and cytokine analysis showed no notable changes over time in different groups or substantial differences across groups at a certain time point (eFigures 2, 3, 4, 5, and 6 in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 3</a>).</p>            <a class="article-section-id-anchor" id="247319382"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Immunogenicity Outcomes
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319383"></a>
<p class="para">None of the participants had any detectable neutralizing antibody response against live SARS-CoV-2 at baseline or in the alum groups during the follow-up. In the phase 1 trial, the geometric mean titer (GMT) of neutralizing antibody at day 14 after the third injection was 316 (95% CI, 218-457) in the low-dose group, 206 (95% CI, 123-343) in the medium-dose group, and 297 (95% CI, 208-424) in the high-dose group (<a href="#jpc200005t3" class="table-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 3</a>). In the phase 2 trial using the medium dose, the GMT was 121 (95% CI, 95-154) in the group who received injections on days 0 and 14 and 247 (95% CI, 176-345) in the group who received injections on days 0 and 21. Seroconversion was noted in all participants (100%) receiving vaccines in the low- and high-dose groups in phase 1, 23 of 24 participants (95.8%) in the medium-dose group in phase 1, and 41 of 42 participants (97.6%) in the 2 groups in phase 2, but none in the alum-only group.</p>            <a class="article-section-id-anchor" id="247319385"></a>
<p class="para">The GMTs of the specific IgG antibody were 415 (95% CI, 288-597), 349 (95% CI, 258-472), and 311 (95% CI, 229-422) in the low-dose, medium-dose, and high-dose groups in the phase 1 trial, as well as 74 (95% CI, 56-97) in the medium-dose group who received injections on days 0 and 14 and 215 (95% CI, 157-296) in the group who received injections on days 0 and 21 in the phase 2 trial (<a href="#jpc200005t3" class="table-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 3</a>). Seroconversion was noted in all participants (100%) in phase 1 and those who received injections on days 0 and 21 in phase 2, while it was 85.7% (36/42) in the group who received injections on days 0 and 14 in phase 2 and none in the alum-only group.</p>            <a class="article-section-id-anchor" id="247319386"></a>
<p class="para">The dynamic changes of the antibody responses in the phase 1 trial were further examined (<a href="#jpc200005f2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 2</a>; eTable 5 in <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 3</a>). Most participants started to generate antibody responses after the second injection, and remained at high levels 14 days after the third injection. The antibody responses 14 days after the second injection in the phase 2 trial are also shown in <a href="#jpc200005f3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 3</a>, and results in more time points are currently not available.</p>            <a class="article-section-id-anchor" id="247319389"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Discussion
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319390"></a>
<p class="para">To our knowledge, this is the first report of phase 1 and 2 clinical trials of a whole-virus inactivated COVID-19 vaccine among healthy adults. The inactivated vaccine was well tolerated in all dose groups under different injection procedures with no vaccine-related serious adverse events. The most common adverse reaction was injection site pain, which was mild and self-limiting. The incidence rate of adverse reactions in the current study (15.0% among all participants) was lower compared with results of other candidate vaccines.<sup><a href="#jpc200005r3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a></sup><sup>-<a href="#jpc200005r3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup> Although all these studies reported that the adverse reactions were mostly mild and moderate in severity and self-limiting, the incidence rates in the vaccine groups (mostly &gt;60% and in some studies 100%) were higher compared with the control group. Therefore, the inactivated vaccine in the current study suggests a relatively better safety profile compared with vaccines using other platforms. However, these comparisons should be cautiously interpreted given the small sample size in the studies, and that few serious adverse events occurred.</p>            <a class="article-section-id-anchor" id="247319391"></a>
<p class="para">The neutralizing antibody response was monitored over 14 days after injections in the current preliminary report, and the results suggested that the inactivated vaccine may effectively induce antibody production. The results in both phases indicated that a longer interval (21 days and 28 days) between the first and second injections produced higher antibody responses compared with a shorter interval schedule (14-day group). The antibody titers started to increase after the second injection and further increased after the third injection, suggesting the need for a booster injection. Nevertheless, the optimal interval between injections and times of booster injections of the inactivated vaccine remain unclear, and the full analysis of the trial data with extended follow-up and other intervention groups is needed.</p>            <a class="article-section-id-anchor" id="247319392"></a>
<p class="para">The observed humoral immune response was likely generated by the vaccine, not through natural infections, because the screening procedure (including serological screening and nucleic acid testing) was conducted to try to ensure that none of the participants was infected with SARS-CoV-2 before enrollment. Furthermore, no new COVID-19 cases were reported at the study area and no participant developed any symptoms of SARS-CoV-2 infection during the trial.</p>            <a class="article-section-id-anchor" id="247319393"></a>
<p class="para">Convalescent serum samples in a comparison group were unavailable to provide a benchmark to interpret the magnitude of the antibody responses. However, when compared with published results from other COVID-19 vaccine trials, the neutralizing antibody titers (measured by the PRNT assay in the current study) were comparable with the levels in other studies using a similar method, such as the mRNA-1273 vaccine,<sup><a href="#jpc200005r7" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">7</a></sup> the BNT162b1 RNA vaccine,<sup><a href="#jpc200005r5" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">5</a></sup><sup>,<a href="#jpc200005r6" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">6</a></sup> and the ChAdOx1 nCoV-19 vaccine,<sup><a href="#jpc200005r8" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup> and higher than the Ad5-vectored vaccine.<sup><a href="#jpc200005r3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a></sup><sup>,<a href="#jpc200005r4" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">4</a></sup> However, such direct comparisons should be interpreted cautiously because of different vaccine doses in those trials and different assay methods. Comparison of the specific IgG antibody titers across studies cannot be done because of varied assay methods.</p>            <a class="article-section-id-anchor" id="247319394"></a>
<p class="para">Epidemiological studies have reported that neutralizing antibody titers vary widely in convalescent serum samples and may be related to several factors (eg, age, sex, disease severity, and days since infection),<sup><a href="#jpc200005r13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup><sup>-<a href="#jpc200005r13" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup> but none of those studies used the PRNT method. In addition, some studies have indicated that the antibody titers may decline over time in patients recovered from COVID-19,<sup><a href="#jpc200005r19" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">19</a></sup><sup>-<a href="#jpc200005r19" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">21</a></sup> particularly in those who were asymptomatic. A study of 56 patients recovered from SARS found that the neutralizing and IgG antibodies quickly declined after 16 months and continued to decline further to a very low level or even became undetectable after 3 years.<sup><a href="#jpc200005r22" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">22</a></sup> Trials of SARS vaccines also suggest that the neutralizing antibody responses may decline over time.<sup><a href="#jpc200005r23" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">23</a></sup><sup>,<a href="#jpc200005r24" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">24</a></sup> However, a recent study suggested that patients who had recovered from SARS (nâ€‰=â€‰23) still possessed long-lasting memory T cells reactive to SARS nucleocapsid protein 17 years after infection.<sup><a href="#jpc200005r25" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">25</a></sup> Thus, it is unclear whether vaccine-induced antibody levels could persist and, if not, whether the long-lasting memory T cells could affect susceptibility and pathogenesis of SARS-CoV-2 infection. The participants in the current study are scheduled to be followed up to 1 year. A phase 3 trial has been initiated (Chinese Clinical Trial Registry No. ChiCTR2000034780), which will provide information on immune persistence and efficacy.</p>            <a class="article-section-id-anchor" id="247319395"></a>
<p class="para">One concern about COVID-19 vaccines is the antibody-dependent enhancement (ADE) phenomenon that vaccine could make the subsequent SARS-CoV-2 infection more severe.<sup><a href="#jpc200005r26" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">26</a></sup><sup>,<a href="#jpc200005r27" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">27</a></sup> The ADE phenomenon has been reported in studies of Middle East respiratory syndromeâ€“CoV and SARS-CoV vaccines in animal challenge models.<sup><a href="#jpc200005r26" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">26</a></sup><sup>,<a href="#jpc200005r27" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">27</a></sup> However, this was not observed in the preclinical study in an immunization-challenge model of rhesus macaques using the same vaccines in the current study or in reports from preclinical studies of other COVID-19 vaccine candidates, including 2 other inactivated COVID-19 vaccines.<sup><a href="#jpc200005r10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup><sup>,<a href="#jpc200005r11" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">11</a>,<a href="#jpc200005r28" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">28</a></sup> Studies have shown that previous infection of SARS-CoV-2 could protect against rechallenge in rhesus macaques.<sup><a href="#jpc200005r29" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">29</a></sup><sup>,<a href="#jpc200005r30" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">30</a></sup></p>            <a class="article-section-id-anchor" id="247319396"></a>
<p class="para">Another concern with whole-inactivated virus, particularly with alum adjuvant that can induce T helper 2 cellâ€“biased responses, was vaccine-associated enhanced respiratory disease (VAERD). VAERD was reported in young children in the 1960s when whole-inactivated virus vaccine with alum adjuvant was tested for measles and respiratory syncytial virus.<sup><a href="#jpc200005r31" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">31</a></sup><sup>,<a href="#jpc200005r32" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">32</a></sup> However, most of the inactivated vaccines against COVID-19 under development used alum adjuvant,<sup><a href="#jpc200005r10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup><sup>,<a href="#jpc200005r11" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">11</a></sup> and no evidence of VAERD has been seen. Instead, alum may reduce immunopathology compared with unadjuvanted coronavirus vaccines.<sup><a href="#jpc200005r33" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">33</a></sup> In the current study, notable changes in the lymphocyte subset distribution or various cytokines (including T helper 2 cellâ€“related cytokines IL-4, IL-5, and IL-10) in various vaccine groups or alum-only group were not observed. However, T-cellâ€”mediated immune responses on stimulation were not measured in the current study. Furthermore, alum is the most widely tested adjuvant component and has been commonly used in many types of vaccines on the market.<sup><a href="#jpc200005r34" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">34</a></sup> Nevertheless, safety, including the potential possibility of ADE and VAERD, will be closely monitored in the extended follow-up visits as well as in the phase 3 trial.</p>            <a class="article-section-id-anchor" id="247319397"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Limitations
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319398"></a>
<p class="para">This study has several limitations. First, the interim analysis was not prespecified in the original protocol; it was added during the study to provide necessary information for the design of a phase 3 trial. Therefore, results from the unplanned interim analysis should be cautiously interpreted.</p>            <a class="article-section-id-anchor" id="247319399"></a>
<p class="para">Second, the current analysis reported results from only some groups, and the study was likely underpowered for comparisons of adverse events. Therefore, the full analysis of the entire trial population (extended follow-up and other injection schedule groups as specified in the protocol) is needed to provide a comprehensive profile of the inactivated vaccine in terms of tolerability, immunogenicity, and immune persistence.</p>            <a class="article-section-id-anchor" id="247319400"></a>
<p class="para">Third, although the inactivated vaccine elicited robust antibody responses, whether it could protect individuals against COVID-19 remains unknown.</p>            <a class="article-section-id-anchor" id="247319401"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Conclusions
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="247319402"></a>
<p class="para">In this interim report of the phase 1 and phase 2 trials of an inactivated COVID-19 vaccine, patients had a low rate of adverse reactions and demonstrated immunogenicity; the study is ongoing. Efficacy and longer-term adverse event assessment will require phase 3 trials.</p>            <a class="article-section-id-anchor" id="247319403"></a>
                        <div class="h3 cb section-type-acknowledgements  has-back-to-top">
                                <a href="#top" class="section-jump-link back-to-top" data-tab-toggle=".tab-nav-full-text">Back to top</a>

                            <div class="heading-text thm-col sb-sc">
                                Article Information
                            </div>
                        </div>
<p class="authorInfoSection"><strong>Corresponding Authors:</strong> Xiaoming Yang, MD, China National Biotec Group Company Limited, 4 Hui-Xin E St, Chaoyang District, Beijing, China (<a href="mailto:yangxiaoming@sinopharm.com" target="_blank">yangxiaoming@sinopharm.com</a>); An Pan, PhD, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Rd, Qiaokou District, Wuhan, China (<a href="mailto:panan@hust.edu.cn" target="_blank">panan@hust.edu.cn</a>).</p><p class="para"><strong>Accepted for Publication:</strong> August 3, 2020.</p><p class="parapublished-online"><strong>Published Online:</strong> August 13, 2020. doi:10.1001/jama.2020.15543</p><p class="paraauthor-contributions"><strong>Author Contributions:</strong> Dr Xiaoming Yang and Mr Xia had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Mr Xia and Drs Duan and Yuntao Zhang contributed equally and are joint first authors. Drs Shen and Yuan and Mr W Guo are joint last authors.</p><p class="para"><i>Concept and design: </i>Xia, Shen, W. Guo, Duan, Yuan, Yuntao Zhang, Li, Yunkai Yang, Chen, L. Zhang, Wu, Xiaoming Yang.</p><p class="para"><i>Acquisition, analysis, or interpretation of data:</i> Xia, Zhao, H. Zhang, Xie, Peng, Yanbo Zhang, W. Zhang, Gao, You, X. Wang, Z. Wang, Shi, Y. Wang, Xuqin Yang, L. Huang, Q. Wang, Lu, Yongli Yang, J. Guo, Zhou, Wan, W. Wang, S. Huang, Du, Meng, Pan.</p><p class="para"><i>Drafting of the manuscript: </i>Xia, S. Huang, Du, Meng, Pan.</p><p class="para"><i>Critical revision of the manuscript for important intellectual content: </i>Xia, Shen, W. Guo, Duan, Yuan, Yuntao Zhang, Zhao, H. Zhang, Xie, Li, Peng, Yanbo Zhang, W. Zhang, Yunkai Yang, Chen, Gao, You, X. Wang, Z. Wang, Shi, Y. Wang, Xuqin Yang, L. Zhang, L. Huang, Q. Wang, Lu, Yongli Yang, J. Guo, Zhou, Wan, Wu, W. Wang, Xiaoming Yang.</p><p class="para"><i>Statistical analysis:</i> Yanbo Zhang, Z. Wang, Yongli Yang, Pan.</p><p class="para"><i>Obtained funding:</i> Xia, Shen, W. Guo, Duan, Yuan, Yuntao Zhang, X. Wang, Z. Wang, Xiaoming Yang.</p><p class="para"><i>Administrative, technical, or material support: </i>Xia, H. Zhang, Yunkai Yang, Chen, Z. Wang.</p><p class="para"><i>Supervision:</i> Shen, W. Guo, Duan, Yuan, Yuntao Zhang, Xiaoming Yang.</p><p class="parafinancial-disclosure"><strong>Conflict of Interest Disclosures:</strong> Mr Xia, Mr W Gou, and Drs Duan, Yuntao Zhang, X. Wang, Z. Wang, Yuan, Shen, and Xiaoming Yang reported receiving grants from the Ministry of Science and Technology of the Peopleâ€™s Republic of China during the conduct of the study. Drs Yuntao Zhang, Yunkai Yang, X. Wang, Xuqin Yang, Q. Wang, and Xiaoming Yang reported being employees of the China National Biotec Group Co Ltd. Drs Duan, Li, Z. Wang, Lu, J. Guo, Zhou, Wan, Wu, W. Wang, S. Huang, Meng, and Shen; Mr Chen; and Mr L. Zhang reported being employees of the Wuhan Institute of Biological Products Co Ltd. Dr Du reported being a student of the Wuhan Institute of Biological Products Co Ltd. Dr Yongli Yang reported receiving personal fees from Wuhan Institute of Biological Products Co Ltd during the conduct of the study. No other disclosures were reported.</p><p class="parafunding-statement"><strong>Funding/Support:</strong> This study was supported by the National Program on Key Research Project of China (2020YFC0842100) and Major Science and Technology Project of the National New Drug Development of China (2018ZX09734-004). The vaccine was developed and the study was sponsored by the China National Biotec Group Co Ltd and the Wuhan Institute of Biological Products Co Ltd.</p><p class="para"><strong>Role of the Funder/Sponsor:</strong> The China National Biotec Group Co Ltd and the Wuhan Institute of Biological Products Co Ltd were the study sponsors and designed the trial, provided the study product, and oversaw all trial operations. The sponsors used contract clinical research organizations to coordinate interactions with regulatory authorities and oversee clinical site operations. Data were collected by the clinical site research staff, managed by a blinded contract research organization data management team, monitored by a contract research organization, and overseen by the sponsor and an independent data and safety monitoring board. The interim analysis was performed by an independent statistician who was not involved in the trial after the data were collected, checked, and locked for the specific groups before unblinding. Manuscript preparation was performed by the study authors and the decision to submit the manuscript for publication was made by the study authors.</p><p class="paradata-sharing-statement"><strong>Data Sharing Statement:</strong> See <a class="supplement-link section-jump-link" data-tab-toggle=".tab-nav-supplemental" href="#note-JPC200005-1">Supplement 4</a>.</p><p class="para"><strong>Additional Contributions:</strong> We are grateful for all investigators at the Henan provincial and Wuzhi county Center for Disease Control and Prevention who contributed to the site work of the trials. We appreciate the contributions of the members in the data and safety monitoring board, including Xiaoju Zhang, MD, and Qiuxing Zhang, MD, from the Henan Province Peopleâ€™s Hospital, and Guoli Yan, MD, from the Henan University of Chinese Medicine. They received remuneration for their work. We thank all the participants in the trial for their dedication to the trial.</p>            <a class="article-section-id-anchor" id="247319404"></a>
                        <div class="h3 cb section-type-references  ">

                            <div class="heading-text thm-col sb-sc">
                                References
                            </div>
                        </div>
<div class="references"><div class="reference"><a class="reference-number" id="jpc200005r1">1.</a><div class="reference-content">World Health Organization. WHO coronavirus disease (COVID-19) dashboard. Accessed July 30, 2020. <a href="https://covid19.who.int/">https://covid19.who.int/</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r2">2.</a><div class="reference-content">World Health Organization. Draft landscape of COVID-19 candidate vaccines. Accessed July 30, 2020. <a href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r3">3.</a><div class="reference-content">Zhu
        Â FCï»¿, Li
        Â YHï»¿, Guan
        Â XHï»¿, 
    Â et al. Â Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Lancet</i>. 2020;395(10240):1845-1854. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(20)31208-3">10.1016/S0140-6736(20)31208-3</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32450106" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safety%2C%20tolerability%2C%20and%20immunogenicity%20of%20a%20recombinant%20adenovirus%20type-5%20vectored%20COVID-19%20vaccine%3A%20a%20dose-escalation%2C%20open-label%2C%20non-randomised%2C%20first-in-human%20trial.&amp;author=FC%20Zhu&amp;author=YH%20Li&amp;author=XH%20Guan&amp;publication_year=2020&amp;journal=Lancet&amp;volume=395&amp;pages=1845-1854" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/S0140-6736(20)31208-3" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/S0140-6736(20)31208-3" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r4">4.</a><div class="reference-content">Zhu
        Â FCï»¿, Guan
        Â XHï»¿, Li
        Â YHï»¿, 
    Â et al. Â Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Lancet</i>. Published online July 20, 2020. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(20)31605-6">10.1016/S0140-6736(20)31605-6</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32702299" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Immunogenicity%20and%20safety%20of%20a%20recombinant%20adenovirus%20type-5-vectored%20COVID-19%20vaccine%20in%20healthy%20adults%20aged%2018%20years%20or%20older%3A%20a%20randomised%2C%20double-blind%2C%20placebo-controlled%2C%20phase%202%20trial.&amp;author=FC%20Zhu&amp;author=XH%20Guan&amp;author=YH%20Li&amp;publication_year=&amp;journal=Lancet&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r5">5.</a><div class="reference-content">Sahin
        Â Uï»¿, Muik
        Â Aï»¿, Derhovanessian
        Â Eï»¿, 
    Â et al. Concurrent human antibody and T<sub>H</sub>1 type T-cell responses elicited by a COVID-19 RNA vaccine. <i>medRxiv</i>. Preprint posted July 20, 2020. doi:<a href="http://dx.doi.org/10.1101/2020.07.17.20140533">10.1101/2020.07.17.20140533</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r6">6.</a><div class="reference-content">Mulligan
        Â MJï»¿, Lyke
        Â KEï»¿, Kitchin
        Â Nï»¿, 
    Â et al. Phase 1/2 study to describe the safety and immunogenicity of a COVID-19 RNA vaccine candidate (BNT162b1) in adults 18 to 55 years of age: interim report. <i>medRxiv</i>. Preprint posted July 1, 2020. doi:<a href="http://dx.doi.org/10.1101/2020.06.30.20142570">10.1101/2020.06.30.20142570</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r7">7.</a><div class="reference-content">Jackson
        Â LAï»¿, Anderson
        Â EJï»¿, Rouphael
        Â NGï»¿, 
    Â et al; mRNA-1273 Study Group. Â An mRNA vaccine against SARS-CoV-2 - preliminary report.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â N Engl J Med</i>. Published online July 14, 2020. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2022483">10.1056/NEJMoa2022483</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32663912" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=An%20mRNA%20vaccine%20against%20SARS-CoV-2%20-%20preliminary%20report.&amp;author=LA%20Jackson&amp;author=EJ%20Anderson&amp;author=NG%20Rouphael&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r8">8.</a><div class="reference-content">Folegatti
        Â PMï»¿, Ewer
        Â KJï»¿, Aley
        Â PKï»¿, 
    Â et al; Oxford COVID Vaccine Trial Group. Â Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.Â <i xmlns:helper="urn:XsltStringHelper">Â  Lancet</i>. Published online July 20, 2020. doi:<a href="http://dx.doi.org/10.1016/S0140-6736(20)31604-4">10.1016/S0140-6736(20)31604-4</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32702298" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safety%20and%20immunogenicity%20of%20the%20ChAdOx1%20nCoV-19%20vaccine%20against%20SARS-CoV-2%3A%20a%20preliminary%20report%20of%20a%20phase%201%2F2%2C%20single-blind%2C%20randomised%20controlled%20trial.&amp;author=PM%20Folegatti&amp;author=KJ%20Ewer&amp;author=PK%20Aley&amp;publication_year=&amp;journal=Lancet&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r9">9.</a><div class="reference-content">Stern
        Â PLï»¿. Â Key steps in vaccine development.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Ann Allergy Asthma Immunol</i>. 2020;125(1):17-27. doi:<a href="http://dx.doi.org/10.1016/j.anai.2020.01.025">10.1016/j.anai.2020.01.025</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32044451" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Key%20steps%20in%20vaccine%20development.&amp;author=PL%20Stern&amp;publication_year=2020&amp;journal=Ann%20Allergy%20Asthma%20Immunol&amp;volume=125&amp;pages=17-27" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.anai.2020.01.025" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.anai.2020.01.025" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r10">10.</a><div class="reference-content">Gao
        Â Qï»¿, Bao
        Â Lï»¿, Mao
        Â Hï»¿, 
    Â et al. Â Development of an inactivated vaccine candidate for SARS-CoV-2.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Science</i>. 2020;369(6499):77-81. doi:<a href="http://dx.doi.org/10.1126/science.abc1932">10.1126/science.abc1932</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32376603" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Development%20of%20an%20inactivated%20vaccine%20candidate%20for%20SARS-CoV-2.&amp;author=Q%20Gao&amp;author=L%20Bao&amp;author=H%20Mao&amp;publication_year=2020&amp;journal=Science&amp;volume=369&amp;pages=77-81" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1126/science.abc1932" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1126/science.abc1932" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r11">11.</a><div class="reference-content">Wang
        Â Hï»¿, Zhang
        Â Yï»¿, Huang
        Â Bï»¿, 
    Â et alï»¿ Â Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Cell</i>. Published online June 6, 2020. doi:<a href="http://dx.doi.org/10.1016/j.cell.2020.06.008">10.1016/j.cell.2020.06.008</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Development%20of%20an%20inactivated%20vaccine%20candidate%2C%20BBIBP-CorV%2C%20with%20potent%20protection%20against%20SARS-CoV-2.&amp;author=H%20Wang&amp;author=Y%20Zhang&amp;author=B%20Huang&amp;publication_year=&amp;journal=Cell&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r12">12.</a><div class="reference-content">Duan
        Â Kï»¿, Liu
        Â Bï»¿, Li
        Â Cï»¿, 
    Â et al. Â Effectiveness of convalescent plasma therapy in severe COVID-19 patients.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Proc Natl Acad Sci U S A</i>. 2020;117(17):9490-9496. doi:<a href="http://dx.doi.org/10.1073/pnas.2004168117">10.1073/pnas.2004168117</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32253318" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effectiveness%20of%20convalescent%20plasma%20therapy%20in%20severe%20COVID-19%20patients.&amp;author=K%20Duan&amp;author=B%20Liu&amp;author=C%20Li&amp;publication_year=2020&amp;journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&amp;volume=117&amp;pages=9490-9496" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1073/pnas.2004168117" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1073/pnas.2004168117" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r13">13.</a><div class="reference-content">Long
        Â QXï»¿, Liu
        Â BZï»¿, Deng
        Â HJï»¿, 
    Â et al. Â Antibody responses to SARS-CoV-2 in patients with COVID-19.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nat Med</i>. 2020;26(6):845-848. doi:<a href="http://dx.doi.org/10.1038/s41591-020-0897-1">10.1038/s41591-020-0897-1</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32350462" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antibody%20responses%20to%20SARS-CoV-2%20in%20patients%20with%20COVID-19.&amp;author=QX%20Long&amp;author=BZ%20Liu&amp;author=HJ%20Deng&amp;publication_year=2020&amp;journal=Nat%20Med&amp;volume=26&amp;pages=845-848" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/s41591-020-0897-1" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/s41591-020-0897-1" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r14">14.</a><div class="reference-content">Luchsinger
        Â LLï»¿, Ransegnola
        Â Bï»¿, Jin
        Â Dï»¿, 
    Â et al. Serological analysis of New York City COVID19 convalescent plasma donors. <i>medRxiv</i>. Preprint posted June 9, 2020. doi:<a href="http://dx.doi.org/10.1101/2020.06.08.20124792">10.1101/2020.06.08.20124792</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r15">15.</a><div class="reference-content">Robbiani
        Â DFï»¿, Gaebler
        Â Cï»¿, Muecksch
        Â Fï»¿, 
    Â et al. Â Convergent antibody responses to SARS-CoV-2 in convalescent individuals.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nature</i>. Published online June 18, 2020. doi:<a href="http://dx.doi.org/10.1038/s41586-020-2456-9">10.1038/s41586-020-2456-9</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32555388" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Convergent%20antibody%20responses%20to%20SARS-CoV-2%20in%20convalescent%20individuals.&amp;author=DF%20Robbiani&amp;author=C%20Gaebler&amp;author=F%20Muecksch&amp;publication_year=&amp;journal=Nature&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r16">16.</a><div class="reference-content">Wang
        Â Xï»¿, Guo
        Â Xï»¿, Xin
        Â Qï»¿, 
    Â et al. Â Neutralizing antibodies responses to SARS-CoV-2 in COVID-19 inpatients and convalescent patients.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Clin Infect Dis</i>. Published online June 4, 2020. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa721">10.1093/cid/ciaa721</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32497196" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Neutralizing%20antibodies%20responses%20to%20SARS-CoV-2%20in%20COVID-19%20inpatients%20and%20convalescent%20patients.&amp;author=X%20Wang&amp;author=X%20Guo&amp;author=Q%20Xin&amp;publication_year=&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r17">17.</a><div class="reference-content">Wu
        Â Fï»¿, Wang
        Â Aï»¿, Liu
        Â Mï»¿, 
    Â et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. <i>medRxiv</i>. Preprint posted April 20, 2020. doi:<a href="http://dx.doi.org/10.1101/2020.03.30.20047365">10.1101/2020.03.30.20047365</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r18">18.</a><div class="reference-content">Zhao
        Â Jï»¿, Yuan
        Â Qï»¿, Wang
        Â Hï»¿, 
    Â et al. Â Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Clin Infect Dis</i>. Published online March 28, 2020. doi:<a href="http://dx.doi.org/10.1093/cid/ciaa344">10.1093/cid/ciaa344</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32221519" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Antibody%20responses%20to%20SARS-CoV-2%20in%20patients%20of%20novel%20coronavirus%20disease%202019.&amp;author=J%20Zhao&amp;author=Q%20Yuan&amp;author=H%20Wang&amp;publication_year=&amp;journal=Clin%20Infect%20Dis&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r19">19.</a><div class="reference-content">Liu
        Â Tï»¿, Wu
        Â Sï»¿, Tao
        Â Hï»¿, 
    Â et al. Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan: implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2. <i>medRxiv</i>. Preprint posted June 16, 2020. doi:<a href="http://dx.doi.org/10.1101/2020.06.13.20130252">10.1101/2020.06.13.20130252</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r20">20.</a><div class="reference-content">Long
        Â QXï»¿, Tang
        Â XJï»¿, Shi
        Â QLï»¿, 
    Â et al. Â Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nat Med</i>. Published online June 18, 2020. doi:<a href="http://dx.doi.org/10.1038/s41591-020-0965-6">10.1038/s41591-020-0965-6</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32555424" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Clinical%20and%20immunological%20assessment%20of%20asymptomatic%20SARS-CoV-2%20infections.&amp;author=QX%20Long&amp;author=XJ%20Tang&amp;author=QL%20Shi&amp;publication_year=&amp;journal=Nat%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r21">21.</a><div class="reference-content">Ibarrondo
        Â FJï»¿, Fulcher
        Â JAï»¿, Goodman-Meza
        Â Dï»¿, 
    Â et al. Â Rapid decay of antiâ€“SARS-CoV-2 antibodies in persons with mild Covid-19.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â N Engl J Med</i>. Published online July 21, 2020. doi:<a href="http://dx.doi.org/10.1056/NEJMc2025179">10.1056/NEJMc2025179</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32706954" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Rapid%20decay%20of%20anti%E2%80%93SARS-CoV-2%20antibodies%20in%20persons%20with%20mild%20Covid-19.&amp;author=FJ%20Ibarrondo&amp;author=JA%20Fulcher&amp;author=D%20Goodman-Meza&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r22">22.</a><div class="reference-content">Cao
        Â WCï»¿, Liu
        Â Wï»¿, Zhang
        Â PHï»¿, Zhang
        Â Fï»¿, Richardus
        Â JHï»¿. Â Disappearance of antibodies to SARS-associated coronavirus after recovery.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â N Engl J Med</i>. 2007;357(11):1162-1163. doi:<a href="http://dx.doi.org/10.1056/NEJMc070348">10.1056/NEJMc070348</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/17855683" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Disappearance%20of%20antibodies%20to%20SARS-associated%20coronavirus%20after%20recovery.&amp;author=WC%20Cao&amp;author=W%20Liu&amp;author=PH%20Zhang&amp;author=F%20Zhang&amp;author=JH%20Richardus&amp;publication_year=2007&amp;journal=N%20Engl%20J%20Med&amp;volume=357&amp;pages=1162-1163" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1056/NEJMc070348" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1056/NEJMc070348" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r23">23.</a><div class="reference-content">Lin
        Â JTï»¿, Zhang
        Â JSï»¿, Su
        Â Nï»¿, 
    Â et al. Â Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Antivir Ther</i>. 2007;12(7):1107-1113.<a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/18018769" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Safety%20and%20immunogenicity%20from%20a%20phase%20I%20trial%20of%20inactivated%20severe%20acute%20respiratory%20syndrome%20coronavirus%20vaccine.&amp;author=JT%20Lin&amp;author=JS%20Zhang&amp;author=N%20Su&amp;publication_year=2007&amp;journal=Antivir%20Ther&amp;volume=12&amp;pages=1107-1113" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r24">24.</a><div class="reference-content">Martin
        Â JEï»¿, Louder
        Â MKï»¿, Holman
        Â LAï»¿, 
    Â et al; VRC 301 Study Team. Â A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Vaccine</i>. 2008;26(50):6338-6343. doi:<a href="http://dx.doi.org/10.1016/j.vaccine.2008.09.026">10.1016/j.vaccine.2008.09.026</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/18824060" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20SARS%20DNA%20vaccine%20induces%20neutralizing%20antibody%20and%20cellular%20immune%20responses%20in%20healthy%20adults%20in%20a%20phase%20I%20clinical%20trial.&amp;author=JE%20Martin&amp;author=MK%20Louder&amp;author=LA%20Holman&amp;publication_year=2008&amp;journal=Vaccine&amp;volume=26&amp;pages=6338-6343" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1016/j.vaccine.2008.09.026" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1016/j.vaccine.2008.09.026" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r25">25.</a><div class="reference-content">Le Bert
        Â Nï»¿, Tan
        Â ATï»¿, Kunasegaran
        Â Kï»¿, 
    Â et al. Â SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nature</i>. Published online July 15, 2020. doi:<a href="http://dx.doi.org/10.1038/s41586-020-2550-z">10.1038/s41586-020-2550-z</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32668444" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2-specific%20T%20cell%20immunity%20in%20cases%20of%20COVID-19%20and%20SARS%2C%20and%20uninfected%20controls.&amp;author=N%20Le Bert&amp;author=AT%20Tan&amp;author=K%20Kunasegaran&amp;publication_year=&amp;journal=Nature&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r26">26.</a><div class="reference-content">Eroshenko
        Â Nï»¿, Gill
        Â Tï»¿, Keaveney
        Â MKï»¿, Church
        Â GMï»¿, Trevejo
        Â JMï»¿, Rajaniemi
        Â Hï»¿. Â Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nat Biotechnol</i>. 2020;38(7):789-791. doi:<a href="http://dx.doi.org/10.1038/s41587-020-0577-1">10.1038/s41587-020-0577-1</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32504046" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Implications%20of%20antibody-dependent%20enhancement%20of%20infection%20for%20SARS-CoV-2%20countermeasures.&amp;author=N%20Eroshenko&amp;author=T%20Gill&amp;author=MK%20Keaveney&amp;author=GM%20Church&amp;author=JM%20Trevejo&amp;author=H%20Rajaniemi&amp;publication_year=2020&amp;journal=Nat%20Biotechnol&amp;volume=38&amp;pages=789-791" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/s41587-020-0577-1" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/s41587-020-0577-1" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r27">27.</a><div class="reference-content">Graham
        Â BSï»¿. Â Rapid COVID-19 vaccine development.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Science</i>. 2020;368(6494):945-946. doi:<a href="http://dx.doi.org/10.1126/science.abb8923">10.1126/science.abb8923</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32385100" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Rapid%20COVID-19%20vaccine%20development.&amp;author=BS%20Graham&amp;publication_year=2020&amp;journal=Science&amp;volume=368&amp;pages=945-946" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1126/science.abb8923" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1126/science.abb8923" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r28">28.</a><div class="reference-content">Corbett
        Â KSï»¿, Flynn
        Â Bï»¿, Foulds
        Â KEï»¿, 
    Â et al. Â Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â N Engl J Med</i>. Published online July 28, 2020. doi:<a href="http://dx.doi.org/10.1056/NEJMoa2024671">10.1056/NEJMoa2024671</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32722908" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Evaluation%20of%20the%20mRNA-1273%20vaccine%20against%20SARS-CoV-2%20in%20nonhuman%20primates.&amp;author=KS%20Corbett&amp;author=B%20Flynn&amp;author=KE%20Foulds&amp;publication_year=&amp;journal=N%20Engl%20J%20Med&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r29">29.</a><div class="reference-content">Chandrashekar
        Â Aï»¿, Liu
        Â Jï»¿, Martinot
        Â AJï»¿, 
    Â et al. Â SARS-CoV-2 infection protects against rechallenge in rhesus macaques.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Science</i>. Published online May 20, 2020. doi:<a href="http://dx.doi.org/10.1126/science.abc4776">10.1126/science.abc4776</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32434946" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=SARS-CoV-2%20infection%20protects%20against%20rechallenge%20in%20rhesus%20macaques.&amp;author=A%20Chandrashekar&amp;author=J%20Liu&amp;author=AJ%20Martinot&amp;publication_year=&amp;journal=Science&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r30">30.</a><div class="reference-content">Deng
        Â Wï»¿, Bao
        Â Lï»¿, Liu
        Â Jï»¿, 
    Â et al. Â Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Science</i>. Published online July 2, 2020. doi:<a href="http://dx.doi.org/10.1126/science.abc5343">10.1126/science.abc5343</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32616673" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Primary%20exposure%20to%20SARS-CoV-2%20protects%20against%20reinfection%20in%20rhesus%20macaques.&amp;author=W%20Deng&amp;author=L%20Bao&amp;author=J%20Liu&amp;publication_year=&amp;journal=Science&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="jpc200005r31">31.</a><div class="reference-content">Fulginiti
        Â VAï»¿, Eller
        Â JJï»¿, Downie
        Â AWï»¿, Kempe
        Â CHï»¿. Â Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated measles virus vaccines.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â JAMA</i>. 1967;202(12):1075-1080. doi:<a href="http://jamanetwork.com/article.aspx?doi=10.1001/jama.1967.03130250057008">10.1001/jama.1967.03130250057008</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/6072745" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Altered%20reactivity%20to%20measles%20virus%3A%20atypical%20measles%20in%20children%20previously%20immunized%20with%20inactivated%20measles%20virus%20vaccines.&amp;author=VA%20Fulginiti&amp;author=JJ%20Eller&amp;author=AW%20Downie&amp;author=CH%20Kempe&amp;publication_year=1967&amp;journal=JAMA&amp;volume=202&amp;pages=1075-1080" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1001/jama.1967.03130250057008" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1001/jama.1967.03130250057008" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r32">32.</a><div class="reference-content">Kim
        Â HWï»¿, Canchola
        Â JGï»¿, Brandt
        Â CDï»¿, 
    Â et al. Â Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Am J Epidemiol</i>. 1969;89(4):422-434. doi:<a href="http://dx.doi.org/10.1093/oxfordjournals.aje.a120955">10.1093/oxfordjournals.aje.a120955</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/4305198" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Respiratory%20syncytial%20virus%20disease%20in%20infants%20despite%20prior%20administration%20of%20antigenic%20inactivated%20vaccine.&amp;author=HW%20Kim&amp;author=JG%20Canchola&amp;author=CD%20Brandt&amp;publication_year=1969&amp;journal=Am%20J%20Epidemiol&amp;volume=89&amp;pages=422-434" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1093/oxfordjournals.aje.a120955" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1093/oxfordjournals.aje.a120955" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r33">33.</a><div class="reference-content">Hotez
        Â PJï»¿, Corry
        Â DBï»¿, Bottazzi
        Â MEï»¿. Â COVID-19 vaccine design: the Janus face of immune enhancement.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nat Rev Immunol</i>. 2020;20(6):347-348. doi:<a href="http://dx.doi.org/10.1038/s41577-020-0323-4">10.1038/s41577-020-0323-4</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32346094" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=COVID-19%20vaccine%20design%3A%20the%20Janus%20face%20of%20immune%20enhancement.&amp;author=PJ%20Hotez&amp;author=DB%20Corry&amp;author=ME%20Bottazzi&amp;publication_year=2020&amp;journal=Nat%20Rev%20Immunol&amp;volume=20&amp;pages=347-348" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/s41577-020-0323-4" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/s41577-020-0323-4" xmlns:helper="urn:XsltStringHelper"> </span></div></div><div class="reference"><a class="reference-number" id="jpc200005r34">34.</a><div class="reference-content">Hotez
        Â PJï»¿, Corry
        Â DBï»¿, Strych
        Â Uï»¿, Bottazzi
        Â MEï»¿. Â COVID-19 vaccines: neutralizing antibodies and the alum advantage.Â ï»¿ <i xmlns:helper="urn:XsltStringHelper">Â Nat Rev Immunol</i>. 2020;20(7):399-400. doi:<a href="http://dx.doi.org/10.1038/s41577-020-0358-6">10.1038/s41577-020-0358-6</a><a class="pubmed-link" href="https://www.ncbi.nlm.nih.gov/pubmed/32499636" target="_blank" xmlns:helper="urn:XsltStringHelper">PubMed</a><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=COVID-19%20vaccines%3A%20neutralizing%20antibodies%20and%20the%20alum%20advantage.&amp;author=PJ%20Hotez&amp;author=DB%20Corry&amp;author=U%20Strych&amp;author=ME%20Bottazzi&amp;publication_year=2020&amp;journal=Nat%20Rev%20Immunol&amp;volume=20&amp;pages=399-400" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a><a href="https://doi.org/10.1038/s41577-020-0358-6" class="crossref-doi" target="_blank" xmlns:helper="urn:XsltStringHelper">Crossref</a><span class="inst-open-url-holders" data-targetId="10.1038/s41577-020-0358-6" xmlns:helper="urn:XsltStringHelper"> </span></div></div></div>

</div>
 
    </div>

        <div class="movable-ad bta">
    <div class="widget-WidgetLoader widget-instance-AMA_AdTag_textbreak_bta_dual">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_textbreak_bta_dual" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:8,&quot;adSection&quot;:&quot;textbreak&quot;,&quot;adPosition&quot;:&quot;bta&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{}}"></div>
 
    </div>

        </div>
    </div> 

</div> 

<div class="hidden-jobs-ad hide">
    <div class="widget-WidgetLoader widget-instance-AMA_JobsAd">
        
<div class="SCM-SharedWidgets-AsyncJobsAdLoader" data-url="/AMA/JobsAd/AMA_JobsAd" data-params="{&quot;parameters&quot;:{&quot;SiteId&quot;:3},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

</div>



<script>
                var App = App || {};
                App.ArticleSplitScreen = App.ArticleSplitScreen || {};
                App.ArticleSplitScreen.siteName = 'jama';
                App.ArticleSplitScreen.siteId = 3;
                App.ArticleSplitScreen.journalId = 67;
                App.ArticleSplitScreen.adDisplay = 'ArticleContentsSkyBox';
                App.ArticleSplitScreen.adSection = "scholarly";
                App.ArticleSplitScreen.adPosition = "contab";
                App.ArticleSplitScreen.controlId = "AMA_AdTag_Contents_Skybox";
                App.ArticleSplitScreen.fromGoogle = "False";
                App.ArticleSplitScreen.slotLocationOverride = "50";

</script> 
    </div>


 
    </div>

    </section>


    <section id="secFooterControl" class="master-footer">
        

        <script>
            var App = App || {};

            function scmByClass(className) {
                return document.getElementsByClassName(className);
            }

            function scmById(id) {
                return document.getElementById(id);
            }

            function scmquery(selector) {
                return document.querySelector(selector);
            }

            function queryAll(selector) {
                return document.querySelectorAll(selector);
            }

            function isTrueString(string) {
                if (typeof string === 'string') {
                    return string.toLowerCase() === 'true';
                }

                return undefined;
            }

            function updateViewportDimensions() {
                var w = window, d = document, e = d.documentElement, g = d.getElementsByTagName('body')[0], x = w.innerWidth || e.clientWidth || g.clientWidth, y = w.innerHeight || e.clientHeight || g.clientHeight;
                return { width: x, height: y };
            }

            var viewport = updateViewportDimensions();

            var debounce = function (func, wait, immediate) {
                var timeout;
                return function () {
                    var context = this, args = arguments;
                    var later = function () {
                        timeout = null;
                        if (!immediate) func.apply(context, args);
                    };
                    var callNow = immediate && !timeout;
                    clearTimeout(timeout);
                    timeout = setTimeout(later, wait);
                    if (callNow) func.apply(context, args);
                };
            };

            (function (App) {
                App.mobileUpperBreakpoint = 767;
                App.mobileAltBreakpoint = 640;
                App.mobileMinBreakpoint = 547;
                App.tabletUpperBreakpoint = 1023;

                function setVariables() {
                    viewport = updateViewportDimensions();
                    App.isMobile = (viewport.width <= App.mobileUpperBreakpoint);
                    App.isMobileAlt = (viewport.width <= App.mobileAltBreakpoint);
                    App.isTablet = (viewport.width > App.mobileUpperBreakpoint && viewport.width <= App.tabletUpperBreakpoint);
                    App.isTabletDown = (viewport.width <= App.tabletUpperBreakpoint);
                    App.isDesktop = (viewport.width > App.tabletUpperBreakpoint);
                    App.activeViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large';
                }

                setVariables();

                App.cachedViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large';
                App.isAnyArticle = !!(scmByClass('widget-ArticleFullView').length || scmByClass('pg_abstract').length
                    || scmByClass('widget-MagazineView').length || scmByClass('widget-ChannelsMagazineView').length);
                App.isSplitScreen = !!scmByClass('widget-ArticleFullView').length;
                App.isAbstract = !!scmByClass('pg_abstract').length;
                App.isMag = !!(scmByClass('widget-MagazineView').length);
                App.isChannel = !!(scmByClass('channel-site').length);
                App.isChannelMag = !!(scmByClass('widget-ChannelsMagazineView').length);
                App.isFreeArticle = !!(scmquery('.widget-ArticleTopInfo .free-access') ||
                                        scmquery('.widget-ArticleTopInfo .open-access') ||
                                        scmquery('.widget-ArticleTopInfo .icon-free') || 
                                        scmquery('.widget-ChannelsMagazineView .free-access'));
                App.isTollFreeAccess = false;
                App.isIssue = !!scmByClass('pg_issue').length || !!scmByClass('pg_newonline').length || !!scmByClass('pg_currentissue').length || !!scmByClass('pg_pastissues').length;
                App.isNewOnline = !!scmByClass('pg_newonline').length;
                App.isCurrentIssue = !!scmByClass('pg_currentissue').length;
                App.isPastIssues = !!scmByClass('pg_pastissues').length;
                App.isJournal = !!scmByClass('pg_journal').length;
                App.isNetworkHome = !!scmByClass('pg_index').length;
                App.isSearch = !!scmByClass('pg_searchresults').length;
                App.isAdvancedSearch = !!scmByClass('pg_advancedsearch').length;
                App.isPlayer= !!scmByClass('pg_multimediaplayer').length;
                App.isSelfServe = !!scmByClass('pg_sspage').length;
                App.isCmsPage = !!scmByClass('pg_cmspage').length; 
                App.isMyAccount = !!scmByClass('pg_myaccount').length;
                App.supportsFlexbox = !!scmByClass('flexbox').length;
                App.isCollection = !!scmByClass('pg_collection').length;
                App.isPaidUser = isTrueString(scmById('hfAppIsPaidUser').getAttribute('value'));
                App.isMember = isTrueString(scmById('hfAppIsMember').getAttribute('value'));
                App.isIndividual = isTrueString(scmById('hfAppIsIndividual').getAttribute('value'));
                App.hasAccess = isTrueString(scmById('hfAppHasAccess').getAttribute('value'));
                App.isReferredFromGoogle = isTrueString(scmById('hfAppIsReferredFromGoogle').getAttribute('value'));
                var subscribedTo = scmById('hfAppSubscribedTo').getAttribute('value');
                App.userSubscribedTo = subscribedTo ? subscribedTo.split(',') : undefined;
                App.isLucy = isTrueString(scmById('hfAppIsLucy').getAttribute('value'));
                App.currentJournalCount = 26;
                App.isChannelPage = !!(scmByClass('channels-page'));
                App.updateAppVariables = debounce(function () {
                    setVariables();
                }, 50, false);
            })(App);
        </script>
        

        
<div class="footer-ad-wrapper">
    <div id="BodyContent_Footer_divAds" class="footer-ad desktop-only">
        
            <div class="widget-WidgetLoader widget-instance-AMA_AdTag_AnchorboardAd_btf">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_AnchorboardAd_btf" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:11,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;btf&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>
</div>
</div>

 
 <div class="ad-riser-wrap desktop-only">
     <div class="ad-riser--dismiss t-c">X</div>
         <div class="widget-WidgetLoader widget-instance-AMA_AdTag_Riser">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_Riser" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:12,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;Riser&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

 </div>


<div class="footer-wrap">
    
    <footer class="footer" id="footer">
        
        <div id="footer-microsite" class="footer-microsite">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Left" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    @media (min-width: 1024px) {.split-screen .footer-microsite-contents {border-bottom:0 !important;}}
    .footer-microsite-contents {margin-bottom:1em;width:100%;}
    .footer-network-other .link-apps:before {width: 23px;}
    .footer-network-other .link-institutions-librarians:before {width: 23px;}
    .jn-ss-footer-border-top {border-top:1px solid #555;padding-top:15px;}
    .jn-ss-footer-border-bottom {border-bottom:1px solid #555;padding-bottom:10px;padding-right:3px;}
</style>
<div class="footer-heading-wrap">
<h3 id="BodyContent_Footer_h3SiteName" class="footer-heading is-b footer-microsite-heading" data-mobile-tog-target=".footer-microsite-links-wrap">JAMA</h3>
</div>
<div class="footer-microsite-links-wrap">
<div class="footer-microsite-contents  jn-ss-footer-border-bottom">
<h4 id="BodyContent_Footer_ContentHeader" class="footer-subheading">Content</h4>
<a href="/journals/jama">Home</a>
<a href="/journals/jama/newonline">New Online</a>
<a href="/journals/jama/currentissue">Current Issue</a>
</div>
<div class="footer-microsite-contents  jn-ss-footer-border-bottom">
<h4 class="footer-subheading">Podcasts</h4>
<a href="/journals/jama/pages/covid-19-interviews#audio">Coronavirus (COVID-19)&nbsp;Q&amp;A</a>
<a href="/journals/jama/pages/jama-clinical-reviews">Clinical Reviews</a>
<a href="/journals/jama/pages/jama-editors-summary">Editors' Summary</a>
<a href="/journals/jama/pages/jama-medical-news">Medical News</a>
<a href="/journals/jama/pages/jama-author-interviews">Author Interviews</a>
<a href="/journals/jama/pages/jamaevidence-jama-guide-to-statistics-and-methods">JAMAevidence: <em>JAMA Guide to Statistics and Methods</em></a>
<a href="/journals/jama/pages/jamaevidence-the-rational-clinical-examination">JAMAevidence: The Rational Clinical Examination</a>
<a href="/journals/jama/pages/jamaevidence-users-guides-to-the-medical-literature">JAMAevidence: Users' Guides to the Medical Literature</a>
</div>
<div class="footer-microsite-services cf">
<h4 id="BodyContent_Footer_ServiceHeader" class="footer-subheading">Journal Information</h4>
<a href="/journals/jama/pages/for-authors">For Authors</a>
<a href="/journals/jama/pages/jama-editors">JAMA Editors</a>
<a href="/journals/jama/editors-and-publishers">Editors &amp; Publishers</a>
<a href="/pages/rss">RSS</a>
<a href="/journals/jama/pages/contact-us">Contact Us</a>
</div>
<div class="footer-network-other  jn-ss-footer-border-bottom">
<a href="https://edhub.ama-assn.org/jn-learning" class="link-network-other is-b link-learning">JN Learning / CME</a>
<a href="https://store.jamanetwork.com" class="link-network-other is-b link-store" target="_blank">Store</a>
<a href="/pages/apps" class="link-network-other is-b link-mobile" target="_blank">Apps</a>
<a href="https://careers.jamanetwork.com/" class="link-network-other is-b link-jobs" target="_blank">Jobs</a>
<a href="/pages/resources-for-librarians" class="link-network-other is-b link-institutions-librarians" target="_blank">Institutions</a>
<a href="/pages/reprints-and-permissions" class="link-network-other is-b link-reprints-permissions">Reprints &amp; Permissions</a>
</div>
<div id="BodyContent_Footer_divSubscribe" class="footer-microsite-subscribe">
<img src="//cdn.jamanetwork.com/UI/app/img/covers/jama.jpg" class="subscribe-image" alt="Journal Cover">
<div class="subscribe-meta">
<h4 class="subscribe-heading footer-subheading">Subscribe</h4>
<a href="https://store.jamanetwork.com/productDetails.aspx?productcodeID=64" class="subscribe-submit btn">Go</a>
</div>
</div>
</div>





        </div>

        
        <div id="footer-network" class="footer-network">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Middle" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .footer-network-sites {width: 62.85542%;}
    .footer-network-info {width: 35.93976%}
    .jn-ss-subheading-mt {margin-top: 1.5em;}
    .jn-registered:after {content: "\00AE";font-size: 50%;vertical-align: top;}
    .jn-trademark:after {content: "\2122";font-size: 50%;vertical-align: top;}
</style>
<div class="footer-heading-wrap">
<h3 class="footer-heading is-b jn-registered" data-mobile-tog-target=".footer-network-links-wrap"><strong>JAMA</strong> Network</h3>
</div>
<div class="footer-network-links-wrap">
<div class="footer-network-sites">
<div class="internal">
<h4 id="BodyContent_Footer_JournalHeader" class="footer-subheading">Publications</h4>
<a href="/journals/jama">JAMA</a>
<a href="/journals/jamanetworkopen" target="_blank">JAMA Network Open</a>
<a href="/journals/jamacardiology">JAMA Cardiology</a>
<a href="/journals/jamadermatology">JAMA Dermatology</a>
<a href="/journals/jama-health-forum">JAMA Health Forum</a>
<a href="/journals/jamainternalmedicine">JAMA Internal Medicine</a>
<a href="/journals/jamaneurology">JAMA Neurology</a>
<a href="/journals/jamaoncology">JAMA Oncology</a>
<a href="/journals/jamaophthalmology">JAMA Ophthalmology</a>
<a href="/journals/jamaotolaryngology">JAMA Otolaryngologyâ€“Head &amp; Neck Surgery</a>
<a href="/journals/jamapediatrics">JAMA Pediatrics</a>
<a href="/journals/jamapsychiatry">JAMA Psychiatry</a>
<a href="/journals/jamasurgery">JAMA Surgery</a>
<a href="/journals/archneurpsyc">Archives of Neurology &amp; Psychiatry (1919-1959)</a>
</div>
<div class="external">
<h4 class="footer-subheading">Sites</h4>
<div id="BodyContent_Footer_ssFooterSiteMenu">
<div class="selfServe">
<a target="_blank" href="https://sites.jamanetwork.com/art-and-images-in-psychiatry/">Art and Images in Psychiatry</a>
<a target="_blank" href="/channels/ai">Artificial Intelligence (AI) Resource Center</a>
<a target="_blank" href="/journals/jama/pages/2023-most-viewed-jama">Best of the JAMA Network</a>
<a target="_blank" href="/channels/caring-for-the-critically-ill-patient">Caring for the Critically Ill Patient</a>
<a target="_blank" href="/journals/jama/pages/crosswords">Clinical Crosswords from JAMA</a>
<a target="_blank" href="/journals/jama/pages/coronavirus-alert">Coronavirus Resource Center</a>
<a target="_blank" href="https://ebm.jamanetwork.com/index.html">Evidence-Based Medicine: An Oral History</a>
<a target="_blank" href="/pages/fishbein-fellowship">Fishbein Fellowship</a>
<a target="_blank" href="/channels/genomics/">Genomics and Precision Health</a>
<a target="_blank" href="/channels/hypertension">Hypertension</a>
<a target="_blank" href="/channels/health-forum/archive">JAMA Forum Archive</a>
<a target="_blank" href="https://sites.jamanetwork.com/audio">JAMA Network Audio</a>
<a target="_blank" href="/pages/video">JAMA Network Video</a>
<a target="_blank" href="/pages/conferences">JAMA Network Conferences </a>
<a target="_blank" href="/pages/jama-summit">JAMA Summit </a>
<a target="_blank" href="/journals/jamasurgery/pages/statistics-and-methods">JAMA Surgery Guide to Statistics and Methods</a>
<a target="_blank" href="/channels/medical-news">Medical News</a>
<a target="_blank" href="/channels/monkeypox">Mpox (Monkeypox)</a>
<a target="_blank" href="https://sites.jamanetwork.com/research-ethics/">Research Ethics</a>
<a target="_blank" href="/pages/collections">Topics and Collections</a>
<a target="_blank" href="/pages/visual-abstracts">Visual Abstracts</a>
<a target="_blank" href="/channels/war">War and Health</a>
<a target="_blank" href="/channels/womens-health">Women's Health</a>
<h4 class="footer-subheading jn-ss-subheading-mt">Featured Articles</h4>
<a href="/journals/jama/fullarticle/2799240">Antiretroviral Drugs for HIV Treatment and Prevention in Adults - 2022 IAS-USA Recommendations</a>
<a href="/journals/jama/fullarticle/2781397">CONSERVE 2021 Guidelines for Reporting Trials Modified for the COVID-19 Pandemic</a>
<a href="/journals/jama/fullarticle/2808296">Creation and Adoption of Large Language Models in&nbsp;Medicine</a>
<a href="/journals/jamaoncology/fullarticle/2787350">Global Burden of Cancer, 2010-2019</a>
<a href="/journals/jama/fullarticle/2797443">Global Burden of Long COVID</a>
<a href="/journals/jamadermatology/fullarticle/2790344">Global Burden of Melanoma</a>
<a href="/journals/jamadermatology/fullarticle/2787350">Global Burden of Skin Diseases, 1990-2017</a>
<a href="/journals/jamaneurology/fullarticle/2793874">Global Disparities in Parkinson Disease</a>
<a href="/journals/jama/fullarticle/2799547">Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension</a>
<a href="/journals/jamapsychiatry/fullarticle/2799486">Mass Violence and the Complex Spectrum of Mental Illness and Mental Functioning</a>
<a href="/journals/jamapsychiatry/fullarticle/2793903">Neuropsychiatry Sequelae of COVID-19</a>
<a href="/journals/jamaneurology/fullarticle/2810313">A New Framework for Dementia Nomenclature</a>
<a href="/journals/jama/fullarticle/2800656">Organization and Performance of US Health Systems</a>
<a href="/journals/jama-health-forum/fullarticle/2791195">Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy</a>
<a href="/journals/jama-health-forum/fullarticle/2791195">Promoting EDI in Genetics Research</a>
<a href="/journals/jamacardiology/fullarticle/2781972">PTSD and Cardiovascular Disease</a>
<a href="/journals/jama/fullarticle/2810754">Red Blood Cell Transfusion: 2023 AABB International Guidelines</a>
<a href="/journals/jamapediatrics/fullarticle/2797600">Reimagining Childrenâ€™s Rights in the US</a>
<a href="/journals/jama/fullarticle/2794049">Spirituality in Serious Illness and Health</a>
<a href="/journals/jama/fullarticle/2796374">The US Medicaid Program: Coverage, Financing, Reforms, and Implications for Health Equity</a>
<h4 class="footer-subheading jn-ss-subheading-mt">USPSTF Recommendation Statements</h4>
<a href="/journals/jama/fullarticle/2779985">Screening for Colorectal Cancer</a>
<a href="/journals/jama/fullarticle/2779190">Screening for Hypertension</a>
<a href="/journals/jama/fullarticle/2777244">Screening for Lung Cancer</a>
<a href="/journals/jama/fullarticle/2796244">Screening for Prediabetes and Type 2 Diabetes In Children</a>
<a href="/journals/jama/fullarticle/2783414">Screening for Prediabetes and Type 2 Diabetes In Adults</a>
<a href="/journals/jama/fullarticle/2795521">Statins for Primary Prevention of Cardiovascular Disease</a>
<a href="/journals/jama/fullarticle/2793446">Vitamin and Mineral Supplements for Primary Prevention of of Cardiovascular Disease and Cancer</a>
<h4 class="footer-subheading jn-ss-subheading-mt">Blogs</h4>
<a target="_blank" href="https://amastyleinsider.com/">AMA Style Insider</a>
</div>
</div>
</div>
</div>
<div id="footer-network-info" class="footer-network-info">
<div class="information-for-links">
<h4 id="BodyContent_Footer_InfoHeader" class="footer-subheading">Information</h4>
<a href="/pages/for-authors">For Authors</a>
<a href="/pages/resources-for-librarians">For Institutions &amp; Librarians</a>
<a href="/pages/advertisers">For Advertisers</a>
<a href="/pages/subscription-agents">For Subscription Agents</a>
<a href="https://careers.jamanetwork.com/" target="_blank">For Employers &amp; Job Seekers</a>
<a href="https://media.jamanetwork.com" rel="nofollow" target="_blank">For the Media</a>
<a href="/pages/equity-diversity-inclusion">Equity, Diversity, Inclusion</a>
<a href="/pages/commenting-policy">Online Commenting Policy</a>
<a href="/pages/access-at-jama-network">Public Access and Open Access Policy</a>
<a href="/pages/offensive-content-statement">Statement on Potentially Offensive Content</a>
</div>
<div class="services-links">
<h4 id="BodyContent_Footer_JAMANetworkProductsHeader" class="footer-subheading">JAMA Network Products</h4>
<a href="http://www.amamanualofstyle.com/" class="footer-service-link" target="_blank">AMA Manual of Style</a>
<a href="https://jamaevidence.mhmedical.com/" class="footer-service-link" target="_blank"><span class="jn-registered">JAMAevidence</span></a>
<a href="http://www.peerreviewcongress.org/" class="footer-service-link" target="_blank">Peer Review Congress</a>
</div>
<div class="learning-links">
<h4 id="BodyContent_Footer_LearningHeader" class="footer-subheading">JN Learning</h4>
<a href="https://edhub.ama-assn.org/jn-learning">Home</a>
<a href="https://edhub.ama-assn.org/jn-learning/state-cme">State CME</a>
<a href="https://edhub.ama-assn.org/jn-learning/pages/clinical-challenge-courses">Clinical Challenge CME</a>
<a href="https://edhub.ama-assn.org/jn-learning/course/288 ">Atrial Fibrillation Course</a>
<a href="https://edhub.ama-assn.org/jn-learning/course/294 ">Women's Health Course</a>
<a target="_blank" href="https://edhub.ama-assn.org/pages/auto-credit-reporting">CME / MOC Reporting Preferences</a>
<a href="https://edhub.ama-assn.org/jn-learning/pages/about-cme">About CME &amp; MOC</a>
</div>
</div>
</div>





        </div>
        
        <div id="footer-resources-wrap" class="footer-resources-wrap">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Right" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .footer-resources-wrap .footer-subheading {color: grey;display:block !important;font-size: 1.17647em;font-weight: 400;text-transform: uppercase;}
</style>
<div class="footer-heading-wrap">
<h3 class="footer-heading is-b footer-resources-heading" data-mobile-tog-target=".footer-resources">Help</h3>
</div>
<div class="footer-resources">
<a href="https://store.jamanetwork.com" class="footer-service-link" target="_blank">Subscriptions &amp; Renewals</a>
<a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-alerts" class="footer-service-link" rel="nofollow">Manage Emails</a>
<a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-profile" class="footer-service-link" rel="nofollow">Update My Address</a>
<a href="https://support.jamanetwork.com/hc/en-us" class="footer-service-link">Support Center</a>
<a href="/myaccount " class="footer-service-link">My Account</a>
<h4 class="footer-subheading jn-ss-subheading-mt">JAMA Career Center</h4>
<a href="https://careers.jamanetwork.com/" class="footer-service-link" target="_blank">Physician Job Listings</a>
</div>








    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Socials" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .widget-instance-AMA_Journal_Home_Socials .iconsocial {display: inline-block !important;width: 34px;height: 34px;min-width: unset !important;margin: 0 2px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;}
    .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 7px 7px;background-repeat: no-repeat;background-size: 18px;}
    .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram:hover, .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram:focus {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png);border-color: #C13584;}
    .footer-resources-wrap .iconsocial {display: inline-block !important;width: 32px;height: 32px;min-width: unset !important;margin: 0 2px 0 3px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;}
    .footer-resources-wrap .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 6px 6px;background-repeat: no-repeat;background-size: 18px;}
    .footer-resources-wrap .iconsocial.instagram:hover, .footer-resources-wrap .iconsocial.instagram:focus {background-color: #C13584;border-color: #191919;}
    #load-instagram-image { background: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png) no-repeat -9999px -9999px; }
</style>
<div id="BodyContent_Footer_divSocial" class="social-links footer-social-links">
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.facebook.com/JAMAJournal/" class="social-link is-b facebook"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://twitter.com/JAMA_current" class="social-link is-b twitter"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.instagram.com/jamanetwork/?hl=en" class="iconsocial instagram"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.linkedin.com/company/jamanetwork/" class="social-link is-b linked-in"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.youtube.com/jamanetwork" class="social-link is-b you-tube"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.pinterest.com/jamanetwork/" class="social-link is-b pinterest"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="/rss/site_3/67.xml" class="social-link is-b rss"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://jamanetwork.com/journals/jama/pages/jama-editors-summary" class="social-link is-b podcast"></a>
<div id="load-instagram-image">&nbsp;</div>
</div>




<div id="BodyContent_Footer_divEmailUpdate" class="footer-email-updates">
                
                    <div class="widget-EmailListSignUp widget-instance-AMAv2_EmailListSignUp_Footer">
        <div class="email-signup">
    
    <div class="email-signup--text sb-pc">Get the latest from JAMA</div>
    <div class="email-signup--input-wrap is-b">
        <input type="text" name="email" class="email-signup--input" placeholder="Email address" title="Email address" />
        <a rel="nofollow" href="javascript:;" class="email-signup--submit sb-sc btn">Sign Up</a>
    </div>
    <div class="email-signup--link"> <a class="email-signup--privacy" href="/pages/privacy-policy">Privacy Policy</a> | <a class="email-signup--terms" href="/pages/terms-of-use">Terms of Use</a></div>
    <div class="email-signup--user-message"></div>
</div> 
    </div>
</div>
        </div>

        
        <div class="footer-bar" itemscope itemtype="https://schema.org/Organization">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Bottom_Bar" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .nav-journals a.theme-jama-health-forum:before {background: #133763;}
    .jn-bottom-bar {color: #fff; float: left;font-size: 10px;padding: 13px 20px;width: 33.33%;}
    .jn-bottom-bar p {line-height: 2;}
    @media (max-width: 900px) {.jn-bottom-bar {float: none;width: 100%;}}
    .jn-footer-copyright {font-size:12px;line-height:1.5;margin-bottom:10px;}
    .jn-footer-pipe {margin:0 10px;}
    .footer-bar-jn-logo img {width: 230px;}
    @media (max-width: 900px) {.footer-bar-jn-logo img {width: 200px;}}
    [data-thm=umb] .jobs-ad--text h6 {color: #d71635 !important;}
    [data-thm=jama] .jobs-ad--text h6 {color: #d71635 !important;}
    [data-thm=jaman] .jobs-ad--text h6 {color: #ed0973 !important;}
    [data-thm=cardi] .jobs-ad--text h6 {color: #be1e32 !important;}
    [data-thm=derm] .jobs-ad--text h6 {color: #006f3b !important;}
    [data-thm=faci] .jobs-ad--text h6 {color: #ed1c24 !important;}
    [data-thm=jama-] .jobs-ad--text h6 {color: #fb5252 !important;}
    [data-thm=intem] .jobs-ad--text h6 {color: #006e96 !important;}
    [data-thm=neur] .jobs-ad--text h6 {color: #981b1e !important;}
    [data-thm=oncol] .jobs-ad--text h6 {color: #3b923f !important;}
    [data-thm=ophth] .jobs-ad--text h6 {color: #66bc29 !important;}
    [data-thm=otol] .jobs-ad--text h6 {color: #34b6e4 !important;}
    [data-thm=peds] .jobs-ad--text h6 {color: #0084c0 !important;}
    [data-thm=psych] .jobs-ad--text h6 {color: #005276 !important;}
    [data-thm=surg] .jobs-ad--text h6 {color: #f47920 !important;}
    .blockquote .para {margin: 0 0 1em 1em;}
    .jn-footer-copyright {display: block;}
    .inline-block {display: inline-block;}
    #selfserve-maintenance {display:block;margin:20px 0;max-height:none !important;min-height:200px;visibility:visible;}
</style>
<a class="footer-bar-jn-logo d-b no-mw mb1" href="/" title="JAMA Network Home"><img class="mw-100" src="https://cdn.jamanetwork.com/ImageLibrary/global/jn-signature-reversed-r.svg?versionId=81373" alt="Jama Network Logo"></a>
<div class="jn-bottom-bar">
<p>
<span class="jn-footer-copyright">Â© 2024 American Medical Association. <span class="inline-block">All rights reserved,</span> including those for text and data mining, AI training, <span class="inline-block">and similar technologies.</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/terms-use" rel="nofollow" class="p0">Terms of Use</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/privacy-policy" rel="nofollow" class="p0">Privacy Policy</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/accessibility-statement" rel="nofollow" class="p0">Accessibility Statement</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a onclick="OneTrust.ToggleInfoDisplay()" rel="nofollow" class="p0" id="CookieFooter">Cookie Settings</a></span>
</p>
</div>
<!-- 
	#selfserve-maintenance {display:block;margin:20px 0;max-height:none !important;min-height:200px;visibility:visible;}
	-->





            <a class="footer-bar-sis no-mw relative nudge-down" href="https://www.silverchair.com" target="_blank"><img class="footer-bar-sis-img mt05 mw-100" width="600" height="70" src="//cdn.jamanetwork.com/UI/app/img/powered.png" alt="Silverchair Logo" /></a>
        </div>
    </footer>

</div>
<div class="ss-ui-only">
        <div class="widget-SelfServeContent widget-instance-AMA_SS_UI_Only">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SsUiOnly" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

.


</div>

 
    </div>

</div>

    </section>


        

        
        
        <div id="revealModal" class="reveal-modal" data-reveal>
            <div id="revealContent"></div>
            <a class="close-reveal-modal icon-close"></a>
        </div>

        
        <div class="artmet-modal" id="MetricsModal">
            <div class="artmet-modal-contents">
                <a class="artmet-close-modal">&#215;</a>
            </div>
        </div>

        
        
    


            <div class="widget-SigninModals widget-instance-AMA_SigninModals">
        <div class="js-modal-no-access-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Access your subscriptions</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2769612">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_NoAccess_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_PurchaseOptions_NoAccessAndPaidPDF">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
<hr>
<button class="modal--btn js-btn-subscribe-journal" type="button" role="button">
<div class="text-truncate">Subscribe to journal</div>
</button>
<div class="modal--btn-desc">Get full journal access for 1 year</div>
<button class="modal--btn js-btn-purchase-article" type="button" role="button">
<div class="text-truncate">Buy article</div>
</button>
<div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)â€”<br>
<em>Sign in or create a free account</em></div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_NoAccessAndPaidPDF</div>-->


</div>

 
    </div>

            <div class="widget-DeepDyve widget-instance-AMA_NoAccess_DeepDyve">
                <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jama.2020.15543&amp;fieldName=journal_doi&amp;affiliateId=JAMA" data-doi="10.1001/jama.2020.15543" data-fieldname="journal_doi" 
                data-issneissn="0098-7484" data-affiliate="JAMA">Rent article</button>
        <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div>
 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-paid-pdf-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Access your subscriptions</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2769612">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_PaidPdf_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_PurchaseOptions_NoAccessAndPaidPDF">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
<hr>
<button class="modal--btn js-btn-subscribe-journal" type="button" role="button">
<div class="text-truncate">Subscribe to journal</div>
</button>
<div class="modal--btn-desc">Get full journal access for 1 year</div>
<button class="modal--btn js-btn-purchase-article" type="button" role="button">
<div class="text-truncate">Buy article</div>
</button>
<div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)â€”<br>
<em>Sign in or create a free account</em></div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_NoAccessAndPaidPDF</div>-->


</div>

 
    </div>

            <div class="widget-DeepDyve widget-instance-AMA_PaidPDF_DeepDyve">
                <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jama.2020.15543&amp;fieldName=journal_doi&amp;affiliateId=JAMA" data-doi="10.1001/jama.2020.15543" data-fieldname="journal_doi" 
                data-issneissn="0098-7484" data-affiliate="JAMA">Rent article</button>
        <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div>
 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-free-pdf-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Sign in to access free PDF</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2769612">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_FreePdf_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_FreePdf_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-save-search-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Save your search</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2769612">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_SaveSearch_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_SaveSearch">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_SaveSearch" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
		<hr />
		<button class="modal--btn js-btn-subscribe-now">Subscribe now</button>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_SaveSearch</div>-->


</div>

 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-follow-collection-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Customize your interests</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2769612">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_FollowCollection_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_FollowCollection">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_FollowCollection" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--sub-title">Create a personal account or sign in to:</div>
		<ul>
			<li>Register for email alerts with links to free full-text articles</li>
			<li>Access PDFs of free articles</li>
			<li>Manage your interests</li>
			<li>Save searches and receive search alerts</li>
		<ul>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_FollowCollection</div>-->


</div>

 
    </div>

            <div class="modal--link-wrap">
        <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a>
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-user-comment-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Make a comment</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f2769612">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_UserComment_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_UserComment">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_UserComment" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--sub-title">Create a personal account or sign in to:</div>
		<ul>
			<li>Register for email alerts with links to free full-text articles</li>
			<li>Access PDFs of free articles</li>
			<li>Manage your interests</li>
			<li>Save searches and receive search alerts</li>
		<ul>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_UserComment</div>-->


</div>

 
    </div>

            <div class="modal--link-wrap">
        <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a>
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="hidden-true js-modal-page-data"
     data-store-url="https://store.jamanetwork.com"
     data-store-purchase-url="https://jamanetwork.com/oauthsignin?return_url=https://store.jamanetwork.com"
     data-store-subscribe-url="https://store.jamanetwork.com/index.aspx?productcode=64">
</div>






 
    </div>

        

        
        <script src="//cdn.jamanetwork.com/UI/app/vendor/jquery-2.2.4.min.js?v=638473295270790799"></script>
        <script>window.jQuery || document.write('<script src="/UI/app/vendor/jquery-2.2.4.min.js">\x3C/script>')</script>

        <script src="//cdn.jamanetwork.com/UI/app/dist/app.min.js?v=638488852374030681"></script>
        
    
    
    <script src="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.js" type="text/javascript"></script>

    
    
        <script src="//d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script>
    
    <script defer src='//js.trendmd.com/trendmd.min.js' data-trendmdconfig='{"element":"#trendmd-suggestions"}'></script>
        <script type='text/javascript' src='https://platform-api.sharethis.com/js/sharethis.js#property=643701de45aa460012e1032e&amp;product=sop' async='async'></script>


    <script>
        var App = App || {};
        App.showCmePromo = false;
    </script>


    </form>
    

    
    
    <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/scss/modules/_trendMD.css">
</body>
</html>

 contentType 9 text/html url 61 https://jamanetwork.com:443/journals/jama/fullarticle/2769612 responseCode 3 200 